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Abstract 
The ability of the pancreatic β-cell to secrete insulin in response to changes in glucose 
concentration is the cornerstone of glucose homeostasis.  The β-cell couples glucose 
metabolism to electrical activity via the modulation of ion channel activity.  Defects in β-
cell ion channels can result in the dysregulation of insulin secretion and, consequently, in 
glucose homeostasis.  Congenital hyperinsulinism of infancy (CHI) is an inherited disorder 
of inappropriate insulin secretion often caused by gene defects in the subunits of KATP 
channels (ABCC8, KCNJ11).  In 50% of CHI patients, no genetic basis has yet been 
discovered.  I aimed to characterise the expression, and function, of two novel ion channel 
families in the healthy human pancreas and the hyperinsulinaemic pancreas. 
 
Hyperpolarisation-activated cyclic nucleotide-gated channels (HCN channels) are selective 
for K+ /Na+ under physiological conditions and are responsible for the rhythmic electrical 
behaviour (pacemaker behaviour) in the heart and brain.  Two-pore potassium channels 
(K2P channels) are potassium-selective channels whose activity contributes to, and 
maintains, the resting membrane potential of living cells.   
 
HCN and K2P gene and protein expression was investigated by RT-PCR and 
immunofluorescence.  HCN1, 2, 3, and 4 mRNA and mRNA from six K2P channels was 
detected in isolated mouse islets.  Immunofluorescence revealed the presence of HCN1, 
HCN2 and HCN4 in mouse β-cells.    The role of HCN channels in glucose-stimulated 
insulin secretion (GSIS) was assessed in isolated mouse islets. The HCN channel agonist 
lamotrigine had no effect on GSIS (n=3), but GSIS was significantly inhibited by the HCN 
16 
 
channel blocker zatebradine (n=3) thereby confirming that HCN channels may play a role 
in glucose homeostasis.   
 
Tissue was isolated from adult control human pancreas and from six patients following 
pancreatectomy for CHI.  HCN and K2P channel expression was also assessed in 
pancreatic tissue from ABCC8-knockout mice.  HCN1-4 mRNA and the mRNA of four 
K2P channels were detected in islets isolated from adult control and CHI patient pancreatic 
tissue.  Co-expression of HCN channel isoforms with insulin confirmed that HCN1, -2 and 
-4 were β-cell-specific in control human islets.  By contrast, in all patient tissues 
expression of HCN channels was altered, and in 5 out of 6 cases, HCN channels were not 
expressed in β-cells.  The K2P channel TWIK-1 was found to be expressed predominantly 
in the healthy human exocrine pancreas.  In contrast, its expression was consistently 
detected in the β-cells of CHI patients.  We found similar data for both HCN channels and 
TWIK-1 in islets of ABCC8-knockout mice, but not their litter-mate controls (n=3). 
 
These studies provide the first data on the expression of HCN and K2P channels in the 
human pancreas and reveal that CHI is associated with an altered expression profile of both 
ion channel families. Significantly, we found that HCN and K2P expression in β-cells is 
altered in CHI patients and we speculate that this is as a consequence of physiological 
remodelling.    
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1.1  Diabetes  
Diabetes describes a wide variety of conditions that occur due to functional abnormalities 
in the endocrine pancreas.  It is characterised by recurrent or persistent episodes of 
hyperglycaemia and can lead to numerous complications including cardiovascular disease, 
neuropathy, and retinopathy (reviewed by Orasanu and Plutzky, 2009).  The monitoring 
and controlling of blood glucose levels, combined with regular visits to clinics, is required 
to successfully manage diabetes and represents an additional burden for patients. 
 
The most common type of diabetes is diabetes mellitus.  Diabetes mellitus is generally 
grouped into two forms; Type I and Type II.  Type I diabetes results from the autoimmune 
destruction of pancreatic β-cells, and Type II diabetes is characterised by insulin resistance 
in peripheral tissues and the consequential failure of β-cells to produce sufficient quantities 
of insulin. 
 
Type I diabetes treatment is generally reliant upon the administration of exogenous insulin.  
However, this does not prevent diabetes-associated complications (Warnock et al., 2008).  
The transplantation of pancreatic islets has also been used and slows the progression of 
diabetes-associated complications (Warnock et al., 2008).  Due to the limited availability 
of suitable donor material, and the long-term loss of function associated with transplanted 
islets, alternative therapies are needed (reviewed by Lakey et al., 2003).  Therefore the 
focus of much recent research has been on finding an alternative source of pancreatic β-
cells, for example, by differentiating other pancreatic cells, such as ductal cells (Bouwens 
et al., 1997) or exocrine cells (Baeyens and Bouwens, 2008), towards an insulin-secreting 
cell phenotype. 
21 
 
In some cases of Type II diabetes, lifestyle changes combined with an exercise plan can 
help to control the disease.  If this alone is not sufficient, pharmacological agents are used 
(reviewed by Nathan et al., 2009).  In this case, the first-line treatment is Metformin.  This 
reduces hyperglycaemia and reduces diabetes-associated complications by suppressing 
hepatic glucose production (gluconeogenesis) and enhancing insulin sensitivity in 
peripheral tissues.  A second-line of treatment for Type II diabetes is the use of 
sulphonylureas such as Glibenclamide.  This class of drugs act to inhibit the ATP-sensitive 
potassium channels found in the pancreatic β-cell membrane, resulting in enhanced insulin 
secretion.  Many other therapeutic agents are available for the treatment of type II diabetes 
including Glinides, Thiazolidinediones, and Gliptins.  All of which act to reduce 
hyperglycaemia by either enhancing insulin secretion, reducing hepatic glucose production 
or improving insulin sensitivity.  The application of treatment depends on the severity of 
the disease and the patient’s tolerance of the drugs (Nathan et al., 2009). 
 
Diabetes is a common and growing health concern.  In 2000 the world-wide figure of 
diabetes sufferers was approximately 171 million (Wild et al., 2004).  This is predicted to 
rise to an estimated 366 million by the year 2030 (Wild et al., 2004).  Therefore, a fuller 
understanding of glucose homeostasis and associated disorders is required to provide 
potential therapeutic applications.  This begins with an understanding of the structure and 
function of the healthy pancreas. 
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1.1.2  Structure of the pancreas 
The pancreas contains two distinct populations of cells, the exocrine cells which are 
responsible for the secretion of enzymes into the digestive tract via pancreatic ducts, and 
the endocrine cells which secrete hormones into the bloodstream (Slack, 1995).   
 
The adult human pancreas weighs approximately 70-150 grams and can be divided into 
discrete regions termed the head, neck, body and tail.  The pancreas is joined to the 
duodenum via the main pancreatic duct and the ampulla of Vater (Figure 1.1).  The 
exocrine pancreas makes up the majority of the pancreas and consists of acinar cells, 
centroacinar cells and duct cells. These cells are grouped into structures termed acini 
(Figure 1.1).  Acinar cells are responsible for the secretion of digestive enzymes, and the 
centroacinar cells secrete the non-enzymatic components of the pancreatic juice (Slack, 
1995).  . 
 
 
Figure 1.1  Structure of the adult human pancreas.  The upper diagram shows that 
structure of the whole adult pancreas in relation to the duodenum.  The lower 
diagram shows the structure of the exocrine acini.  From Slack, 1995. 
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1.1.3  The pancreatic islet 
Embedded throughout the exocrine pancreas are cell aggregates that make up the endocrine 
pancreas.  These aggregates were termed “islets of Langerhans” after their discoverer, Paul 
Langerhans (1847-1888) and make up just 1-2% of total pancreatic mass (Kulkarni, 2004).  
There are 2000-4000 cells in a rodent islet.  Human islets vary significantly in size with 
some islets containing 1000-2500 cells, and others as many as 12,000 cells (Weir and 
Bonner-Weir, 1990, Peakman et al., 1994).  70% of these cells are insulin-producing β-
cells, 5% are somatostatin-producing δ-cells, 15-20% are glucagon-producing α-cells and 
less than 5% are pancreatic-polypeptide producing PP cells and grehlin producing ε-cells 
(Cabrera et al., 2006). 
 
                      
 
 
 
 
Islet architecture shows a large degree of variation between species (Figure 1.2).  In the 
mouse islet, β-cells form a core surrounded by α-, δ-, and PP cells.  This contrasts with the 
human islet where all cell types appear to be randomly distributed.  Species differences 
Figure 1.2.  Islet Architecture.  Insulin-immunoreactive (red), glucagon-
immunoreactive (green), and somatostatin-reactive (blue) cells highlight 
interspecies differences in the islets of Langerhans (Cabrera et al., 2006). 
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also exist in the cell composition of islets.  Quantitative enumeration has revealed that 
human islets contain more glucagon-immunoreactive cells than mouse islets (38% verses 
18%), whereas mouse islets contain more insulin-immunoreactive cells (77% verses 55%) 
(Cabrera et al., 2006).  This may reflect evolutionary differences brought about by 
diversity in metabolic demands and diets/feeding habits (Kim et al., 2009).  Furthermore, 
in contrast to mouse islets, human islets show greater heterogeneity in terms of their 
composition (Brissova et al., 2005).  It has been proposed that the arrangement of the 
human islet has functional implications, which may result in it being more susceptible to 
paracrine interactions (Cabrera et al., 2006).   
 
1.2  Glucose homeostasis and the β-cell 
The pancreatic β-cell acts as a ‘fuel-sensor’ for the entire body.  The glucose-sensing 
ability of the β-cell and the release of insulin are central to glucose homeostasis 
(Meglasson and Matschinsky, 1986).  Pancreatic β-cells secrete appropriate amounts of 
insulin in response to the prevailing blood glucose level.  An increase in insulin secretion, 
in response to elevated blood glucose, stimulates the uptake of glucose, glycogen 
synthesis, and also results in the inhibition of glycogenolysis and gluconeogenesis 
(Madison et al., 1960, Friedman et al., 1970, Cherrington et al., 1976, Rizza et al., 1981, 
Rhodes and White, 2002).  As a result of insulin secretion, approximately 75% of orally 
administered glucose is taken up by the skeletal muscle (Katz et al., 1983), with the liver 
and adipose tissue representing the other major sites of glucose uptake (reviewed by 
Nussey and Whitehead, 2001).  Although glucose is the primary stimulus for β-cell insulin 
secretion, free fatty acids (Crespin et al., 1973), amino acids (Fajans et al., 1972) and gut 
hormones (Mosjov et al., 1987) can also stimulate the secretion of insulin from pancreatic 
β-cells. 
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The islets of Langerhans are richly innervated and hormone secretion can be influenced 
through both parasympathetic and sympathetic innervation.  The nervous innervation of the 
islets was originally appreciated by their discoverer (Langerhans, 1869).  Parasympathetic 
stimulus is brought about by activation of the vagus nerve.  This causes postganglionic 
nerve fibres innervating the islets to secrete acetylcholine which stimulates insulin release 
from β-cells via activation of nicotinic receptors (Ahrén and Taborsky, 1986).  Islet cells 
have been shown to also express muscarinic receptors, whose activation in β-cells directly 
stimulates insulin secretion (Van der Zee et al., 1992).  Cholinergic stimulation of islets 
has been shown to augment insulin secretion by causing the release of Ca2+ from 
intracellular stores (Kelley et al., 1995).  Sympathetic activation results in the release of 
noradrenaline, which acts via α2-adrenorecptors to reduce insulin secretion.  This is 
achieved via the opening of KATP channels (ATP-sensitive potassium channels) and the 
consequent β-cell hyperpolarisation (Nilsson et al., 1988).  The neural stimulation of islets 
is thought to be partly responsible for the regular pulsatile action of insulin release from 
the whole pancreas, as well as during times of hypoglycaemia where the release of 
adrenaline stimulates glucagon secretion (Havel and Taborsky, 1989, Ahrén, 2000).  
 
Insulin-secretion by the pancreatic β-cell is also subject to regulation by local interactions 
(paracrine) with different cells within the same islet and in turn, regulates the secretory 
action of other islet cells.  Glucagon was discovered in 1923 and the α-cells of the pancreas 
were subsequently shown to be its source (Murlin et al., 1923, Sutherland and Duve, 
1948).  The release of glucagon from pancreatic α-cells results in an increase in blood 
glucose levels (Unger et al., 1962, Lins et al., 1983).  Glucagon promotes hepatic glucose 
output by stimulating glycogenolysis and gluconeogenesis.  Elevation of glucagon also 
enhances the secretion of insulin from β-cells (Samols et al., 1965).  This is of particular 
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importance during prolonged periods of physical exercise, as it allows the effective uptake 
of glucose by target tissues such as the skeletal muscle (reviewed by Shu et al., 2007).  In 
contrast, insulin secreted by β-cells, in conjunction with zinc, acts to inhibit glucagon 
secretion (Maruyama et al., 1984, Franklin et al., 2005).  In humans, intraislet 
hyperinsulinaemia has been shown to prevent glucagon secretion normally triggered by 
hypoglycaemia, despite the presence of an intact autonomic response (Banarer et al., 
2002).  Adding further complication to the paracrine interaction of islet cells is the action 
of somatostatin.  Secretion of somatostatin from δ-cells, in response to hyperglycaemia, 
amino acids and autonomic input, inhibits insulin secretion from both rodent and human β-
cells, as well as inhibiting glucagon secretion from α-cells (Koerker et al., 1974, Orci and 
Unger 1975, Jo et al., 2009).  The precise significance of these interactions, in terms of 
global glucose homeostasis, is not entirely understood.  However, the microcirculation and 
architecture of islets are considered to be of importance regarding which paracrine 
interactions are significant within an islet (Cabrera et al., 2006).    
 
Insulin secretion from β-cells is also subject to autocrine regulation and insulin has been 
shown to positively regulate its own biosynthesis, secretion, and proliferation via the β-cell 
insulin receptor (Leibiger et al., 1998, Xu et al., 1998).  These effects are evident in type II 
diabetes where β-cell mass initially increases to compensate for insulin resistance.  
However, as the disease develops, β-cell mass decreases due to enhanced apoptosis (which 
is also partly attributable to insulin resistance) (reviewed by Leibiger et al., 2008).  The 
most controversial aspect of insulin feedback signalling is the effect of insulin on its own 
secretion.  Early reports suggested that insulin had a negative effect on further insulin 
secretion (Iversen et al., 1971).  However, insulin secretion was later found to have a 
positive effect on ongoing insulin secretion (Aspinwall et al., 1999).  This was supported 
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by insulin receptor knockout mouse studies (Kulkarni et al., 1999).  More recent studies 
have suggested that insulin has an immediate negative effect upon insulin secretion by 
causing the opening of KATP channels (Khan et al., 2001).  These results present a 
conflicting view of insulin autocrine regulation that has yet to be resolved.   
 
Physical cell-to-cell contact through gap junctions is another important factor for islet cell 
function.  Glucose has been shown to elicit an insulin response from β-cells within islets 
30-fold greater than that from single islets (Pipeleers et al., 1982).  Single β-cells can also 
show enhanced basal insulin secretion along with a poor insulin response to glucose 
stimulation (Bavamian et al., 2007).  This effect can be partially reversed after re-
aggregation of β-cells (Bavamian et al., 2007).  Within an islet, β-cells are known also to 
be electrically coupled and the bursting of action potentials, in response to 10mM glucose, 
is approximately synchronous.  Single β-cells however, show irregular electrical activity 
when compared with β-cells from intact islets (Rorsman and Trube, 1986, Sherman et al., 
1988).  Therefore, physical contact between islet cells is also important in producing an 
appropriate response to changes in glucose concentration.    
 
1.2.1  The consensus model of stimulus-secretion coupling in β-cells  
Extensive experimental work spanning more than two decades has led to a widely accepted 
model of glucose-stimulated insulin secretion (GSIS) termed the consensus model (also 
known as the triggering pathway) (Figure 1.3) (reviewed by Rorsman 1997, Dunne, 2000, 
Henquin 2009).  Dean and Matthews were the first to show that glucose caused the firing 
of action potentials in β-cells (Dean and Matthews, 1968).  From these early studies it was 
recognised that, to produce these effects, glucose must be metabolised by the β-cell and 
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that the subsequent exocytosis of insulin is dependent on the influx of Ca2+ (Matthews and 
Sakamoto, 1975, Henquin and Meissner, 1984).  At low glucose concentrations, ATP-
sensitive potassium channels (KATP channels) in the β-cell plasma membrane are open.  
This results in a high resting potassium conductance, giving an estimated membrane 
potential of -65mV, therefore β-cells are hyperpolarised and electrically silent (Ashcroft 
and Rorsman, 1989).  As the extracellular glucose concentration rises, glucose is 
transported into the rodent β-cell by the low affinity glucose transporter GLUT-2 (GLUT-1 
is the predominant glucose transporter in the human β-cell) (De Vos et al., 1995).  
Glucokinase then phosphorylates glucose to glucose-6-phosphate which subsequently 
undergoes glycolysis to produce pyruvate, NADH, and ATP (Meglasson and Matschinsky, 
1984).  Pyruvate crosses the inner mitochondrial membrane and is converted to acetyl CoA 
which then enters the tricarboxylic acid cycle (TCA cycle).  Adenosine triphosphate (ATP) 
is produced by the TCA cycle and from the subsequent reoxidation of NADH and FADH2 
by the electron transport chain (which allows the production of ATP by ATP synthase)
 
(Meglasson and Matschinsky, 1986).  This causes a rise in the cytosolic concentration of 
ATP and a decrease in the cytosolic concentration of MgADP (Cook and Hales, 1984, 
Ashcroft et al., 1984, Dunne and Petersen, 1986, Detimary et al., 1996).  As a result, KATP 
channel activity is reduced causing membrane depolarisation to the threshold potential at 
which the L-type voltage-dependent calcium channels (VDCCs) open.  The subsequent 
influx of Ca2+ and increase in cytosolic Ca2+ concentration triggers exocytosis of insulin-
containing granules (Bokvist et al., 1995).  
 
The triggering pathway or consensus model for stimulus-secretion coupling in the β-cell 
was previously referred to as the KATP-dependent pathway.  This was because the 
triggering Ca2+ signal that is essential for insulin secretion is predominantly brought about 
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the closure of the KATP channels.  This is currently seen as misleading because agents that 
do not act on KATP channels can also generate the triggering Ca2+ signal (Henquin, 2009). 
 
ATP-sensitive potassium channels (KATP channels) link the metabolic sensing of glucose in 
pancreatic β-cells with stimulus-secretion coupling (Cook and Hales, 1984).  Functional 
KATP channels are heteromultimeric complexes formed by 2 distinct subunits; Kir6.x and 
SURx (Clement et al., 1997).  Two isoforms of Kir6.x (Kir6.1 and Kir6.2) and three 
isoforms of SURx (SUR1, SUR2A and SUR2B) exist.  In pancreatic β-cells, KATP channels 
are thought to exist as an octomeric complex of four Kir6.2 subunits and four SUR1 
subunits (reviewed by Aguilar-Bryan and Bryan, 1999).  The weak inward rectifier, Kir6.2, 
shares sequence homology with the K+-selectivity domain of voltage-gated potassium 
channels and is thought to form the K+-selective pore of KATP channels (Clement et al., 
1997).  SUR1, an ATP-binding cassette protein and receptor with high affinity for 
sulfonylureas, acts as a conductance regulator of Kir6.2 and plays a key role in the 
pharmacological modulation of KATP channels (Aguilar-Bryan et al., 1995).  Selective β-
cell KATP channels openers (such as diazoxide) and KATP channels blockers (such as 
sulfonylureas) modulate KATP channels activity by binding to SUR1.  These modulators are 
often used in the treatment of CHI (see Section 1.3.10) and diabetes (see Section 1.1) in 
order to restore normal blood glucose levels.       
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1.2.2  The amplifying pathway of stimulus-secretion coupling in β-cells 
Evidence for an amplifying pathway (previously referred to as the KATP-independent 
pathway) of stimulus-secretion coupling in β-cells has come predominantly from KATP 
subunit knockout (KO) mice and the pharmacological modulation of KATP channels.  It has 
been shown that glucose is still able to increase insulin secretion in the presence of 
sulphonylurea concentrations that will close all KATP channels (Panten et al., 1988, Best et 
al., 1992).  When mouse or rat islets are depolarised by KCl in the presence of diazoxide (a 
KATP channel opener), glucose is still able to influence insulin secretion in a way that is 
dependent on metabolism and elevated intracellular Ca2+ concentrations ([Ca2+]i) (Gembal 
Figure 1.3.  The consensus or triggering pathway of stimulus-secretion coupling in β-cells.  
Glucose is transported into the β-cell, where it is metabolised causing an increase in the 
ATP:MgADP ratio.  This causes KATP channels to close, depolarising the cell sufficiently to 
open VDCCs and the subsequent influx of calcium results in the exocytosis of insulin-
containing granules. 
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et al., 1992, Komatsu et al., 1992).  Furthermore, glucose has been reported to increase 
insulin secretion in mice lacking the KATP channel subunits Kir6.2 (Ravier et al., 2009) or 
SUR1 (Nenquin et al., 2004). 
 
The amplifying pathway has also been demonstrated in human islets (Straub et al., 1998).  
In healthy β-cells, this pathway is silent unless the triggering pathway is activated, i.e. the 
amplifying pathway does not influence insulin secretion if [Ca2+]i (intracellular Ca2+ 
concentration) is not increased (Henquin, 2009).  However, in order to achieve a full 
biphasic response to glucose (see Section 1.2.3), the activation of both pathways is needed.  
This is evident as blocking KATP channels with sulphonylureas fails to stimulate insulin 
secretion to the same magnitude as glucose (Zawalich and Zawalich, 1988).  The 
amplifying pathway has been shown to be active in the β-cells of congenital 
hyperinsulinism patients who had loss-of-function mutations in the gene encoding the 
SUR1 subunit (ABCC8) (Straub et al., 2001).  No defects were found in VDCCs but β-
cells were spontaneously active and generating Ca2+ action currents that were insensitive to 
diazoxide.  In these patients, stimulation of islets with tolbutamide failed to initiate insulin 
secretion, whereas glucose was still able to promote insulin secretion (Straub et al., 2001).   
 
The precise mechanism of the amplifying pathway is currently unknown.  Induction of 
electrical activity by glucose, in the presence of tolubutamide, has been shown to be 
sensitive to inhibition by a blocker of the volume-regulated anion channel (Best, 2002).  It 
has also been proposed that a re-evaluation of the roles of cAMP, amongst others 
(including NADPH, glutamate and granule translocation) may prove to be important 
factors (Henquin, 2009). 
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1.2.3  The biphasic manner of GSIS 
It has been known for many years that insulin secretion from pancreatic β-cells occurs in a 
biphasic manner.  The first phase of insulin secretion consists of a short, rapid release of 
insulin and the second phase displays a sustained increase in the rate of insulin secretion 
until it reaches a plateau (Straub and Sharp, 2002).  This has been demonstrated in both the 
rat pancreas (Figure 1.4) and human plasma insulin responses (Cerasi and Luft, 1963, 
Curry et al., 1968).  The response of mouse islets to stimulatory concentrations of glucose 
has generally been found to be monophasic.  Simultaneous measurements of insulin 
secretion and intracellular Ca2+ concentration ([Ca2+]i) revealed that when stimulated at 
high glucose for an extended period of time, the Ca2+ response of mouse β-cells is biphasic 
(Figure 1.5) (Henquin et al., 2002).  The initial rise in [Ca2+]i is accompanied by a sharp 
rise in insulin secretion. Following the initial peak [Ca2+]i declined slightly and rapid 
oscillations were observed.  Insulin secretion was observed to decrease and stabilise at a 
level far below that seen in the initial response (but still above basal).   
 
 
 
Figure 1.4.  First and second phase insulin secretion in rat islets.  The application of 
glucose is indicated by the arrow (at approximately 10 minutes).  After a short delay, 
the first phase of insulin secretion is clear (shown as a sharp spike).  Following this is 
the second phase of insulin secretion, shown as a slower steady increase in the rate of 
insulin secretion.  From Straub and Sharp, 2002.  
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The differences observed between the second phase of insulin secretion in mouse and rat 
has been attributed several factors including greater cAMP production in the rat β-cell (Ma 
et al., 1995), and the expression of distinct isoforms of protein kinase C (PKC) (Zawalich 
and Zawalich, 1996).  This is thought to result in a greater potentiation of the triggering 
signal in rat islets.  It is important to note that, in perifused isolated human islets, the 
insulin-response to glucose more closely resembles that of the mouse than that of the rat 
(Takei et al., 1994).  This is true also in terms of the intracellular Ca2+ response which is 
oscillatory in human and mouse β-cells, but not rat β-cells (Falke et al., 1989, Martin and 
Soria, 1996, Antunes et al., 2000).  
 
Figure 1.5.  Simultaneous measurement of insulin secretion and [Ca2+]i in a single 
mouse islet.  Prolonged exposure of mouse islets to 20mmol/l glucose resulted in an 
initial sharp increase in insulin secretion (line with circles) followed by a slight 
decrease and plateau.  Intracellular  Ca2+ (continuous line) responses were oscillatory 
and also showed an initial peak followed by a decrease and plateau.  From Henquin et 
al., 2002.  
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1.2.4  The contribution of the triggering and amplifying pathways to biphasic insulin 
secretion 
The triggering [Ca2+]i signal produced via KATP channels is essential to both phases of 
insulin secretion.  If the rise in [Ca2+]i is prevented, both phases of insulin secretion are 
abrogated (Henquin et al., 2002).  The mechanisms that underline the second phase of 
insulin secretion are not as well defined as those that govern the first.  However, the 
amplifying pathway is generally regarded to be responsible for the second phase of insulin 
secretion (Henquin, 2009).  One mechanism has been proposed that aims to take into 
account previously suggested models (Straub and Sharp, 2002).  This model is based on 
the fact they there are generally three groups of insulin granules that exist in the β-cell.  
Two of these groups are docked at the plasma membrane and are termed IR (immediately-
releasable) and RR (readily-releasable) granules.  The third group consists of granules at 
various stages of development that are not docked.  The first phase of insulin secretion is 
thought to be due to the release of IR granules brought about by Ca2+-induced exocytosis.  
Once these have been depleted there is a time delay or ‘nadir’ before the second phase of 
insulin secretion occurs.  During this time RR granules need to be converted to IR granules 
and physically moved to the plasma membrane.  This conversion is considered to be the 
main rate-limiting step of biphasic insulin secretion (Straub and Sharp, 2002).  It is clear 
that as the rate of exocytosis increases and plateaus that the rate-limiting step is affected.   
 
1.3  Congenital Hyperinsulinism (CHI) 
Congenital Hyperinsulinism is the most common cause of transient and permanent 
hypoglycaemia (Stanley, 1997).  It is best defined as an inappropriate secretion of insulin 
for the level of glycaemia (Dunne et al., 2004).  CHI is a potentially life-threatening 
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disorder which requires prompt and effective treatment to prevent permanent brain damage 
and other associated neurological damage (Stanley, 1997).   
 
Hypoglycaemia in children is defined as a plasma glucose level below 2.8-3mmol/l 
(Stanley, 1997).  Hypoglycaemia as a result of CHI, in the neonatal period, generally 
occurs within 72 hours after birth and is revealed in 50% of patients by seizures (Arnoux et 
al., 2010).    Large amounts of intravenous glucose (~ 16mg/kg/min) are required to 
maintain plasma glucose levels above 3mmol/l (Arnoux et al., 2010).  The brain is 
particularly vulnerable to hypoglycaemia as a result of inappropriate insulin release.  
Insulin decreases plasma glucose by inhibiting glucose release from the liver and 
stimulating glucose uptake in muscles and adipose tissue.  Insulin also inhibits lipolysis, 
therefore preventing ketogenesis (Arnoux et al., 2010).  The production of ketones from 
fatty acid metabolism is essential during fasting and starvation, as ketones, unlike free fatty 
acids, can cross the blood-brain barrier and therefore provide the brain with a major energy 
substrate during starvation and an alternative to glucose (Dunne et al., 2004).  Long-term 
neurological damage as a result of CHI is a common complication.  One study found that 
44% of patients suffered mental retardation and 25% suffered from recurrent epilepsy 
(Meissner et al., 2003).  More recent studies have reported that 29% of patients have long-
term learning difficulties (Mazor-Aronovitch et al., 2007).               
 
The majority of CHI cases are sporadic, although familial cases are well documented 
(Thomas et al., 1996, Dunne et al., 1997, Dunne et al., 2004).  The incidence of CHI in the 
general population is estimated to be 1 in 40,000-50,000 and as high as 1 in 2,500 in 
isolated communities with high consanguinity (James et al., 2009). 
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1.3.1  Historical context 
The first description of hyperinsulinism of infancy was given by George Laidlaw and 
published in 1938 (Laidlaw, 1938).  Laidlaw coined the term ‘Nesidioblastosis’ to describe 
the histological appearance of islets that were surgically removed from 6 patients suffering 
from hypoglycaemia (Laidlaw, 1938).  However, nesidioblastosis was later found to be 
present in the pancreas of both infants and adults who displayed no abnormalities in 
glucose homeostasis (Witte et al., 1984, Fong et al., 1989).  Nesidioblastosis is now used 
to describe the neodifferentiation of islets from the pancreatic ductal epithelium and is not 
related to the abnormal proliferation of β-cells (Sempoux et al., 1998). 
 
The concept of “Hyperinsulinism” was not completely accepted until the 1980s.  Early 
descriptions of neonatal hypoglycaemia were interpreted as a failure of the β-cell to adapt 
from the foetal state to an extrauterine pattern of nutrient supply (Hartman and Jaudon 
1937, Dunne et al., 2004). 
 
1.3.2  Classifying CHI 
CHI represents a group of heterogeneous disorders at a clinical, genetic, morphological and 
functional level (Dunne et al., 2004).  Transient CHI is known to occur in neonates born to 
diabetic mothers with poorly controlled diabetes.  This is the result of high glucose levels 
causing hypersecretion of insulin from the foetal pancreas (Stanley and Baker, 1999).  This 
generally resolves within a matter of days following birth.  The complexity of CHI is 
reflected in its association with other syndromes.  Beckwith-Wiedmann syndrome, which 
can result from paternal isodisomy of chromosome 11p15.5, can cause β-cell hyperplasia 
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and therefore patients can experience transient or prolonged periods of hypoglycaemia 
(Giurgea et al., 2006b). 
 
Advances in β-cell physiology have allowed the classification of more persistent CHI into 
two main subgroups; channelopathies, caused by defects in the KATP channel genes; 
metabolopathies, caused by alterations in intracellular signalling molecule concentrations 
or the accumulation of intermediate metabolites associated with insulin secretion (Hussain, 
2008). 
 
1.3.3  The Channelopathies 
KATP channels couple cell metabolism to the electrical activity of the cell membrane by 
sensing changes in the concentration of intracellular nucleotides (Ashcroft, 2005).  In 
pancreatic β-cells, KATP channels are composed of the inward rectifying potassium 
channels Kir6.2 (KCNJ11) and the high affinity sulphonylurea receptor SUR1 (ABCC8) 
(Inagaki et al., 1995).  Functional channels are composed of four Kir6.2 subunits, which 
form a central pore, and four surrounding SUR1 subunits (Clement et al., 1997).  Kir6.2 
confers the biophysical properties of the channel such as K+ selectivity, whereas SUR1 acts 
as a regulator of Kir6.2 activity (Ashcroft, 2005).  The precise metabolic regulation of the 
β-cell KATP channel is complex and still debated (Tarasov et al., 2004).  It is, however, 
widely accepted that rises in the intracellular concentration of ATP close KATP channels, 
and that rises in the MgADP concentration open KATP channels (Tarasov et al., 2004).   It 
has been proposed that MgADP, potentially generated as a result of MgATP hydrolysis, at 
the SUR1 subunit causes a shift in the ATP concentration response curve into a range that 
the channel pore (Kir6.2) can respond to dynamic changes in the intracellular 
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concentration of ATP (Tarasov et al., 2004).  This may be of particular importance as the 
intracellular concentration of ATP in β-cells is in the mM range (Dunne, 2004).  As KATP 
channels are inhibited in vitro by <10µM ATP, generation of MgADP (as a result of 
MgATP hydrolysis at the SUR1 subunit) combined with a high sensitivity for ADP, may 
be essential for normal KATP channel function.  Therefore, the sensitivity of the KATP 
channel to nucleotides appears to involve both subunits. 
 
The ABCC8 and KCNJ11 genes are located on chromosome 11p15.1 and are separated by 
only 4.5kb of DNA (Aguilar-Bryan et al., 1995).  To date, over 150 mutations in ABCC8 
and 25 in KCNJ11 have been reported as the underlying cause of Hyperinsulinism 
(Flanagan et al., 2009).  Mutations in these genes result in KATP channel defects via a 
variety of mechanisms.  Recessive mutations identified in KCNJ11 and ABCC8 have been 
identified, in patients with a severe form of CHI, which greatly enhance the rate of Kir6.2 
and SUR1 turnover (Crane and Aguilar-Bryan, 2004).  A recessive mutation in exon 35 of 
ABCC8 truncates 200 amino acids including the residue L1544, which is integral in 
ensuring the exit of the channels from the endoplasmic reticulum (ER) and their 
subsequent trafficking to the plasma membrane (Taschenberger et al., 2002). Rescue of 
this mutation restores KATP surface expression and channels function normally (Cartier et 
al., 2001).  The loss of ADP-dependent gating, due to a recessive mutation in the ABCC8 
gene, has been reported as a cause of CHI (Matsuo et al., 2000).  As a consequence, 
constitutive inhibition of KATP channels was achieved, resulting in inappropriate insulin 
secretion. 
 
Not all mutations in the KATP channel subunit genes result in the complete absence of 
functional channels.  Indeed, CHI channelopathies can be defined as type 1, where 
39 
 
functional KATP currents are completely absent from β-cells, and type 2, where KATP 
currents are recordable but present defects in function or channels are present in limited 
numbers (Dunne et al., 2004).  CHI caused by channelopathies is further divided, 
histologically and genetically, into diffuse CHI (Di-CHI) and focal CHI (Fo-CHI).  A 
study on more than 110 patients with early-onset, aggressive CHI (who required 
pancreatectomy), found that 85% of patients carried defects in the KATP channel subunit 
genes (Dunne et al., 2004).  In the same study, type 1 disease accounted for ~10% of Di-
CHI and ~ 55% Fo-CHI patients.  Type 2 disease accounted for over 60% of Di-CHI 
patients and ~45% of Fo-CHI patients. 
 
In the diffuse form of CHI, all pancreatic β-cells are affected.  Histologically, Di-CHI islets 
contain numerous β-cells with abnormal, large nuclei (Rahier et al., 2000).  Di-CHI is most 
commonly caused by recessive mutations in KCNJ11 or ABCC8 (James et al., 2009) but 
can be caused also by dominant mutations (Huopio et al., 2000).  Patients with Di-CHI are 
usually unresponsive to medical therapy and therefore often require a pancreatectomy of at 
least 95% (Hussain, 2008).  A near-total pancreatectomy often results in complications 
including life-long diabetes and pancreatic exocrine insufficiency (Hussain, 2008).  
Therefore, there is a need to develop alternative therapies. 
 
Fo-CHI is characterised by the presence of focal lesions that appear, histologically, as a 
small region of islet adenomatosis (hyperplastic islets) of a diameter measuring 2-10mm 
(Rahier et al., 2000, Sempoux et al., 2003).  Islets within focal lesions appear to have 
normal structure but display a higher level of β-cell proliferation compared to age-related 
control subjects (Sempoux et al., 2003).  Outside of focal lesions islets appear small with 
packed endocrine cells having scant cytoplasm (Sempoux et al., 2003).  Fo-CHI has a 
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sporadic and non-Mendelian mode of KATP channel dysfunction inheritance (Dunne et al., 
2004).  A loss of heterozygosity (LOH) for the maternal chromosome region 11p15, 
leading to the expression of paternally derived genes containing mutations in ABCC8 or 
KCNJ11, causes the focal lesion (de Lonlay et al., 1997).   The focal proliferation of β-
cells may be a result of the loss of other maternally expressed genes in the chromosome 
region 11p15.  CDKN1C (cyclin-dependent kinase inhibitor 1C), previously known as 
p57kip2, is linked with the regulation of cell proliferation and can lead to cell cycle arrest by 
the inhibition of G1 cyclin-dependent kinase complexes (Matsuoka et al., 1995).  Loss of 
CDKN1C from Fo-CHI lesions has been demonstrated in 48/48 patients (Suchi et al., 
2006).  LOH also results in an imbalanced expression of several other genes that may 
contribute to proliferation including, Pidd, a p53-induced protein that promotes apoptosis 
(Dunne et al., 2004). 
 
Di-CHI and Fo-CHI are not distinguishable by clinical features or classic radiology of the 
pancreas, such as MRI and CT scans (Giurgea et al., 2006a).  Techniques such as 
pancreatic venous sampling were used until recently to localise the site of insulin secretion 
and diagnose Di-CHI or Fo-CHI (Brunelle et al., 1989).  Venous blood samples would be 
collected from various areas of the pancreas in order to measure plasma insulin, glucose 
and C-peptide levels.  Fo-CHI would be defined as a patient with high plasma insulin and 
C-peptide levels in one or more samples and low levels in the remaining samples (Brunelle 
et al., 1989).  However, the recent introduction 18[F]-DOPA PET scanning has provided a 
non-invasive and accurate tool for diagnosing and localising Fo-CHI lesions (Giurgea et 
al., 2006a).  Positron emission tomography had previously been used extensively for the 
brain examination of patients with Parkinson’s disease (de Lonlay et al., 2006).  It was 
originally considered for use in CHI as β-cells had been shown to take up L-DOPA, and 
41 
 
that islet cells contain active DOPA decarboxylase, which is involved in the conversion of 
L-DOPA to dopamine (de Lonlay et al., 2006).  CHI patients are injected intravenously 
with the 18[F]-DOPA and islets containing DOPA decarboxylase take up 18[F]-DOPA.  
Focal lesions are defined by having a minimum standardised uptake value (SUV) 50% 
higher than the maximum value detected in presumably unaffected tissue (Otonkoski et al., 
2006).  This is effective as focal lesions have been shown to contain high levels of DOPA 
decarboxylase, which is diffusely present in focal lesion β-cells (de Lonlay et al., 2006).  
The same study verified that the level of DOPA decarboxylase is low in the healthy 
pancreas, and that this level does not differ in Di-CHI β-cells.  A recent study which 
examined 50 patients, reported a 100% accuracy for 18[F]-DOPA PET scans in the 
differentiation of Di-CHI and Fo-CHI (Hardy et al., 2007a). 
 
1.3.4  The Metabolopathies 
1.3.5  Glutamate dehydrogenase hyperinsulinism (GDH-HI) 
Activating mutations in the glutamate dehydrogenase (GDH) gene, GLUD1, are the second 
most common cause of CHI (James et al., 2009).  Post-prandial hypoglycaemia after a high 
protein meal and elevated serum ammonium levels are characteristic of GDH-HI patients 
and it is therefore also know as hyperinsulinism-hyperammonaemia syndrome (Palladino 
and Stanley, 2010).  Dominant mutations in GLUD1 have been described although most 
reported cases are sporadic (James et al., 2009).  Patients generally respond well to the 
KATP channel agonist diazoxide that controls the disease relatively well (Palladino and 
Stanley, 2010). 
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GDH is a mitochondrial matrix enzyme that catalyses the oxidative deamination of 
glutamate to α-ketoglutarate and ammonium (Fahien et al., 1988).  In pancreatic β-cells, α-
ketoglutarate enters the tricarboxylic acid cycle which consequently results in the 
production of ATP (Fahien et al., 1988).  GDH is considered to play a key role in 
glutaminolysis (the metabolism of the amino acid glutamine) which in turn is central to 
amino acid-stimulated insulin secretion (Kelly et al., 2002).  GDH activity is tightly 
regulated by the effectors leucine and GDP, and inhibited by elevated concentrations of 
GTP and ATP (Fahien et al., 1988).  Mutations in GLUD1 are thought to affect the GTP-
binding domain of the enzyme, thereby, reducing the inhibition of GDH by GTP.  This 
results in an increased rate of glutamate oxidative deamination in the presence of leucine 
and a consequent increase in ATP production (Kelly et al., 2002).  Interestingly, β-cells 
cultured in low glucose have been shown to produce significantly more urea than those 
cultured in high glucose (Webb et al., 2000).  This is considered to be an adaptation of the 
β-cell to utilise amino acids as an energy source in low glucose conditions.   
 
1.3.6  Glucokinase Hyperinsulinism (GK-HI) 
Glucokinase (GK) is commonly referred to as the ‘glucose-sensor’ as the release of insulin 
from β-cells tightly correlates with the activity of GK (Matschinsky, 2002).  GK controls 
the phosphorylation of glucose to glucose-6-phosphate, which is a rate-limiting step in the 
glycolytic pathway.  GK activity is not inhibited by the formation of glucose-6-phosphate, 
unlike the enzyme hexokinase, and therefore the rate of glucose phosphorylation in β-cells 
is directly related to the physiological concentrations of plasma glucose (Matschinsky, 
2002).  The Michaelis constant of GK for glucose is approximately 10mM, and it is this 
value that defines the range of glucose concentrations that are physiologically relevant to 
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GSIS (Meglasson and Matschinsky, 1986).  Hence, any changes in GK activity can have 
significant physiological consequences. 
 
Heterozygous inactivating mutations in the glucokinase gene are known to cause maturity-
onset diabetes of the young (MODY) whilst heterozygous inactivating mutations cause 
PNDM (Hussain, 2010). GK-HI is caused by activating mutations, which increase the 
affinity of GK for glucose and, therefore, lowers the glucose threshold for GSIS 
(Christesen et al., 2008).  To date, there is no evidence to suggest that there is an increase 
in GK expression in GK-HI (Christesen et al., 2008). 
 
GK-HI accounts for approximately 7% of CHI cases (Christesen et al., 2008).  The 
reported clinical symptoms of GK-HI range from asymptomatic to hypoglycaemic and 
seizures.  As KATP channel function remains intact, patients generally respond well to 
diazoxide treatment (Christesen et al., 2008). 
 
1.3.7  L-3-hydroxyacyl-co enzyme A dehydrogenase hyperinsulinism (HADH-HI) 
HADH encodes the enzyme L-3-hydroxyacyl-coenzyme A dehydrogenase (HADH, 
formerly referred to as SCHAD or short-chain-3-hydroxyacyl-coenzyme A 
dehydrogenase).  This enzyme is found in the mitochondria and catalyses the penultimate 
reaction in the β-oxidation of fatty acids.  The oxidation of fatty acids is an essential 
response to energy depletions (as a result of fasting, illness or increased physical activity) 
and results in the formation of acetyl-CoA, which can be fed directly into the TCA cycle 
(James et al., 2009).  When in excess, acetyl-CoA is converted into ketone bodies in the 
liver, which provide an essential energy source to the brain under starvation conditions 
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(Dunne et al., 2004).  Recent evidence from the β-cell line INS-1 suggests that β-cells are 
also capable of taking up and metabolising ketone bodies.  Acetoacetate and β-
hydroxybutyrate stimulate insulin release from INS-1 cells when combined with lactate or 
monomethyl succinate, but cannot stimulate insulin by themselves (MacDonald et al., 
2008).  It is thought that the ketone bodies are then converted to acetyl-CoA, and combined 
with oxaloacetate (supplied by methyl succinate) acts synergistically to increase 
mitochondrial citrate levels (MacDonald et al., 2008). 
 
HADH-HI is caused by loss of function mutations in HADHI and is inherited in an 
autosomal recessive manner.  Incidences of HADH-HI are rare, with only a few reported 
cases (Clayton et al., 2001, Molven et al., 2004, Hussain et al., 2005).  Clinical 
presentation ranges from severe neonatal hypoglycaemia to mild, late onset, interminttent 
hyperinsuliaemic hypoglycaemia.  The precise mechanism of how HADH mutations cause 
hyperinsulinism is not fully understood.  Suppression of HADH expression by RNA 
interference resulted in enhanced basal insulin secretion that was not sensitive to diazoxide 
indicating a KATP channel-independent mechanism (Hardy et al., 2007b).  Recent 
experiments in HADH KO mice revealed that HADH inhibits the activity of GDH via 
protein-protein interactions (Li et al., 2010).  Similar to GDH-HI patients, HADH KO mice 
were hypersensitive to leucine stimulated-insulin secretion.  It was suggested HADH 
deficiency causes hyperinsulinism by a loss of GDH inhibition by HADH leading to 
increased sensitivity of GDH to allosteric activation by leucine (Li et al., 2010).  This 
suggests that a subsequent increase in ATP production may bring about HI.  Further 
studies are required to clarify the exact nature of the underlying mechanism.   
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1.3.8  Exercise-induced Hyperinsulinism (EI-HI) 
Patients with EI-HI experience hyperinsulinaemic hypoglycaemia following periods of 
strenuous (anaerobic) exercise.  A pyruvate load test in healthy individuals did not elicit an 
insulin response.  However, EI-HI patients show a sharp increase in plasma insulin 
following a pyruvate load test (Otonkoski et al., 2003).  The inability of pyruvate to mimic 
the effect of glucose on insulin secretion is due to low levels of monocarboxylate 
transporters.  These transporters mediate the movement of monocarboxylates, such as 
pyruvate and lactate, across plasma membranes.  Activating mutations have been described 
in the promoter region of SLC16A1, which encodes the monocarboxylate transporter 1 
(MCT1), resulting in the expression of MCT1 in pancreatic β-cells (Otonkoski et al., 
2003).  This would allow the transport of pyruvate (and lactate) (generated during exercise) 
into the β-cell.  Transport of pyruvate into the mitochondria would then result in an 
increase in TCA cycle activity, and subsequently, insulin secretion.  Lactate generated 
during exercise may also be transported into the β-cell and converted by lactate 
dehydrogenase to pyruvate, although this would also require increased expression of 
lactate dehydrogenase (Otokoski et al., 2003).      
 
Mutations in SLC16A1 are inherited in an autosomal dominant manner.  The severity of the 
disease varies with some patients experiencing very few symptoms (as aerobic exercise is 
well tolerated), and others experiencing severe and recurrent hypoglycaemic episodes 
(Otonkoski et al., 2003).   Diazoxide therapy can relieve symptoms but does not 
completely prevent hypoglycaemic episodes (Otonkoski et al., 2003). 
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1.3.9  HNF4α mutations and hyperinsulinism 
HNF4α (Hepatocyte nuclear factor 4 α) is a transcription factor belonging to the nuclear 
hormone receptor superfamily and is expressed in pancreatic β-cells where it regulates the 
expression of several key genes involved in GSIS such as insulin, GLUT2 and 
mitochondrial uncoupling protein-2 (Wang et al., 2000).  Heterozygote mutations in 
HNF4α, inherited in an autosomal dominant manner, are known to cause maturity-onset 
diabetes of the young subtype1 (MODY1) (Yamagata et al., 1996).  MODY1 patients have 
normal insulin sensitivity but display impaired GSIS. 
 
Heterozygous mutations in HNF4α are also known to cause both transient and permanent 
hyperinsulinaemic hypoglycaemia (Pearson et al., 2007).  A recent study that examined 
220 CHI patients (who were responsive to diazoxide therapy) found that mutations in 
HNF4α were the third most common cause of CHI (5%) after KATP channel mutations 
(15%) and GLUD1 mutations (5.9%) (Flanagan et al., 2010).  Seven of the eleven patients 
with HNF4α mutations did not have a parent affected with diabetes (Flanagan et al., 2010).  
In the same study, an underlying genetic cause for CHI could be confirmed for only 27% 
of patients. 
 
1.3.10  CHI therapeutic management 
Diazoxide is the first option in the treatment of CHI.  It is a potent inhibitor of insulin 
secretion that can be administered orally.  Patients with CHI as a result of metabolopathies 
generally respond well to diazoxide therapy (Dunne et al., 2004).  The responsiveness of 
patients with CHI as a result of channelopathies varies greatly and there is no clear link 
between KATP channel mutation and efficacy (Touati et al., 1998).  Successful management 
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of CHI has been reported to be as low as 15% and as high as 60% (Aynsley-Green et al., 
2000).  Diazoxide therapy can cause serious side effects including congestive heart failure, 
vomiting, sodium and water retention and is associated with decreased immunoglobulin G 
levels leading to problems with infection (Dunne et al., 2004).   
 
Octreotide is a somatostatin analogue and represents the second-line therapy for CHI.  It is 
a potent inhibitor of insulin secretion that causes its effect by a variety of mechanisms.  
Somatostatin causes hyperpolarisation of the β-cell membrane by modulating the activity 
of KATP channels, G-protein-regulated inward rectifier potassium channels and inhibits 
glucose metabolism in a Ca2+-dependent manner (Daunt et al., 2006).  Inhibition of insulin 
secretion is achieved also by lowering the concentration of cytoplasmic cAMP and direct 
interaction with the β-cell exocytotic machinery (Renström et al., 1996).  A recent study 
claimed that hypoglycaemia, as a result of hyperinsulinism, was successfully treated with 
octreotide in 14/21 patients (Vezzosi et al., 2008).  Octreotide is often used in conjunction 
with diazoxide to prevent the need for a subtotal pancreatectomy (Arnoux et al., 2010).  
The expression of somatostatin receptors in a wide variety of tissues causes several side 
effects with long-term somatostatin therapy.  Inhibition of several hormones, including 
growth hormone, thyroid stimulating hormone and serotonin, contributes to side effects 
that include growth suppression, nausea and abdominal distension (Dunne et al., 2004). 
As the entry of Ca2+ is central to the stimulation of insulin secretion, VDCC blockers such 
as nifedipine have been used in the therapy of CHI (Bas et al., 1999, Müller et al., 2004).  
The efficacy of nifedipine is highly variable in the treatment of CHI and considered to be 
ineffective in the majority of patients (Kapoor et al., 2009).  Nifedipine can be 
administered orally and has had relatively few side effects however, hypotension can occur 
as nifedipine is also used successfully to treat hypertension (Snider et al., 2008). 
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Glucagon delivered intravenously or subcutaneously, can be used to treat periods of 
hypoglycaemia (Aynsley-Green et al., 2000).  Glucagon helps to stabilise glycaemia by 
increasing the rates of glycogenolysis and gluconeogenesis.  However, as glucagon can 
also act to stimulate insulin release, its administration is generally reserved for the short-
term acute stabilisation of patients (Aynsley-Green et al., 2000). 
 
1.3.11  CHI Prognosis 
With the exception of transient neonatal hyperinsulinism, CHI patients who respond to 
medical therapy remain drug dependent for many years.  Patients who show a positive 
response to diazoxide and/or octreotide have been known to have complete remission.  
This can occur in several months for Fo-CHI patients and several years for Di-CHI patients 
(Arnoux et al., 2010).  The removal of lesions from Fo-CHI patients will often result in a 
complete cure.  A subtotal pancreatectomy in Di-CHI patients is often accompanied by 
exocrine insufficiency and diabetes mellitus (Figure 1.6) (Arnoux et al., 2010).  Recent 
evidence from long-term follow-up studies suggests that glucose intolerance and insulin-
dependent diabetes also occur in non-pancreatectomised patients (Gussinyer et al., 2008).  
 
1.3.12  Future research 
Despite the advances in CHI research, 50% of CHI cases have no known genetic cause and 
in some populations, mutations in the known genes account for only 20% of cases (James 
et al., 2009).  The complications associated with a subtotal pancreatectomy and side-
effects associated with common medical therapy warrant further research to find 
alternative sources of therapy.  Therefore, further investigation is likely to identify novel 
genetic aetiologies, insights into β-cell physiology and CHI pathology, and potentially 
49 
 
provide new therapeutic options.  The unregulated entry of Ca2+ into the β-cell resulting in 
inappropriate insulin secretion, as a result of KATP channel mutation, is responsible for the 
majority of, and the most severe, cases of CHI (Dunne et al., 2004).  The study of novel 
ion channels and their function in CHI β-cells may provide new ways to push the resting 
potential of the CHI β-cell away from the threshold for VDCC activity and, therefore, 
eliminate inappropriate insulin secretion. 
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Figure 1.6. Summary of the practical management of CHI.  Green arrows indicate a positive response and 
red arrows a negative response.  Figure adapted from Arnoux et al., 2010. 
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1.4  Potassium channels 
The idea of selective potassium (K+) permeability in the membrane of excitable cells was 
originally conceived by Julius Bernstein in 1902 (Hille, 1992).  A K+ current was later 
described by Hodgkin and Huxley as part of the action potential mechanism in squid giant 
axons (Hodgkin and Huxley, 1952).  The development and refinement of the patch-clamp 
technique revolutionised the study of single channels in the cell membrane (Neher and 
Sakmann, 1976, Hammill et al., 1981, Latorre and Miller, 1983).  Potassium currents show 
remarkable diversity and vary widely in their kinetics, voltage-dependence, pharmacology 
and single-channel conductance (Rudy, 1988).  In general, K+ channels tend to dominate 
cell conductance and are largely responsible for the maintenance of the negative membrane 
potential (Hille, 1992).  
 
Potassium channels have been found in cellular membranes throughout the plant and 
animal kingdoms.  Indeed, all fully sequenced genomes contain at least one K+ channel 
(Miller, 2000).  The ubiquity of K+ channels is reflected in the wide range of fundamental 
cell properties they are central to, including cell growth, volume regulation and membrane 
excitability. 
 
Mammalian K+ channels can be divided into three groups based upon membrane topology 
(Figure 1.7).  The first group is the voltage-gated and Ca2+-activated K+ channels (Kv), 
consisting of 6 transmembrane domain (TMD) proteins.  These channels are activated by 
depolarisation, allowing the efflux of K+, and repolarise the membrane potential after an 
action potential.  The second group is the inward rectifier (Kir) K+ channels, consisting of 
2TMD proteins.  These channels allow the entry of K+ into the cell when the 
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electrochemical gradient is favourable.  This helps to stabilise the membrane potential.  
The third group is known as the two-pore domain K+ channels (K2P) or ‘leak’ K+ 
channels, and consist of 4TMD proteins.  The prevailing electrochemical K+ gradient 
across the membrane determines current flow in these channels, and is independent of 
voltage (O’Connell et al., 2002).  Every K+ channel shares a signature sequence of amino 
acids that is present within the pore (P) domain.  The sequence is TXXTXGYG and this is 
what gives K+ channels the ability to discriminate between K+ and other cations 
(Heginbotham et al., 1994).  Kir and Kv channels both possess only one P domain, 
whereas K2P channels possess two such domains (Miller, 2000, O’Connell et al., 2002).  
 
 
 
 
Figure 1.7.  Predicted Secondary structure of major K+ channel families.  M represents 
the transmembrane domains, P represents pore regions (O’Connell et al., 2002). 
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1.5  K2P channels 
The first K2P channel to be discovered was TOK-1, found in Saccharomyces cerevisiae by 
using the peptide sequence of the P domain and searching gene databases (Ketchum et al., 
1995).  TOK-1 was unique as it contained 8 TMDs instead of 4, which are commonly 
found in K2P channels.  Consequently, other functional channels were cloned from 
Drosophila melanogaster, Caenorhabditis elegans, and mammals.      
 
To date, there are 15 known human K2P channels (Figure 1.8) (Goldstein et al., 2005).  
The identification of distinct K2P channels is difficult as there are currently no specific 
inhibitors of any K2P channel.  The presence of other conducting K+ channels in a cell 
complicates the identification process.  Hence, the most effective way to identify K2P 
channels is from their single-channel conductance and gating kinetics (Kang and Kim, 
2004).  
 
 
  Figure 1.8.  Unrooted dendrogram displaying K2P channels and their general properties.  
Missing from this Dendrogram is the K2P channel, TRESK (also known as TRESK-2, KCNK18 
and TRIK) (Lesage, 2003). 
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1.5.1  K2P channels as dimers 
Evidence from X-ray crystallography on the Kir channel, KcsA, showed it to be a 
multimeric channel, composed of four identical subunits, organised around a central pore 
(Doyle et al., 1998).  It is now thought that all functional K+ channels form either 
homomeric or heteromeric channels with four P domains (O’Connell et al., 2002).  Hence, 
K2P channels would form dimers and Kv and Kir channels would form tetramers.  
Experimental evidence from K2P channels supports this.  For example, the mutation of a 
cysteine 69 on the extracellular loop between M1 and P1 of TWIK-1 abolished its current.  
Cysteine 69 is likely to form a disulphide bridge between subunits, stabilising the channel.  
Mutation of cysteine 69 is thought to have prevented (homo)dimerisation and therefore 
channel function (Lesage et al., 1996b).  This mechanism is not the case for all K2P 
channels as not all have a cysteine residue at position 69, such as TASK-1.  However, 
evidence from TASK-1 and TASK-3 constructs also reveals evidence for dimerisation, and 
in particular heterodimerisation.  A construct of TASK-1 and TASK-3 displayed properties 
that are intermediate between the two channels, suggesting the formation of heterodimers 
(Czirjak and Enyedi, 2002). 
 
1.5.2  General features of K2P channels 
Each subset of K2P channels exhibits expression patterns (Figure 1.9) and pharmacological 
properties specific to those channels.  However, K2P channels also share common 
functional features.  All functional K2P channels have been classified as background 
channels as they are generally active across the physiological range of membrane 
potentials.  This reflects their proposed role of setting the resting membrane potential in 
both excitable and non-excitable cells (Lesage and Lazdunski, 2000).  Pharmacological 
properties vary but most K2P channels are insensitive to traditional K+ channel blockers 
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such as TEA+, Ba2+ and Cs+.  K2P channels are also generally sensitive to anaesthetics and 
show varying sensitivity to both inhalation- and local-anaesthetics (e.g.  isoflurane and 
bupivicaine, respectively ) (O’Connell et al., 2002).   
 
 
                    
 
 
 
 
1.5.3  The weak inward rectifiers TWIK-1 and TWIK-2 
The Two pore domain Weak Inward rectifying K+ channel (TWIK-1 ) represents the first 
mammalian K2P channel to be identified and subsequently cloned (Lesage et al., 1996a)  
Human TWIK-1 is widely expressed but shows particularly high expression in the brain 
and heart.  The only tissue that TWIK-1 appears to be absent from is skeletal muscle.  With 
relevance to this study, TWIK-1 shows good expression in the pancreas.  In particular, 
Figure 1.9.  The expression patterns of K2P channels in human tissue.  Samples analysed using 
Southern Blot (Lesage and Lazdunski, 2000). 
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TWIK-1 type currents have been recorded in rat exocrine pancreatic acinar cells (Schmid 
et al., 1997).  When expressed in X.laevis oocytes TWIK-1 currents are time-independent 
and display kinetic behaviour that is dependent upon the membrane potential.  Also inward 
rectification is abolished in the presence of magnesium (Mg2+) and TWIK-1 currents 
display a near-linear current-voltage (IV) relationship, which saturates at depolarisations 
positive to 0mV in the presence of internal Mg2+ (Lesage et al., 1996a).  TWIK-1 current is 
indirectly enhanced following PKC activation and inhibited by intracellular acidification 
but is not sensitive to changes in extracellular pH or PKA activation (Lesage et al., 1996a, 
Lesage and Lazdunski, 2000). 
 
TWIK-2, like TWIK-1, exhibits weak inward K+ rectification in symmetrical K+ solutions 
and an outward rectification in a physiological K+ gradient (Patel et al., 2000).  Human 
TWIK-2 is expressed at high levels in the gastrointestinal tract, the pancreas and the 
vasculature.  However, unlike TWIK-1, TWIK-2 is absent in the brain but shows 
expression in the thymus.  Cloned human and rat TWIK-2 channels expressed in COS cells 
produce currents that are inactivating at depolarised potentials (Patel et al., 2000).  This 
suggests that TWIK-2 is involved in the setting of the resting membrane potential and may 
influence both early and late stages of action potential repolarisation.  Neither TWIK-1 nor 
TWIK-2 have been characterised in the islets of Langerhans. 
 
KCNK7 is related to TWIK-1 and shares a 42% amino acid identity.  However, KCNK7 
cannot form a functional channel by itself and is retained in the endoplasmic reticulum 
(Salinas et al., 1999).  KCNK7 therefore may require additional subunits, chaperones or 
modulator substances to form a functional channel. 
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1.5.4  TASK channels (TWIK related acid-sensitive channels) 
Human TASK channels are expressed widely throughout the body, but do show a more 
restricted expression pattern than TWIK channels.  Three functional TASK channels exist, 
TASK 1, 2, 3 (TASK4 was renamed TALK-2), and one non-functional (TASK-5).  TASK-
2 is often grouped with TALK channels as it is activated by more alkaline pH.  TASK 
channels are characterised by their sensitivity to extracellular pH (Figure 1.10).  A 
conserved sequence in the first P domain of TASK channels is thought to account for their 
sensitivity to pH.  In particular, this depends on the Histidine 98 residue as mutation of this 
residue to asparagine or tyrosine abolishes the pH sensitivity of TASK-3 (Rajan et al., 
2000). 
 
 
 
 
The data in Figure 1.10 suggests that only TASK-1 and TASK-2 would be regulated by pH 
under normal physiological conditions.  However, the activity of these channels will be 
dependent on where they are expressed.  For example, under most conditions TASK-3 
would remain permanently open; however, TASK-3 is expressed in the stomach, amongst 
Figure 1.10.  pH response curves for functional TASK channels.  The shaded area represents the normal pH 
range of extracellular fluid.  KD denotes the dissociation constant that describes half-maximal block of the 
channels (O’Connell et al., 2002). 
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other places, where pH in the lumen is approximately 4.5.  Defining the role of TASK 
channels in relation to pH sensitivity is further complicated as TASK channels can form 
heterodimers, which may affect their pH sensitivity and their activity in certain tissues 
(Czirjak and Enyedi, 2002). 
 
The publication of the Kv1.2 channel structure has led to the development of a TASK-2 
molecular model (Niemeyer et al., 2007).  Molecular simulation based on this model, site 
directed mutagenesis and whole-cell patch clamp techniques have led to the identification 
of a single residue, R224, that is believed to gate the channel (Niemeyer et al., 2007).    
Neutralisation of R224 by mutation (to alanine or glutamine) abolished the pH dependence 
of TASK-2, whereas replacement of R224 with other basic amino acids caused a shift in 
pH sensitivity.  Hence, R224 is proposed to act as the pH sensor for TASK-2.  The same 
study also generated a molecular model of TALK-2.  In this model, K242 occupies the 
equivalent position of R224 and is thought to play a similar role suggesting that this gating 
mechanism is consistent with all alkaline-activated K2P channels. 
 
Human TASK-5 is expressed mainly in the brain, as well as the pancreas, liver, kidney, 
heart, lung, testis and ovaries.  Yet TASK-5 does not form functional channels when 
expressed in X. laevis oocytes, nor does it form functional heterodimers with TASK-1 
(Ashmole et al., 2001). 
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1.5.5  THIK-1 and THIK-2 
The Tandem pore domain Halothane-Inhibited K+ channel (THIK-1) and THIK-2 are 
inhibited by halothane.  Only THIK-1 forms a functional channel when expressed in X. 
laevis oocytes.  In symmetrical K+, THIK-1 displays a weak inward-rectifying current 
(Rajan et al., 2001).  THIK-1 is expressed ubiquitously with a more restricted expression 
pattern in the brain compared to THIK-2, and THIK-2 is expressed in several tissues 
including the brain and kidney.  Available evidence suggests that THIK-1 and THIK-2 do 
not form heterodimers (Rajan et al., 2001).  THIK expression in the islets of Langerhans 
has not been explored. 
 
1.5.6  TREK-1, TREK-2 and TRAAK  
The Human TWIK-Related Arachidonic Acid-stimulated K+ channel (TRAAK) is almost 
only expressed in the nervous system (Medhurst et al., 2001).  Expression of TRAAK in 
COS cells and X. laevis oocytes produces spontaneous currents that are voltage-
independent and non-inactivating.  Similar experiments demonstrated that arachidonic acid 
(AA), and other polyunsaturated fatty acids (PUFAs), but not saturated fatty acids, 
stimulate TRAAK activity (Fink et al., 1998).  TRAAK is also activated by membrane 
stretch.  Membrane depolarisation has been found to act synergistically with membrane 
stretch (Maingret et al., 1999a). 
 
Human TREK-1 (TWIK-related K+ channel) is highly expressed in the brain, spinal cord, 
stomach and, to a lesser extent, the small intestine.  In the central nervous system (CNS) 
TREK-1 is localised in GABA-containing interneurons and hippocampal glutamate-
containing neurons (Medhurst et al., 2001).  In symmetric K+ solutions TREK-1 exhibits 
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an outward rectification current.  TREK-1 activity is enhanced by the increase of 
mechanical pressure to the cell membrane.  At the whole cell level, this reflects that 
TREK-1 is modulated by cellular volume, therefore, hyperosmolarity causes TREK-1 to 
close (Franks and Honore, 2004).  TREK-1 activity is also enhanced by intracellular 
acidosis and heat.  A 10oC increase results in a sevenfold increase in TREK-1 activity and 
acidosis turns TREK-1 into a constitutively open channel (Franks and Honore, 2004).  
Deletional analysis has revealed that the sites that determine TREK-1 sensitivity to 
membrane stretch, temperature and internal acidosis are located in the C-terminal and not 
the N-terminal (Maingret et al., 1999b). 
  
TREK-1 is opened by volatile and non-volatile anaesthetics including chloroform, diethyl, 
halothane and isoflurane.  Opening TREK-1 in this way induces cell hyperpolarisation.  
TREK-1 KO mice have recently provided direct evidence for a role for TREK-1 in 
anaesthesia.  These mice showed a significant decrease in their sensitivity to chloroform, 
halothane and desflurane (Heurteaux et al., 2004).  TREK-1 KO mice exhibited no 
abnormal phenotypes, and expression of other K2P channel mRNAs was not altered.  It 
was therefore proposed that in this model of anaesthesia, neuronal excitability is depressed 
by the opening of background K+ channels (Heurteaux et al., 2004).  This contributes to, or 
is the cause of, general anaesthesia.  Anaesthetics also activate other members of the K2P 
channel family such as TASK-1, TASK-2 and TASK-3.  However, their sensitivity to 
different agents varies. 
 
TREK-1 may also play a key role in neuroprotection.  PUFAs are known to protect against 
epilepsy and spinal cord ischaemia.  PUFAs, including AA, activate TREK-1, but saturated 
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fatty acids do not.  Neuroprotection that is usually impressive in mice with TREK-1 is 
abolished in TREK KO mice (Heurteaux et al., 2004).  
 
TREK-2 was initially cloned from a rat cerebellum cDNA library (Bang et al., 2000).  It is 
expressed widely in the CNS, and is also found in the kidney, stomach, testis and pancreas 
(Medhurst et al., 2001).  TREK-2 is activated by membrane stretch, acidic pH, PUFAs and 
AA (Bang et al., 2000).   
 
A recent study showed that TREK-2 is expressed in MIN6 cells (Kang et al., 2004).  Of the 
nine K2P channels tested only TREK-2, TASK-1, TASK-2, TASK-3, and TRESK-2 were 
expressed in the MIN6 cells.  TALK-1 and TALK-2 were not detected.  As TREK-2 is 
activated by PUFAs, low intracellular pH and cell swelling, it was proposed that TREK-2 
may regulate insulin release during metabolically- stressed conditions (Kang et al., 2004).  
The expression of and contribution to the resting potential of TREK-2 in β-cells is 
unknown.   
 
1.5.7  TALK-1 and TALK-2 
The TWIK-related alkaline pH-activated K+ channel (TALK-1) and TALK-2 channels 
were identified in 2001 by searching for K2P homologues in DNA databases (Girard et al., 
2001).  This study showed that human TALK-1 is expressed exclusively in the pancreas, 
whereas TALK-2 is expressed in the pancreas and several other tissues.  However, a more 
recent study has shown that TALK-1 is also expressed in rat taste receptor cells of the 
tongue (Lin et al., 2004).  In this study, TALK-1 was expressed to a significantly lesser 
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extent than TASK-2 which is also activated by alkaline pH and, therefore, TALK-1 may 
have a primary role in the pancreas rather than the tongue.   
 
Expression of TALK-1 and TALK-2 in X. laevis oocytes has shown that both channels are 
open at all membrane potentials and are likely to be involved in the setting of the resting 
membrane potential (Girard et al., 2001).  Hence, both TALK channels display the 
characteristics of ‘leak’ channels.  In physiological K+ solutions TALK-1 current is 
outwardly-rectifying, whereas in symmetrical K+ solutions, the current is linear.  
Expression of TALK channels in COS cells reveals that alkalinisation of the external 
solution increases channel activity (Girard et al., 2001).  Modification of internal pH did 
not modify TALK currents and it is interesting to note that modulating the activity of PKA 
and PKC did not affect TALK currents.  Coexpression with the GPCRs (G protein-coupled 
receptors) 5-HT2 and α2a (adrenoceptors) and appropriate activation agents also did not 
affect TALK channel activity (Girard et al., 2001). 
 
Four splice variants of TALK-1 from the human pancreas have recently been identified 
(Han et al., 2003).  TALK-1a (referred to previously as TALK-1) and TALK-1b both 
contain all four transmembrane domains, whereas TALK-1c and TALK-1d do not contain 
the fourth, due to the deletion of exon five.  TALK-1a is the only splice variant to contain 
six exons, as TALK-1b lacks exon six.  Expression of the four splice variants in the human 
pancreas was confirmed using RT-PCR.  However, only TALK-1a and TALK-1b formed 
functional channels when expressed in COS-7 cells.  The same study was the first to define 
the single channel properties of both TALK-1a and TALK-1b.  This is important, as 
identifying TALK channels, and other K2P channels, is difficult as no specific channel 
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blockers exist.  The single channel conductance of TALK-1a has been confirmed by a 
separate study (Kang and Kim, 2004).  No TALK-2 splice variants have been found.    
 
TALK channels are sensitive to changes in extracellular pH.  Expression of TALK-2 in 
COS-7 cells revealed that TALK-2 is sensitive mainly to the alkaline range pH 7-10, 
whereas TALK-1 (and TASK-2) is sensitive to a wider range of pH 6-10 (Kang and Kim, 
2004).  The increased activity of these channels at more alkaline pH is due predominantly 
to an increase in the opening frequency with only minor changes in single channel 
conductance.   
 
Evidence exists to suggest that human TALK-1 and TALK-2 are expressed exclusively in 
the exocrine pancreas and are absent in the islets of Langerhans (Duprat et al., 2005).  
However, evidence from our own laboratory shows that TALK channels are present in 
rodent islets (unpublished data, Weston, Smith, Dunne, 2009).  Therefore, it is important 
that these results are clarified. 
 
1.6  Hyperpolarisation-activated cyclic nucleotide-modulated (HCN) channels 
HCN channels also belong to the superfamily of Kv channels, and are activated by the 
binding of cyclic nucleotides.  Following their initial discovery over 30 years ago (Noma 
and Irisawa, 1976), HCN channels were referred to as ‘queer’ or ‘funny’ channels as they 
are activated by hyperpolarisating voltage steps negative to -60mV (Robinson and 
Siegelbaum, 2003).  Under physiological conditions, HCN channels show a weak 
selectivity for Na+ and K+.  Recent evidence shows that HCN channels also conduct Ca2+ 
at physiological extracellular concentrations (Michels et al., 2008).  Four HCN subunits 
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are known to exist to date, HCN1-HCN4.  The majority of native HCN subunits form 
heteromeric tetramers with a central pore.  However, in heterologous expression systems 
the subunits can form homomeric channels (Craven and Zagotta, 2006). 
 
HCN channels have a central role in the regulation of neuronal and cardiac firing rates 
(Altomare et al., 2003).  The sinoatrial node, which sets the pace for action potential firing 
in the heart, expresses HCN channels along with other ion channels.  These channels 
together produce the spontaneous rhythmic firing of cardiac action potentials.  After a 
cardiac action potential, HCN channels are activated by a brief period of hyperpolarisation.  
HCN channels conduct an inward current that depolarises the cell sufficiently to activate 
VDCCs.  This results in the firing of another cardiac action potential (Altomare et al., 
2003).  The intracellular binding of Mg2+ in the HCN selectivity filter is thought to allow 
inwardly rectifying currents as well as preventing any unwanted outward currents at 
depolarised currents (Vemana et al., 2008).  An accelerated heart rate is achieved by the 
elevation of cAMP levels via the binding of neurotransmitters such as noradrenaline 
(Craven and Zagotta, 2006).  HCN channels are then activated and hence contribute by an 
increased rate of channel opening and maximal current.  In the mouse heart, HCN2 and 
HCN4 are thought to be the subunits involved in cardiac firing rates, whereas in the rabbit 
HCN1 and HCN4 are considered responsible (Altomare et al., 2003).  HCN channels 
operate via a similar mechanism in the nervous system.  They may also have a role in 
maintaining the resting potential and membrane resistance (Craven and Zagotta, 2006). 
 
Previous attempts to detect HCN channels in the pancreas had been unsuccessful because 
endocrine tissue was not isolated.  Since this study began, one laboratory has confirmed the 
expression of HCN1-HCN4 in MIN6 cells and rat islets (El-Kholy et al., 2006).  
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Quantitative PCR (QPCR) revealed HCN2 to be the most predominant HCN isoform in 
MIN6 cells, whereas HCN3 and HCN4 were the most predominant in rat islets.  The 
expression levels of the HCN channels in rat islets were comparable to HCN expression in 
the rat brain and heart, where the functional significance of the channels is well 
established.  In MIN6 cells, the level of HCN channels expression exceeded that of Kir6.2 
expression but GSIS was not affected following HCN channel inhibition.  The HCN 
current (Ih) current was observed in isolated pancreatic β-cells.  More recent experiments 
by the same laboratory concluded that HCN channel function in pancreatic β-cells is most 
likely to be significant in hypokalaemic conditions (Zhang et al., 2009).  This appears to be 
contrary to other reports that show Ih to significantly decrease in magnitude in response 
low extracellular K+ levels (DiFrancesco, 1986). 
 
1.6.1  HCN structure 
HCN channels contain six TMD, one P domain, and intracellular N- and C-termini.  S4 
contains several positively-charged amino acids and functions as a voltage sensor in HCN 
channels (Figure 1.11).  In the C-terminus is the cyclic nucleotide binding domain 
(CNBD).  This is connected to S6 and the pore by the C-linker.  Binding of a ligand to the 
CNBD may result in a conformational change in the CNBD.  This change may then be 
conferred to the pore due to movement through the C-linker, hence controlling the 
permeability of the channel (Craven and Zagotta, 2006).  
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HCN and Kv channels all contain positively charged amino acid residues in their S4 
domain yet differ in their voltage dependence.  Kv channels are activated by depolarisation 
whereas HCN channels are activated by hyperpolarisation.  It has been proposed that the 
difference between theses channels is due to the way the channels are coupled to in order 
to open (Bell et al., 2004).   
 
1.7  K2P channels and HCN channels - a counterbalancing act? 
Both HCN and K2P channels are thought to contribute to the setting and maintenance of 
the resting membrane potential.  This is generally assumed because both families represent 
channels that are active below the action potential firing threshold.  A recent study 
suggests that the counterbalancing of HCN2 and TASK-3 is essential in the setting of the 
Figure 1.11.  HCN channel membrane topology.  CNBD denotes the cyclic nucleotide binding 
domain (cGMP is shown bound), and the C-linker domain connects the pore to the CNBD 
(Craven and Zagotta, 2006). 
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resting membrane potential in thalamocortical relay (TC) neurons (Meuth et al., 2006).  TC 
neurons were used as they display two distinct types of activity; at hyperpolarised 
potentials they display rhythmic burst firing, and at depolarised potentials they display 
tonic single-spike activity.  Only by blocking the activity of both TASK-3 channels (by 
acidification) and HCN2 channels (using knockout mice) resulted in a shift from rhythmic 
burst firing to tonic single-spike activity (Meuth et al., 2006).  The contribution of these 
channels in other cell types has not been investigated.   
 
1.8  Thesis aims 
The central importance of ions in the control of cellular excitability has been well 
appreciated for more than a century (Rorsman, 1997).  In the pancreatic β-cell, the link 
between glucose metabolism and ion channel activity is well established and central to 
glucose homeostasis.  Of particular relevance is the role of K+ ions whose movement 
through KATP channels is responsible for maintaining the β-cell resting potential and 
generating the trigger for the Ca2+ influx and the consequential secretion of insulin.  This is 
emphasised by the fact that mutations in KATP channels can cause either hyperglycaemic or 
hypoglycaemic disease conditions. 
 
K2P and HCN channels represent two K+ channels whose expression and role in the 
pancreatic β-cell is largely undefined.  Both channels are considered to be important in 
maintaining the resting membrane potential of the cells in which they are expressed.  In 
disease conditions where K+ channel function is compromised, such as CHI, modulation of 
other K+ channels may present new therapeutic applications by exerting some control over 
cellular excitability.  Indeed, CHI represents a disease that has as many as 50% of cases 
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with no known genetic cause.  Of the known causes, defects in K+ channels resulting in 
stimulus-secretion defects underlie the most severe and the overall majority of cases.      
 
The primary aim of the thesis was, therefore, to characterise the expression of the K2P and 
HCN ion channel families in the healthy endocrine pancreas and the hyperinsulinaemic 
pancreas.  A secondary aim of the thesis was to evaluate the function of these channels in 
relation to stimulus-secretion coupling in the β-cell and, therefore, provide new insights 
into β-cell physiology, pathophysiology and the potential of future therapeutic application. 
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2.  Materials and Methods 
 
2.1.1  RNA extraction from tissues 
All isolated tissues (mouse and human) were dissected into small fragments and 
immediately submerged in RNAlater (Ambion, UK).  Total RNA was extracted using the 
RNeasy Micro Kit (Qiagen, UK) following the manufacturer’s instructions.  Briefly, 3mg 
of each tissue sample was added to RLT lysis buffer containing 1% β-mercaptoethanol 
(Sigma, UK) and homogenised using a tissue tearor (Biospec, USA).  In order to ensure 
complete homogenisation, all samples were also passed through a QIAshredder spin 
column (Qiagen, UK) in a 2ml collection tube by centrifugation at 11,000g (Eppendorf 
Minispin Plus, UK).  The lysate was then centrifuged for 3 minutes at 11,000g and the 
supernatant removed for use in subsequent steps.  One volume of 70% ethanol (Sigma, 
UK) was added to the lysate and mixed by pipetting.  The sample was transferred to an 
RNeasy MinElute spin column in a 2ml collection tube and centrifuged for 15 seconds at 
8000g.  At this point the RNA is bound to the silica membrane within the column.  The 
flow-through was discarded and Buffer RW1 was added to the column and centrifuged at 
8000g for 15 seconds.  On-column DNA digestion was then performed to ensure that no 
DNA was carried through.  DNase 1 stock solution was diluted in Buffer RDD, mixed by 
pippetting and added directly to the membrane of the spin column.  The spin column was 
subsequently left at room temperature for 30 minutes to ensure complete DNA digestion.  
Buffer RW1 was added and centrifuged at 8000g for 15 seconds to wash the spin column, 
and the flow-through discarded.  The RNeasy MinElute spin column was transferred to a 
new 2ml collection tube, Buffer RPE (containing ethanol) was added and centrifuged at 
8000g for 15 seconds.  The flow-through was discarded.  80% ethanol was added to the 
spin column and centrifuged for 2 minutes at 8000g.  The flow-through and collection tube 
were discarded and the spin column placed in a new 2ml collection tube.  The spin column 
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was then centrifuged at 11,000g for 5 minutes with the collection tube lid open in order to 
ensure the silica membrane was dry and no residual ethanol remained.  The spin column 
was placed in a 1.5ml collection tube, RNase-free water was added directly to the silica 
membrane, and centrifuged at 11,000g for 1 minute in order to elute the RNA. 
 
2.1.2  RNA extraction from cell lines and pancreatic islets 
When 60% confluent, NES2Y and MIN6 cell lines were collected using trypsin (as 
described in Section 2.3.1).  Following collection, the cell pellets were resuspended in 1X 
PBS (Invitrogen, UK) and centrifuged at 800g for 5 minutes (Sigma 3-16, SciQuip, UK).  
Pancreatic islets, both mouse and human, were isolated as described in Section 2.3.3.   
Approximately 100 islets were handpicked and added to a 2ml collection tube containing 
KRH 0.1% BSA 3mM glucose.  The supernatant was removed in both cases and total RNA 
extracted using the RNeasy Mini kit (Qiagen, UK) according to the manufacturer’s 
instructions.  The protocol was identical to that for RNA extraction from animal tissues 
(Section 2.1.1) with the exception that 80% ethanol was not added to the spin column prior 
to RNA elution.       
 
2.1.3  Assessment of RNA integrity 
The integrity of all RNA samples was assessed to determine the suitability of the samples 
for subsequent experiments.  RNA was analysed using the Agilent 2100 bioanalyser with 
the RNA 6000 Nano LabChip kit (Agilent Technologies, South Queensway, UK) and was 
performed by the Microarray Facility, University of Manchester, UK.  A representative 
trace of RNA analysis is presented in figure 2.1.  RNA was detected by the Agilent 
bioanalyser by laser-induced fluorescence.  The LabChip contained a number of channels 
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that were made up of a gel and dye mix.  RNA samples were loaded into wells within the 
LabChip and then analysed.  During analysis, RNA passed electrophoretically into the 
channels and was separated on the basis of size.  The Agilent bioanalyser represents an 
improvement in the evaluation of RNA integrity as it allows more components of the total 
RNA to be visualised.  Previously, the estimated ratio of 28S to 18S ribosomal components 
(as seen when RNA is subjected to electrophoresis) was used to evaluate RNA integrity 
(Sambrook and Russell, 2001).  This could be misleading as certain artifacts could not be 
distinguished, such as ‘hidden breaks’ that can occur in the 28S subunit producing two 
molecules of similar size that cannot be distinguished from the 18S subunit (Miller et al., 
2004).  The Agilent bioanlayser is able to give a more comprehensive analysis of the RNA 
integrity, which it gives in the form of the RNA Integrity Number (RIN).  RIN represents 
an aligorithim for assigning integrity values to RNA.  It is independent of RNA sample 
concentration and misinterpretation due to artifacts, therefore allowing accurate evaluation 
of samples.     
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Figure 2.1.  RNA integrity as assessed by the Agilent bioanalyser.  RNA with good integrity is indicated by 
two clear bands on the gel and two clear peaks on the electropherogram, representing the 18s and 28s 
ribosomal RNAs.  This is clear with sample A1.05.  Degraded RNA (represented by sample A2.3) is 
indicated by a lack of bands (completely degraded RNA) or the presence of extra bands which represents 
partially degraded RNA (not shown).  [FU] = fluorescence units.  [nt] = nucleotides.  L = Ladder. 
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2.1.4  Reverse Transcription of RNA 
Total RNA extracted from human and mouse tissues and cell lines, which was of an 
acceptable quality, was converted to cDNA for use in subsequent PCR and QPCR 
experiments.  Total RNA was diluted in Nuclease-free water (Promega, UK) so that each 
sample contained 1µg of RNA in a volume of 10µl.  Therefore the synthesis of cDNA was 
normalised, to a degree, by ensuring the same quantity of RNA was used in each sample.  
Variances in the efficiency of the reverse transcriptase reaction were minimised by 
performing RT reactions in groups according to each experimental protocol.  For example, 
all RNA samples used in QPCR reactions underwent an RT reaction at the same time.  
This ensured that any change observed in subsequent experiments was not due to 
inconsistencies in the amount of RNA or variations in the efficiency of the RT reaction. 
 
To each RNA sample 0.02 µg/µl Oligo (dT) 12-18 primers, 0.04 µg/µl random primers 
(both from Invitrogen, UK) and dNTP mix containing 1.25mM per dNTP (Bioline, UK) 
were added and the samples incubated at 65°C for 5 minutes.  Samples were then chilled 
briefly on ice.  To each sample 10mM DTT, 2U/µl RNase out and 1 X First-Strand buffer 
(all from Invitrogen, UK) were added to each sample and incubated at 42°C for 2 minutes 
followed immediately by 2 minutes at 25°C.  Each RNA sample underwent the RT 
reaction in duplicate.  To one of the samples, 10U/µl Superscript II reverse transcriptase 
(Invotrogen, UK) was added (positive samples) and to the other, Nuclease-free water 
(Promega, UK).  The samples that were not mixed with the reverse transcriptase served as 
a negative control for subsequent reactions.  This helped determine if products from PCR 
reactions were the result of cDNA amplification or a result of DNA contamination in the 
original RNA sample.  RNA samples (both positive and negative) were incubated at 25°C 
for 20 minutes followed immediately by 42°C for 50 minutes.  The sample was then heated 
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at 70°C for 15 minutes in order to inactivate the reverse transcriptase.  All cDNA was 
stored at -20°C until used in subsequent experiments.  A Techne TC-512 thermal cycler 
(Fisher Scientific, UK) was used to perform all RT reaction steps.  
 
2.1.5  Primer Design and optimisation 
Primer3 software (Rozen and Skalestky, 2000) was utilised to design forward and reverse 
primers.  NCBI BLAST software (http://blast.ncbi.nim.nih.gov/Blast.cgi) was used to 
confirm that primers shared 100% sequence identity with the target gene.  All primers were 
synthesised by Eurofins MWG Operon (Germany).  In order to determine the optimal 
annealing temperature for each set of primers, a temperature gradient PCR using the 
appropriate gDNA was performed.  The protocol for this step was identical to all other 
PCR reactions (see Section 2.1.6) with the exception of the annealing temperature step.  
TAE agarose gel electrophoresis was used to analyse PCR products.  The optimal 
annealing temperature was determined to be the temperature at which one clear band was 
observed at the expected band size.  Primer specificity was then confirmed by the 
purification and sequencing of the PCR products.  
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Gene GenBank 
accession 
number 
Primer Sequence 
(5’-3’) 
Product 
size 
 (base 
pairs) 
Annealing    
temperature 
(°C) 
HCN1 NM_010408 F:  AAAGCTGGTTTGTGGTGGAC 
R:  CTGGCGAGGTCATAGGTCAT 
223 57 
HCN2 NM_008226 F:  TGTCGGATGGCTCCTATTTC 
R:  TGTGCAGCAAGATGGAGTTC 
216 57 
HCN3 NM_008227 F:  GCGTAAAGGCTCTGGAAGTG 
R:  AACATGGTAGGCATGGGGTA 
343 57 
HCN4 NM_001081192 F:  CAGCCTCCTGGAGAGTTGTC 
R:  TGAGCTTCAGGTCCTGTGTG 
325 57 
TALK-1 NM_029006 F:  ACTGGGACTTCGGGAGCAGCT 
R:  GAGCCGGGAGCACCTGTGC 
518 58.8 
TALK-2 NM_031460 F:  AAGTCCCAAAGCTGGAGACA 
R:  TCGGGTGATATTCCGTTTGT 
525 60 
TASK-1 NM_010608 F:  GGTGCTCATCGGTTTCGTGTC 
R:  CAGGCTACCGCTTAGGCAGCT 
373 63 
TASK-2 NM_021542 F:  CTCATCAAACAGATTGGGAAGAAG 
R:  GGAAGATGAGCGGGTGGTAGT 
343 58.8 
TASK-3 NM_001033876 F:  
CTGGAGCTGGTAATCCTGCAGTCTGAG 
R:  AAGCTCCAATCTTCACACTGG 
374 65.1 
THIK-1 NM_001164426 
NM_001164427 
NM_146037 
F:  GATGACAACACCAGCCACAAC 
R:  
GTCTGTTTGATCAGGATGGAGATGACG 
516 64.4 
THIK-2 NM_199251 F: TGGGCAACTTCCTCTTCATC 
R: ATTAAGAAAGCGCCATCTCG 
556 60 
TRAAK NM_008431 F:  CTGGAGCAGCCTCACGAGCAG 
R:  
ATGGCTTCTAACTTGCTCCAGCTCTCC 
533 67.2 
TREK-1 NM_001159850 
NM_010607 
F:  
CCATAGGATTTGGAAACATCTCCCCAC 
R:  
CAATCATGCTCAGAACAGCTGCAAAG 
453 66.1 
TREK-2 NM_029911 F:  GCTGGCATCAATTACCGAGAGTG 
R:  GTTGTCCTCAGAAGCGCCCTG 
465 62.2 
TWIK-1 NM_008430 F:  CCATGCCGTTCTGCTGGGATTC 
R:  GGAGAAGGACAGCTGGTCGTGCTCC 
361 55 
TWIK-2 NM_001033525 F:  CCGGGGCACTGACTGATGGC 
R:  GAGGCTGAACCCACGGCCAC 
536 59.1 
β-actin NM007393 F:  GTGGGCCGCTCTAGGCACCAA 
R:  CTCTTTGATGTCACGCACGATTCC 
324 60 
 
 
 
 
 
 
Table 2.1.  Primers designed for target genes of interest in the mouse.  Primers used in RT-PCR experiments 
to assess the expression of HCN and K2P genes in the mouse.  Expected product size and optimal annealing 
temperatures for PCR reactions are also presented.  The presence of more than one GenBank accession 
number represents the presence of transcript variants for that gene.  Primers were designed to ensure all 
transcript variants could be detected.  The primers designed for TALK-2 were based on the human gene 
sequence as sequence for the mouse was not available.  The housekeeping gene, β-actin, was designed by Dr 
E. Wright. 
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Gene GenBank accession 
number/Reference 
Primer Sequence  
(5’-3’) 
Product 
size (bp) 
Annealing 
temperature 
(°C) 
HCN1 NM_021072 F:  CAATGTGGCATCAGATACAG 
R:  TGAGATGAAGTCAACCACAA 
151 60 
HCN2 NM_001194 F:  TTCTTCAAGGATGAGACCAC 
R:  GTGCGCAGATACTTCTTCTT 
164 60 
HCN3 NM_020897 F:  GTATGTCTCCACTGCCAAGT 
R:  ATGCTACAGGGACAGGAAGA 
221 60 
HCN4 NM_005477 F:  GAGAACACCACACCCTGGAT 
R:  GTAGACCTCCGAGTCGATGC 
237 60 
TALK-1 NM_032115 F:  CACAGGCTAGACGCTTCCTC 
R:  TCAAGACCACCTTGGGTCTC 
192 60 
TASK-1 NM_002246 F:  CCTGCAAATTCCGAGAAATG 
R:  TGCAAACGTACACGGAACA 
167 60 
TREK-2 NM_021161 
NM_138317 
NM_138318 
F:  ACAGTGGTAGCCAGGATGGA 
R:  TCCAAGGCGATGGTATTCTT 
176 60 
TWIK-1 NM_002245 F:  GCCTTATTGCCATGTTGGTA 
R:  CCTGGTCTGTGATCGAGGAG 
156 60 
18s 
RNA 
Wang et al. 2005 F:  TCAGCGTGTGCCTACCCTAC 
R:  GGCCTCACTAAACCATCCA 
131 60 
 
 
 
 
 
 2.1.6  Polymerase Chain Reaction 
To a 1µl sample of cDNA generated from the RT reaction (see Section 2.1.4) 1 X PCR 
Buffer, 1.5mM MgCl2, 0.2mM dNTP mix, 0.5 pmol/µl forward and reverse primers, and 
0.03U/µl Taq DNA polymerase (all from Invitrogen, UK) were added.  All samples were 
then added to a TC-512 thermal cycler (Fisher Scientific, UK).  Samples were initially 
denatured at 94°C for 5 minutes, followed 32 cycles of; 94°C for 30seconds, specific 
primer annealing temperature for 30 seconds, and 72°C for 1 minute.  At the end of the 
reaction a final extension step at 72°C for 10 minutes was included to ensure the reaction 
was complete.  Primer annealing temperatures are presented in tables 2.1 and 2.2.  PCR 
Table 2.2.  Primers sequences deigned to recognise target genes of interest in human tissue and cells.  
Primers used in RT-PCR experiments to assess the expression of HCN and K2P genes in human tissue 
and cells.  Expected product size and optimal annealing temperatures for PCR reactions are also 
presented.  The presence of more than one GenBank accession number represents the presence of 
transcript variants for that gene.  Primers were designed to ensure all transcript variants could be detected.  
The housekeeping gene, 18s RNA, was used as an endogenous reference in QPCR experiments. 
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products were visualised by TAE agarose gel electrophoresis (see Section 2.1.7).  Each 
PCR reaction included the cDNA samples, RT negative controls, a negative control (cDNA 
replaced with nuclease-free water (Promega, UK) and a positive control (genomic DNA of 
the appropriate species (all from Promega, UK)).  PCR reactions and subsequent 
experiments were repeated three times unless otherwise stated in the results.  
 
2.1.7  TAE Agarose Gel Electrophoresis  
A 1.5% agarose gel (Melford Laboratories, UK) was prepared by adding agarose to TAE 
Buffer (Bio-Rad, UK).  This mixture was heated in a microwave for approximately two 
minutes or until all agarose was dissolved.  Whilst molten, ethidium bromide (Promega, 
UK) was added to enable visualisation of PCR products.  PCR products were mixed with 
blue/orange 6 X loading dye (Promega, UK) in order to track the migration of PCR 
products during electrophoresis.  The same volume of PCR products (8µl mixed with 2µl 
loading dye) was used in each experiment to ensure any observed changes were genuine.  
A 100 bp DNA ladder (Promega, UK) was used to identify the band size and PCR 
products.  The 100 bp ladder was diluted with nuclease-free water (Promega, UK) and 
mixed with the loading dye.  Once the gel was set, samples were loaded and the TAE 
agarose gel exposed to 100 volts for 60 minutes.  Following electrophoresis, PCR products 
were visualised by exposing the TAE agarose gel to UV light using a UVIdoc gel 
documentation system (UVItec, UK).  
 
2.1.8  Purification of PCR products 
All PCR products were purified using the QIAquick PCR Purification Kit (Qiagen, UK) 
following the manufacturer’s instructions.  Briefly, a supplied pH indicator was added to 
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Buffer PB at a ratio of 1:250.  Then, 5 volumes of Buffer PB were added to 1 volume of 
PCR product and mixed.  The colour of the mixture was checked to ensure the correct pH 
had been reached.  This mixture was applied to a QIAquick spin column in a provided 2ml 
collection tube and centrifuged at 13000g for 45 seconds (Eppendorf Minispin Plus, UK).  
High concentrations of salt in Buffer PB and an acidic pH were required to enable DNA 
binding to the silica membrane.  Flow-through was discarded and the membrane washed 
with the ethanol-containing Buffer PE by centrifugation at 13000g for 45 seconds.  The 
flow-through was discarded and the column centrifuged for 1 minute at 13000g to remove 
any residual ethanol.  In order to elute the DNA, the column was added to a new 1.5ml 
collection tube (supplied) and 50µl of nuclease-free water (Promega, UK) added directly to 
the membrane.  This was incubated at room temperature for 1 minute in order to ensure a 
high DNA yield.  The low salt concentration and pH range of 7-8.5 were optimal for 
elution.  The column was then centrifuged for 1 minute at 13000g and DNA collected for 
sequencing. 
 
2.1.9  Primer verification by PCR product sequencing      
All purified PCR product sequencing was performed by the Sequencing Facility at the 
University of Manchester.  Purified PCR products were sequenced in the forward direction 
only.  NCBI BLAST software (http://blast.ncbi.nim.nih.gov/Blast.cgi) was used to confirm 
that the sequences generated shared 100% sequence identity with the target gene.   
 
2.2.1  Immunohistochemical analysis of mouse and human tissues 
Mouse and Human tissue samples were fixed using 4%PFA (VWR International, UK) for 
24 hours at 4°C.  Following fixation, Immunohistochemistry was performed on paraffin-
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embedded adult mouse tissue and human tissue (Table 2.3).  Fixed tissue was embedded 
and sectioned, to a thickness of 5 µm, by Mrs Anne Warhurst from the Faculty of Life 
Sciences, Histology Facility, University of Manchester, UK).  Paraffin was removed by 
two 5 minute incubations in 100% xylene.  Tissue sections were rehydrated by the use of 
an alcohol gradient consisting of; two 3 minute incubations in 100% ethanol, one 3 minute 
incubation in 90% ethanol, and one 3 minute incubation in 70% ethanol.  Residual ethanol 
was removed by two 3 minute washes in 1 X PBS and then transferred to distilled water 
(MilliQ, Millipore, UK).  Antigen retrieval was achieved by microwave heating the tissue 
sections in citrate buffer (10mM citric acid, 0.05% TWEEN 20, pH 6.0) for 12.5 minutes.  
Tissue sections were left to cool at room temperature, for approximately 20 minutes, and 
then washed with 1L of distilled water.  The area containing the tissue section was then 
outlined using a PAP pen (Abcam, UK).  Three 10 minute washes in 1 X PBS containing 
0.05% TWEEN 20 (Sigma, UK) were performed on tissue sections prior to 
permeabilisation.  Tissue sections were placed in a prepared humidified chamber and 
permeabilised with 0.1% Triton X-100 (Sigma, UK) in 1 X PBS for one hour at room 
temperature.  Tissue sections were then washed briefly in distilled water to remove any 
residual permeabilisation solution.  Tissue sections were then blocked using 5% normal 
serum (from the host species of the secondary antibody) and 1% BSA (Sigma, UK) in 1 X 
PBS for one hour at room temperature in the humidified chamber.  Tissue sections were 
then washed briefly with distilled water.  The appropriate primary antibody (Table 2.3), or 
antibody combinations, were diluted in 1 X PBS containing 3% normal serum and 
incubated with the tissue sections in a humidified chamber overnight at 4°C.  Following 
incubation with the primary antibodies, tissue sections were washed 3 times with 1 X PBS 
containing 0.05% TWEEN 20.  The fluorochrome-conjugated secondary antibodies (Table 
2.3) were then diluted in 3% normal serum in 1 X PBS and incubated with the tissue 
sections at room temperature in a humidified chamber for one hour.  Unbound secondary 
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antibody was removed by three 10 minute washes in 1X PBS containing 0.05% TWEEN 
20.  Prior to mounting, tissue sections were washed briefly in distilled water.  Slides were 
mounted with 22 x 50mm glass coverslips (VWR International, UK) using ProLong gold 
antifade reagent containing DAPI (Invitrogen, UK).  Slides were left at room temperature 
for at least 6 hours to allow the mountant to set and then stored at 4°C until viewed.  Tissue 
sections were viewed on an Olympus BX-51 upright microscope (Olympus, UK).  A 
Coolsnap ES camera (Roper Scientific, USA) in conjunction with Meta Vue software 
(Molecular Devices, UK) were used to capture images.  Specific bandpass filters were 
utilised for DAPI, and the appropriate fluorochromes (Dy488 (Dylight 488 fluorochrome), 
and Cy3 (Cyanine 3 fluorochrome)) to ensure there was no bleed-through from one 
channel to the next.  Images were processed using ImageJ software 
(http://rsb.info.nih.gov/ij).  Due to the potential medical relevance of the images, the 
recently outlined guidelines for digital imaging for pathology were followed wherever 
possible (Pritt et al., 2003). 
 
2.2.2  Immunohistochemical analysis of cell lines 
MIN6 and NES2Y cell lines were seeded onto sterile 15mm diameter glass coverslips 
(Scientific Laboratory Supplies, UK) in a 24-well cell culture plate (Fisher Scientific, UK).  
Cells were then cultured (as described in Section 2.3.1) for 24 hours prior to fixation.  Cell 
culture medium was then removed and the cells washed three times with 1 X PBS.  
Following the removal of the last PBS wash, cells were fixed by the addition of 300µl of 
4% PFA (VWR International, UK) and left overnight at 4°C.  The following day, the PFA 
was aspirated and the cells washed three times with 1 X PBS.  Permeabilisation and 
blocking were performed simultaneously by adding 0.1% Triton X-100 (Sigma, UK) to the 
blocking solution (10% normal serum in 1 X PBS).  Permeabilisation and blocking was 
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performed at room temperature and cells were incubated for 1 hour.  The solution was then 
aspirated and the cells washed three times with 1 X PBS.  The primary antibody (Table 
2.3) was then added to 1 X PBS containing 3% normal serum and incubated with the cells 
at 4°C overnight.  The primary antibody was then removed and the cells washed three 
times with 1 X PBS containing 0.05% TWEEN 20 (Sigma, UK).  The appropriate 
secondary antibody (Table 2.3) was then added to 1 X PBS containing 3% serum and 
incubated with the cells at room temperature for 1 hour after which they were washed with 
1 X PBS containing 0.05% TWEEN 20 (Sigma, UK).  The glass coverslips were then 
removed and mounted onto Superfrost Plus slides (Thermo Scientific, UK) using ProLong 
gold antifade reagent with DAPI (Invitrogen, UK).  Slides were left at room temperature 
for at least 6 hours to allow the mountant to set and then stored at 4°C until viewed.  
Viewing of the slides and subsequent processing followed the same protocol as was used 
for tissue sections (see Section 2.2.1). 
 
Antibody Final Concentration 
Rabbit Anti-Rat HCN1 
(Alomone Labs, Israel) 
4 µg/ml 
Rabbit Anti-Human HCN2 
(Alomone Labs, Israel) 
3.75 µg/ml 
Rabbit Anti-Human HCN4 
(Alomone Labs, Israel) 
4 µg/ml 
Rabbit Anti-Human TWIK-1 
(Alomone Labs, Israel) 
4 µg/ml 
Guinea Pig Anti-Porcine Insulin 
(Invitrogen, UK) 
Used at 1:200 
Mouse Anti-Porcine Glucagon 
(Sigma,UK) 
Used at 1:1000 
DyLight 488 AffiniPure Goat Anti-Guinea Pig IgG 
(Stratech, UK) 
7.5µg/ml 
DyLight 488 AffiniPure Goat Anti-Mouse IgG 
(Stratech, UK) 
7.5µg/ml 
Cy3-conjugated AffiniPure Goat Anti-Mouse IgG 
(Stratech, UK) 
7.5µg/ml 
Cy3-conjugated AffiniPure Goat Anti-Rabbit IgG 
(Stratech, UK) 
7.5µg/ml 
 
 
Table 2.3.  Primary and Secondary antibodies used in Immunofluorescence studies.  Primary 
antibodies are presented in the top half of the table and Secondary antibodies in the lower half.  
Concentrations at which the antibodies were used are also presented. 
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2.2.3  Criteria for true immunofluorescence staining 
Immunofluorescence assays are particularly sensitive to pre-analytical treatment of tissue 
sections and consequently require accurate evaluation of the staining results.  True staining 
was therefore determined based upon several key criteria.  Non-specific staining or 
background staining, as caused by the secondary antibody, was determined, and 
discounted, by comparison with the negative control image (primary antibody omitted).  A 
ubiquitous, weak staining was also classified as background or non-specific staining.  
True-staining was defined as a staining of bright intensity in a select group of cells or 
tissue structure.  It is possible that the target protein was expressed ubiquitously.  In this 
case, true staining was defined as an intense and uneven stain, which may be expected 
given the variety of cell types and tissue structures within each sample.  Furthermore, weak 
staining observed in the same sample as an intense stain was also classed as non-specific 
staining.  This is partly due to the nature of the polyclonal antibodies used. Polyclonal 
antibodies recognise more than one epitope (binding site) on the target antigen.  For this 
reason, they are capable of producing staining of a greater intensity than monoclonal 
antibodies (which recognise only one epitope).   Consequently, polyclonal antibodies are 
used to detect target proteins that are considered to have low expression levels, as binding 
to one antigen may occur at multiple sites therefore enhancing the signal produced 
(Renshaw, 2007).  Among other factors, this makes the use of polyclonal antibodies 
unsuitable for the quantification of protein levels.  Any weak staining observed was 
therefore considered to be nonspecific.  Although polyclonal antibodies contain mostly 
isotype G immunoglobulins, other immunoglobulins are also present.  It is possible that 
any weak staining (observed in the same sample of intense staining) could have been the 
result of a minority of immunoglobulins binding non-specifically.  
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2.3.1  General Cell Culture 
NES2Y and MIN6 cell lines were cultured in 25cm2 cell culture flasks (Fisher Scientific, 
UK).  The culture media for MIN6 cells consisted of DMEM containing 15% FCS, 25 mM 
glucose, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 5µl/l β-
mercaptoethanol (all from Invitrogen, UK).  NES2Y cells were cultured in RPMI-1640 
containing 10% FBS, 5mM glucose, 2mM L-glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin (all from Invitrogen, UK).  All media were sterilised with a 0.22 µM filter 
(Millipore, UK) and replaced every three days.  Cells were passaged by trypsin when 80% 
confluent.  Briefly, cells were washed three times with 1 X PBS (Invitrogen, UK) and then 
incubated at 37°C, 5% CO2 with 0.5g/l trypsin – 0.2g/l EDTA solution (Sigma, UK) for 5 
minutes.  Cells were checked by microscope for a single cell suspension and the trypsin 
inactivated by the addition of 5ml of the appropriate cell culture medium.  This cell 
suspension was centrifuged at 800 g for 5 minutes (Sigma 3-16K, SciQuip, UK).  The 
supernatant was removed, cells resuspended in the appropriate cell medium and split at a 
ratio 1:5 into new 25cm2 cell culture flasks (Fisher Scientific, UK). 
 
The glucose content of the NES2Y medium was adjusted for certain experimental 
protocols.  This was achieved by further addition of glucose (for concentrations above 
5mM) or the dilution of RPMI 1640 with Zero Glucose RPMI-1640 (Sigma, UK).    
 
2.3.2  Mouse Islet culture 
Mouse islets were isolated as described in Section 2.3.3 and 40 islets were added to each 
well of a 6-well culture dish and cultured overnight at 37°C in 5% C02 before subsequent 
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experimentation.  The culture medium consisted of RPMI 1640 containing 10% FCS, 5mM 
glucose, 100µg/ml penicillin and 100µg/ml streptomycin (all from Invitrogen, UK). 
 
2.3.3  Mouse Islet Isolation 
Adult male and female MIP-GFP mice were humanely sacrificed according to Home 
Office-approved procedures (Schedule 1).  The pancreas was removed with the spleen and 
rapidly placed in ice cold KRH, composed of 129 mmol/l NaCl, 5 mmol/l NaHCO3, 4.8 
mmol/l KCl, 1.2 mmol/l KH2PO4, 1.2 mmol/l MgSO4.7H2O, 2.5 mmol/l CaCl2, 5.6 mmol/l 
glucose, 0.1 % BSA (pH 7.4, NaOH).  The pancreas was transferred to a Petri dish and was 
trimmed of the spleen and any fat and then inflated with KRH supplemented with 
1.83mg/ml Turkey egg white trypsin inhibitor (Sigma, UK), 1.83mg/ml Soybean trypsin 
inhibitor (Sigma, UK), and 1.4mg/ml Liberase (Roche, Germany).  The inflated pancreas 
was transferred to a 50ml Falcon tube (BD Biosciences, UK), incubated for 3 minutes in a 
water bath heated to 37°C and then shaken manually at room temperature for 1minute.  
These two steps were repeated and the digest checked under a microscope.  If the digest 
was incomplete the volume would be made up to 50ml by adding KRH and centrifuged for 
1 minute at 150rpm.  The supernatant would be removed and further digestion of the 
pancreas achieved by resuspending the pellet in KRH (supplemented with 1.83mg/ml Egg 
white trypsin inhibitor, 1.83mg/ml Soybean trypsin inhibitor, and 0.67mg/ml Liberase) and 
repeating the incubation steps.  When the majority of islets had become separated from the 
exocrine material, the digestion was stopped by the addition of ice cold KRH.  The islets 
were centrifuged for 1 minute at 150rpm and resuspended in 50mls ice cold KRH. This 
step was repeated 3 times in order to ensure all Liberase was removed and the supernatant 
clear of debris.  The islets were then resuspended in 10mls ice cold KRH.  Islets were 
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handpicked under microscope and cultured overnight (see Section 2.3.2) before use in 
subsequent experiments. 
 
2.3.4  SUR1-/- mouse tissue 
Three SUR1-/- mice and three wild type mice of the same strain were a gift from Gisela 
Drews, Institute of Pharmacy, University of Tübingen, Germany.  All mice were of the 
same sex (male), approximately 6 months old and were all born within 3 weeks of each 
other.  Mouse pancreata were removed and fixed using 4%PFA (VWR International, UK) 
for 24 hours at 4°C.  Following fixation, mouse pancreata were transferred to PBS and sent 
to the Univeristy of Manchester for immunohistochemical analysis.   
 
2.3.5  Human Tissue processing 
Pancreata from CHI patients were received from The Children’s Hospital of Manchester.  
Following surgery, the pancreas was transported to the Department of Pathology at the 
Children’s Hospital of Manchester for immediate histological analysis.  Surplus tissue was 
transported in DMEM (Invitrogen, UK), on ice, to the University of Manchester.  
Pancreata were cleaned, weighed, and processed for further investigation.  All research 
was carried out under National Research Ethics Service approval, with patient consent 
(NRES 07/G1010/88, Trust R&D PIN 5276).  Patient details, including age at surgery and 
identified mutations, are detailed in Table 2.4. 
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Human control pancreata NH-1 and NH-2 were a gift from Professor Neil Hanley, School 
of Biomedicine, University of Manchester, UK.  Archived sections of human foetal 
pancreata were originally provided by the University of Sheffield.  The collection of 
human foetal tissue was carried out by The Centre for Reproductive Medicine and Fertility 
(Sheffield, UK) following strict ethical approval from the Department of Health, under 
guidelines issued by the Polkinghorne Committee. 
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University Code 
Age at 
surgery 
(months) 
Histology Gene Paternal mutation Maternal mutation Genotype 
 
References 
 
N136 
 
19 Focal KCNJ11 S116P (c.346T>C) 
Paternal uniparental 
isodisomy 11p15.5-11p15.1 
in focal lesion 
S116P/N Suchi et al., 2006 
N137 
 
 
2 Diffuse ABCC8 IVS32-9G>A (c.3992-9G>A) 
IVS32-9G>A 
(c.3992-9G>A) 
IVS32-
9G>A/IVS32-
9G>A 
Nestorowicz et al., 1996 
N138 
 
 
4 
 
Diffuse ABCC8 H36R (c.107A>G) 
IVS10+1G>T 
(c.1630+1G>T) 
H36R/IVS10+1G>
T Novel / Nestorowicz et al., 1998 
N139 
 
 
3 Focal ABCC8 V1430fs (mosaic) (c.4287delC) 
Paternal uniparental 
isodisomy 11p15.5-11p15.1 
in focal lesion 
Mosaic for V1430fs Novel 
N140 
N140R 
 
13 
34 
 
Diffuse ABCC8 IVS38-1G>T * (c.4612-1G>T) 
A4V 
(c.11C>T) A4V/IVS38-1G>T Novel 
N141 
 
 
10 
 
Focal ABCC8 R999X (c.2995C>T) No mutation identified R999X/N Suchi et al., 2003 
N142 
 
 
2 
 
Diffuse KCNJ11 Q299R (c.896A>G) 
Q299R 
(c.896A>G) Q299R/Q299R Novel 
N143 
 
 
16 (years) 
 
Insulinoma ABCC8 R620C (c.1858C>T) No mutation identified R620C/N Aguilar-Bryan and Bryan, 1999 
N144 
 
 
3 
 
Diffuse ABCC8 Exon 13 deletion 
c.1818-?_1923+?del 
T172fs 
c.512dupT 
T172fs/ c.1818-
?_1923+?del Novel 
N145 
 
 
5 
 
Focal ABCC8 R842X (c.2524C>T) No mutation identified R842X/N Brunetti-Pierri et al., 2008 
N146 
 
 
6 
 
Diffuse ABCC8 IVS1+1G>A (c.148+1G>A) 
IVS1+1G>A 
(c.148+1G>A) 
IVS1+1G>A/IVS1
+1G>A Novel 
Table 2.4  Human tissue samples and their pathologies as defined by The Children’s Hospital of Manchester..  * = Sample from father not 
available, mutation presumed to be paternal in origin. 
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2.3.6  Static GSIS Assay 
Mouse islets were isolated and cultured overnight as described in Sections 2.3.3 and 2.3.2 
respectively.  Three islets were then added to separate wells of a 96-well plate containing 
KRH 0.1% BSA 0mM glucose, which had been pre-warmed 37°C, and incubated at 37°C 
in 5% C02 for one hour to equilibrate to the assay medium.  An appropriate volume of 1M 
glucose stock solution was then added to each well to give the appropriate final glucose 
concentrations.   Modulators for each test condition were added separately.  The plate was 
then incubated for one hour at 37°C in 5% C02 for one hour.  Following incubation the 
plate was centrifuged at 2000rpm for five minutes and the supernatant transferred to a fresh 
96-well plate for subsequent experiments to determine insulin secretion.  To each well of 
the original plate that contained islets, 25µl of 2% Triton X-100 (Sigma, UK) diluted in 
distilled water was added and incubated overnight at 4°C in order to lyse the islets.  The 
following day, total protein content of islets was quantified as described in Section 2.3.7. 
 
2.3.7  Insulin Secretion ELISA 
Islet Insulin secretion was measured using a Mouse ELISA kit (Mercodia, UK), based on 
the direct sandwich method, following the manufacturer’s protocol.  Briefly, a standard 
curve was produced using the supplied range of calibrators.  Samples were diluted in order 
to be within the readable range of the kit.  A 25µl aliquot of the diluted samples, controls, 
and calibrators were added in triplicate to a 96-well plate coated with monoclonal anti-
insulin antibody as supplied by the manufacturer.  To each well 50µl of peroxidise-
conjugated anti-insulin antibody diluted in conjugate buffer were added and the plate 
incubated at room temperature for two hours on a microplate shaker.  Unbound enzyme-
labelled antibody was then removed by washing the assay plate six times with 350µl wash 
buffer using an Opsys MW automatic plate washer (Dynex Technologies Ltd, Worthing, 
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UK).   Following the final wash, the plate was tapped against an absorbent paper towel in 
order to remove any remaining wash buffer.  The bound conjugate was detected by the 
addition of 200µl of substrate TMB to each well incubated at room temperature for 30 
minutes.  The reaction was terminated by adding 50µl of the acid containing stop solution 
to each well.  This resulted in a colorimetric endpoint that was read immediately at 450nm 
using a Spectramax spectrophotometer (Molecular Devices, USA) with the ascent 
computer software (Multiskan Ascent Labsystems, USA).  
 
Data analysis was performed in Microsoft Excel 2007.  Concentrations of unknown 
samples were extrapolated from the standard curve; dilutions were corrected for; average 
control values were subtracted from sample values; triplicates were averaged; insulin 
secretion was calculated as per islet and normalised to total protein content.  Graphs were 
produced using Microsoft Excel 2007 and statistics using SPSS 16. 
 
2.3.8  Protein extraction and quantification 
Total protein content of islets was quantified using the Pierce BCA Protein Assay (Thermo 
Scientific, UK) according to the manufacturer’s instructions.  This method is based on the 
reduction of Cu2+ to Cu+ by protein in alkaline medium, which is then detected by the 
chelation of BCA with a cuprous ion.  Protein content of unknown samples was 
determined by the use of a standard curve produced by using BSA standards (BioRad, 
UK).  Briefly, the ‘Working Reagent’ was prepared by mixing 50 parts of BCA Reagent A 
with 1 part Reagent B.  The Working Reagent was added to the lysed islets, BSA 
standards, and blank controls and mixed thoroughly on a microplate shaker for 30 seconds.  
The plate was then covered and incubated at 37°C for 30 minutes.  The plate was then 
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cooled to room temperature and read immediately at 550nm using a Spectramax 
spectrophotometer (Molecular Devices, USA) and the ascent computer software 
(Multiskan Ascent Labsystems, USA).   Data analysis was performed in Microsoft Excel 
2007. 
 
2.4.1  Preparation of Poly-l-lysine-coated coverslips 
Poly-l-lysine (Sigma-Aldrich, UK) is an adhesive solution that promotes the adhesion of 
cells through the interaction of the anionic sites on cells and the polycationic nature of the 
molecule.  Glass coverslips of a 15mm diameter (Scientific Laboratory Supplies, UK) were 
coated according to the manufacturer’s instructions.  Briefly, glass coverslips were added, 
one per well, to a 24-well plate.  Poly-l-lysine was diluted in dH2O and 200µl was added to 
each coverslip and left for one hour.  A range of dilutions was used to optimise islet 
adhesion to glass coverslips (1:10, 1:8, 1:5, and 1:3) which were allowed to dry at room 
temperature overnight after the excess poly-l-lysine was removed.  Freshly isolated islets 
were seeded onto coverslips for culture overnight in 800µl RPMI before further 
experiments. 
 
2.4.2  Preparation of Cell-Tak-coated coverslips 
Cell-Tak (BD Biosciences, UK) is an adhesive compound of polyphenolic proteins 
extracted from the marine mussel, Mytilus edulis.  Glass coverslips (as above) were coated 
according to the manufacturer’s absorption protocol.  Briefly, 0.1M sodium bicarbonate 
pH8.0 was added to each coverslip resting in a well of a 24-well plate. An appropriate 
volume of Cell-Tak was added to coverslips at a range of densities to optimise islet 
adhesion; 2µg/cm2, 2.5 µg/cm2, 3 µg/cm2, 3.5 µg/cm2, 4 µg/cm2, 4.5 µg/cm2, and 5µg/cm2.  
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Coverslips were left in sterile conditions for 20 minutes to allow absorption.  Excess Cell-
Tak solution was aspirated and coverslips washed twice with dH2O.  Islets were 
immediately seeded onto coverslips and cultured overnight prior to subsequent 
experiments. 
 
2.4.3  Preparation of Laminin/Fibronectin-coated coverslips 
Laminin (Sigma-Aldrich,UK) and Fibronectin (Sigma-Aldrich, UK) were used separately 
and in combination to promote cell adhesion to glass coverslips.  Laminin was tested at the 
densities 1 µg/cm2, 2 µg/cm2, 3 µg/cm2 and 4 µg/cm2.  Fibronectin was tested at the 
densities 1 µg/cm2, 3 µg/cm2, 5 µg/cm2, and 7 µg/cm2.  Laminin/fibronectin combinations 
were tested at equal densities; 1 µg/cm2, 2 µg/cm2, 3µg/cm2 and 4 µg/cm2.  
Laminin/fibronectin was diluted in RPMI 1640 and was added to each well of a 24-well 
plate containing a glass coverslip.  Glass coverslips were incubated for two hours at room 
temperature and then washed twice with RPMI 1640.  Islets were then immediately seeded 
onto coverslips and cultured overnight prior to subsequent experiments. 
 
2.4.4  Preparation of Matrigel-coated coverslips 
Matrigel (BD Biosciences, UK) is a solubilised basemembrane preparation, extracted from 
the Engelbreth-Holm-Swarm mouse sarcoma (a tumour rich in extracellular matrix 
proteins).  Major components include laminin, collagen IV, enactin and a variety of growth 
factors.  Glass coverslips were coated using the manufacturer’s thin gel method.  Briefly, 
Matrigel (supplied at 12mg/ml) was thawed and mixed to homogeneity using pipette tips 
cooled overnight at -20°C.  Glass coverslips were placed in a 24-well plate and incubated 
on ice for ten minutes before adding Matrigel.  Growth surface area was calculated and an 
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appropriate volume of Matrigel (50µl/cm2) was added to each coverslip.  Plates were 
incubated at 37°C for 30 minutes and islets were immediately seeded onto coverslips and 
cultured overnight prior to subsequent experiments. 
 
2.4.5  Imaging of mouse pancreatic islets using the fluorescent membrane potential 
probe DiBAC4(3) 
The fluorescent membrane potential probe bis-(1,3-dibutylbarbituric acid) tri-methine 
oxonol (diBAC4(3)) has recently been used to monitor the membrane potential changes in 
mouse islet α- and β-cells (Hjortoe et al., 2004).  Attempts to reproduce this method were 
unsuccessful.  Briefly, islets were seeded onto Matrigel-coated glass coverslips and 
incubated overnight.  The following day, islets were incubated at 37°C with diBAC4(3) 
(diluted in 0.1% DMSO) at a final concentration of either 150nM, 300nM, 450nM, 600nM 
or 1µM in order to optimise the protocol.  DiBAC4(3) is considered to take just minutes to 
equilibrate over the plasma membrane (Hjortoe et al., 2004).  Islets were incubated with 
diBAC4(3) for a range of times; 5 minutes, 10 minutes, 20 minutes and 40 minutes in order 
to optimise the protocol for our experimental setup.  Coverslips were then mounted in a 
perfusion chamber (Warner Instruments, USA) and the islets bathed at 37°C in a control 
solution (137mM NaCl, 5.36 mM KCl, 0.81mM MgSO4, 0.34mM Na2HPO4, 0.44mM 
KH2PO4, 4.17mM NaHCO3, 10mM HEPES, 1.26mM CaCl2 and 2.02mM glucose, pH 7.5 
at room temperature). 
 
In order to calibrate diBAC4(3)-measured changes in fluorescence with membrane 
potential, the procedure for slow dyes was adapted from Freedman and Novak, 1989.  
Changes in fluorescence were measured over a range of extracellular K+ concentrations 
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(5.36, 10, 20, 40, 80, and 140mM) in the presence of 1µM valinomycin.  For these 
solutions, NaCl was replaced by KCl on an equimolar basis.  The membrane potential was 
then to be calculated using the Nernst equation and then plotted against fluorescence 
intensity. 
 
In the presence of control or calibration solutions, islets loaded with diBAC4(3) were 
excited at 493nm.  Islets were allowed five minutes to equilibrate to the test solution.  
Light emitted from the cells was detected, through a 515LP emission filter, using a Zeiss 
axiovert S100 epifluorescence microscope (Carl Zeiss Ltd, UK) and images captured with 
a Quantix photometrics CCD camera (Roper Scientific, USA).  Background fluorescence 
was subtracted from that of the islets.  Analysis was performed using Metafluor imaging 
software (Roper Scientific, USA).   
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Chapter Three:  Characterisation of HCN Channels 
 
To date, only three studies relating to the expression of HCN channels in the endocrine 
pancreas have been published.  The first described the presence of functional HCN 
channels in rat β-cells and MIN6 cells (El-kholy et al., 2007).  Transcripts for all HCN 
channel isoforms were found in rat islets, mouse islets and MIN6 cells.  In mouse islets, 
HCN2 mRNA levels were more than 10-fold in abundance compared to those of Kir6.2.  
Electrophysiology studies found that the current carried by HCN channels was similar, in 
terms of its biophysical and pharmacological properties, to those found in cardiac and 
neuronal cells.  HCN channel blockers had no affect on GSIS in rat islets.  Furthermore, 
blocking HCN channels did not affect membrane potential behaviour at basal glucose 
level, which was contrary to the authors’ original prediction (El-kholy et al., 2007).  Their 
latest study expanded on the function of HCN channels in rat β-cells, finding that under 
hypokalaemic conditions suppressing HCN channel activity suppresses insulin secretion 
(Zhang et al., 2009). 
 
Another study by the same group provided evidence for the presence of all HCN channel 
isoforms in rat α-cells and α-cell lines (Zhang et al., 2008).  Block of HCN current 
significantly enhanced glucagon secretion, whilst activation suppressed glucagon secretion.  
It was concluded that HCN channels modulate glucagon secretion via the entry of Na+, 
which lead to changes in intracellular Ca2+ levels. (Zhang et al., 2008) 
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Despite these initial studies, the functional significance of HCN channels, particularly in β-
cells, remains unclear.  To date, no studies have addressed the expression of HCN channels 
in the mouse or human pancreas. 
Aims: 
 
1. To define the expression of HCN channels in mouse α- and β-cells. 
2. To examine the actions of pharmacological modulators of HCN channels in 
glucose-induced insulin release. 
3. To provide the first study related to HCN channel expression in the human 
endocrine pancreas. 
4. To examine the developmental expression of HCN channels in the human 
foetal pancreas. 
5. To explore the possibility that modulation of HCN channels may be of benefit 
in the therapy of CHI. 
 
As HCN channel expression in CHI tissue was profoundly different to controls, an 
additional aim of these studies was; 
 
6. To examine whether loss of KATP channels leads to remodelling of HCN 
channel expression in the endocrine pancreas. 
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3.1  HCN Expression in the Mouse Pancreas and the MIN6 Cell Line 
In order to assess the expression of HCN isoforms in mouse islets, RT-PCR was used to 
detect the presence of mRNA and immunofluorescence to investigate the expression and 
localisation of the corresponding proteins.  Amplification of the housekeeping gene β-actin 
confirmed the integrity of the cDNA samples (Figure 3.1).  RT-PCR detected all HCN 
isoforms in mRNA isolated from mouse islets (Figure 3.1).  Positive controls were used 
confirm the accuracy of the primers.  In 22/22 mouse islets HCN1 co-stained strongly with 
insulin indicating its presence in pancreatic β-cells (Figure 3.2).  In order to evaluate if 
HCN1 was also present in pancreatic α-cells a co-stain with glucagon was performed.  In 
16 out of 16 islets HCN1 was found to be absent from the majority of mouse α-cells, 
indicated by no co-staining with glucagon-positive cells (Figure 3.3).  However, in all 
islets examined there was a minority, often 1 or 2 cells only, that displayed co-staining 
with glucagon (Figure 3.4).  Therefore, the presence of HCN1 in mouse α-cells could not 
be entirely ruled out. 
 
HCN2 and HCN4, similar to HCN1, were found to be present in mouse β-cells (Figure 
3.2).  In 26/26 mouse islets HCN2 co-stained strongly with insulin.  HCN4 showed strong 
co-staining with insulin in 19/19 islets.  Co-staining experiments with glucagon revealed 
that in 18/18 islets HCN4 was absent from the majority of α-cells (Figure 3.3).  However, 
as with HCN1, HCN4 expression in mouse α-cells could not be ruled out entirely as a 
minority of cells showed co-staining with HCN-positive and glucagon-positive cells 
(Figure 3.4).  In 21/21 islets HCN2 was entirely absent from mouse α-cells (Figure 3.3).  
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The MIN6 cell line was used as a mouse β-cell model for HCN isoform expression.  RT-
PCR confirmed the presence of mRNA corresponding to all HCN isoforms in MIN6 cells 
and immunofluorescence studies confirmed the expression of HCN1, HCN2 and HCN4 
proteins (Figure 3.5).  These results are consistent with published data (El-Kholy et al., 
2007) and suggest that MIN6 cells resemble mouse β-cells, in relation to HCN expression.   
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Figure 3.1.  HCN1, HCN2, HCN3 and HCN4 mRNA is expressed mouse islets.  Results were obtained from 1.5% Agarose gel.  PCR products of the correct size were detected for 
all HCN isoforrns in mRNA isolated from mouse islets (I) and from positive controls (Br = Brain, H = Heart).  PCR products of the correct size were detected for the housekeeping 
gene β-actin in mRNA isolated from various mouse tissues (Pa = Pancreas, K = Kidney, Li = Liver, T = Tongue, Sp = Spleen, St = Stomach, I = Islet).  No PCR products were 
detected in the mouse gDNA (genomic DNA) control (G) for HCN1 or β-actin as the primers spanned an intron.  Reverse transcriptase negative control = RT- and water control = 
H20.  
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Figure 3.2.  HCN1, HCN2, and HCN4 are expressed in mouse pancreatic β-cells.  HCN1-, HCN2, and HCN4-immunoreactive antibodies (red) 
co-stained (yellow) with insulin-immunoreactive antibodies (green) in  22/22, 26/26, and 19/19 islets respectively.  Nuclei were stained with 
DAPI (blue).  Scale bars = 100µm.     
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Figure 3.3.  HCN channels are not expressed in the majority of mouse pancreatic α-cells.  HCN1-, HCN2, and HCN4-immunoreactive antibodies 
(red) predominantly did not co-stain (yellow) with glucagon-immunoreactive antibodies (green) in 16/16, 21/21, and 18/18 islets respectively.  
HCN1- and HCN4-immunoreactive antibodies co-stained with a minority of glucagon-positive cells.  Nuclei were stained with DAPI (blue).  Scale 
bars = 100µm.     
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Figure 3.4.  HCN1 and HCN4 are expressed in a minority or pancreatic α-cells.  The left panel 
highlights the expression of HCN1 (red) in glucagon-positive cells (green).  The right panel shows 
the expression of HCN4 in a minority of mouse α-cells as indicated by the co-stain with glucagon 
(yellow).    
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Figure 3.5.  HCN expression in the MIN6 cell line.  The upper panels show that HCN1-, 
HCN2- and HCN4-positive MIN6 cells (red) were detected by immunofluorescence.  Nuclei 
are stained with DAPI (blue).  Scale bar = 10µm.  The lower panel displays PCR products of 
the appropriate size for all HCN isoforms as detected in mRNA isolated from MIN6 cells (+) at 
passage 27.  G = mouse genomic DNA, RT- = no reverse transcriptase control, H20 = water 
control. 
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3.2  HCN Channel Function in Mouse Islets 
The functional significance of HCN channels in pancreatic β-cells has yet to be 
determined.  Using the HCN channel blocker Cilobradine resulted in no significant 
difference between insulin release measured at 0mM or 11.1mM glucose in rat islets (El-
Kholy et al., 2007).  However, the HCN channel blocker ZD7288 significantly inhibited 
insulin secretion at 11.1mM glucose in both rat islets and MIN6 cells (El-Kholy et al., 
2007).  The authors further suggested that this action might not be related to HCN 
channels, but through an effect of ZD7288 on exocytosis directly. 
 
Q-PCR studies have revealed that mouse islets contain a greater abundance of HCN 
channels than rat islets, especially when compared to the KATP subunit Kir6.2 (El-Kholy et 
al., 2007).  This suggests that species differences may exist and it is possible that this may 
result in functional differences.  The functional significance of HCN channels in mouse 
islets has, to date, not been examined.   
 
The binding of cAMP to HCN channels increases channel opening directly by increasing 
the rate of opening and moving the activation potential to more positive potentials 
(DiFrancesco and Tortora, 1991).  Recent evidence suggests that glucose-induced cAMP 
oscillations regulate the magnitude of pulsatile insulin release (Dyachok et al., 2008).  
Therefore cAMP may have a significant role in GSIS.  The possibility that HCN channels 
may contribute to the effects brought about by elevated cAMP in the β-cell has been 
briefly suggested (Kim et al., 2008) but not investigated. 
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Insulin ELISA assays were therefore used to investigate the function of HCN channels in 
mouse islets.  Zatebradine was used as a selective HCN channel inhibitor (blocks only 
HCN current) (Van Bogaert and Pittoors, 2003, El-Kholy et al., 2007) at a concentration of 
3µM.  At this concentration others have shown that Ca2+ channels are not affected by the 
drug, and that inhibitory effects on outward potassium currents are minimised (Bois et al., 
1996, Satoh and Yamada, 2002). 
 
Zatebradine caused a significant (p<0.05) and selective inhibition of GSIS at 10mM 
glucose only (n=3) (Figure 3.6).  In order to compare the effects of HCN channel block on 
GSIS, and to establish that the selective nature of this effect was genuine, the actions of the 
KATP channel opener diazoxide was also tested.  Diazoxide caused a significant (p<0.001) 
inhibition of GSIS at 10mM, 15mM and 20mM glucose (n=3).  This confirmed the 
selective actions of zatebradine on intermediary glucose concentrations. 
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To examine if increasing the activity of HCN channels would have the opposite affect, the 
HCN channel agonist lamotrigine was used at a concentration of 10µM (Zhong and 
Zucker, 2005, Zhang et al., 2008).  Lamotrigine had no affect on GSIS at any 
concentration of glucose (n=3) (Figure 3.7). 
 
* p<0.05 
** p<0.001 
 
Figure 3.6.  Zatebradine and diazoxide inhibit GSIS in mouse islets. Addition of 3µM zatebradine 
inhibited insulin secretion from mouse islets at 10mM glucose only (p<0.05) when compared with 
control islets.  Inhibition of insulin secretion by 200µM diazoxide was significant (p<0.001) at 
10mM glucose and higher glucose concentrations, highlighting the selective inhibition by 
zatebradine.  Mouse islet data are typical of n=3 separate experiments.  Values are expressed as 
means ± SEM.  Comparisons were made using one-way ANOVA.  
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In order to address the possible link between cAMP elevation in β-cells and HCN channel 
activity, the ability of 10µM forskolin to amplify GSIS in the presence of 3 µM 
zatebradine was examined.  As expected, 10µM forskolin caused significant (p<0.05) 
amplification of GSIS at 10mM glucose (n=3) (Figure 3.8).  No amplification of GSIS was 
observed at 5mM glucose or glucose concentrations above 10mM.  Zatebradine again 
caused a significant (p<0.05) and selective (10mM glucose) inhibition of GSIS.  In the 
presence of 3µM zatebradine, 10µM forskolin was unable to significantly amplify GSIS 
when compared to islets stimulated with glucose alone (Figure 3.8).  Forskolin was, 
however, still able to amplify GSIS significantly (p<0.05) in the presence of zatebradine 
Figure 3.7.  Lamotrigine does not affect GSIS in mouse islets. Addition of 10µM lamotrigine had no 
effect on insulin secretion from mouse islets when compared with control islets.  Mouse islet data are 
typical of n=3 separate experiments.  Values are expressed as means ± SEM.   
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(green column) when compared with the insulin response of islets stimulated with glucose 
in the presence of zatebradine (blue column).  This suggests that the amplifying effects of 
forskolin on GSIS do not require HCN channel activity. Another possibility is that the 
inhibition of HCN channels is overcome by the elevation of cAMP.  
 
 
 
 
 
 
 
 
* p<0.05 
 
Figure 3.8.  Forskolin can still amplify GSIS in the presence of zatebradine. Addition of 10µM 
forskolin amplified GSIS at 10mM glucose (p<0.05).  Addition of 3µM zatebradine inhibited 
insulin secretion from mouse islets at 10mM glucose only (p<0.05) when compared with control 
islets.  Forskolin amplified GSIS significantly (p<0.05) at 10mM glucose in the presence of 3µM 
zatebradine when compared with the insulin response of mouse islets in the presence of 3µM 
zatebradine.  Mouse islet data are typical of n=3 separate experiments.  Values are expressed as 
means ± SEM.  Comparisons were made using one-way ANOVA.  
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3.3  Investigation of HCN channel function using the fluorescent membrane potential 
probe diBAC4(3) 
In order to establish the significance of HCN channel function, with regards to the 
membrane potential behaviour of pancreatic β-cells, the fluorescent membrane potential 
probe bis-(1,3-dibutylbarbituric acid) trimethine oxonol (diBAC4(3)) was used.  The use of 
a membrane potential probe provides the advantage of being able to monitor the membrane 
potential of β-cells within intact islets.  This is of importance as normal β-cell behaviour 
has been shown to be partly dependent upon cellular contact with other islet cells as well as 
paracrine interactions (Meda et al., 1990).  Furthermore, monitoring the membrane 
potential of islets in this way may help provide further evidence for the presence of 
functional HCN channels in islet cell types other than β-cells. 
 
DiBAC4(3) has previously been used successfully to identify and monitor the response of 
mouse α- and β-cells to changes in glucose concentration in intact islets (Hjortoe et al., 
2004).  Numerous attempts were made in the current study to adapt that methodology as 
outlined by Hjortoe et al., 2004, but without success.  The primary problem was the 
inability of the mouse islets to attach to glass coverslips.  Previously, our laboratory has 
observed that mouse islets can attach to glass coverslips using fibronectin-coated 
coverslips (10µg/ml), for use in Ca2+ imaging experiments (Johnson et al., 2007).  
However, following incubation with diBAC4(3) islets were found to have become 
detached.  Poly-l-lysine, Cell Tak, Matrigel, and Laminin/Fibronectin were used at a 
variety of concentrations (See Methods, Section 2.4) in order to establish a reliable method 
for the attachment of mouse islets to glass coverslips.  Islets failed to attach to glass 
coverslips coated with all tested concentrations of Poly-l-lysine.  Laminin, Fibronectin, and 
Laminin/Fibronectin combinations failed to aid the attachment of islets to glass coverslips.  
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Moderate success was achieved with all concentrations of Cell-Tak.  Mouse islets attached 
to coverslips prior to incubation with diBAC4(3). However, following the initial incubation 
with diBAC4(3) islets were found to have detached.  This occurred at all concentrations of 
diBAC4(3) that mouse islets were incubated with.  Greater success was achieved using 
Matrigel.  Mouse islets remained attached to glass coverslips even after incubation with 
diBAC4(3).  However, when diBAC4(3) was excited it produced a significant background 
fluorescence which was of comparable strength to that produced by the binding of 
diBAC4(3) to mouse islet proteins.  This problem occurred at all concentrations of 
diBAC4(3) and persisted even when mouse islets were depolarised with 40mM KCl 
resulting in a very poor signal. 
 
3.4  HCN Channel Expression in the Human Foetal Pancreas 
Pancreatic β-cells of the human foetal pancreas become progressively more responsive to 
glucose throughout gestation.  Small, monophasic insulin responses to glucose are 
observed after 17 weeks of gestation, but only after birth are mature biphasic responses 
seen (Otonkoski et al., 1988).     
 
The expression of proteins involved in the GSIS pathway defines the functionally mature 
β-cell.  Scattered insulin-positive cells have been observed as early as 8 wpc (weeks post 
conception) (Piper et al., 2004).  Primitive islet-like structures are first observed at 12 wpc 
and initially consist almost entirely of insulin- and glucagon-positive cells (Piper et al., 
2004, Jeon et al., 2009).  The KATP subunit, Kir6.2, and the GLUT1 transporter have been 
detected as early as 13 wpc (Mally et al., 1994, Weinhaus et al., 2003).  However, further 
investigations showed that these proteins were likely to have been detected in the 
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pancreatic epithelium and are not present in β-cells prior to 16 wpc (Richardson et al., 
2007).  Glucokinase, GLUT1 and KATP channels are detected in only a minority of β-cells 
prior to 15 wpc but are detected in increasing proportions throughout gestation as well as 
postnatally (Richardson et al., 2007).  An incomplete set of the key glucose-sensing 
components in the foetal pancreas explains the poor responses observed previously 
(Otonkoski et al., 1988). 
 
Tracking the expression of HCN channels through development will provide evidence 
relating to the importance of these channels in the neogenesis of the pancreatic β-cell and, 
potentially, the β-cell response to glucose.  As pancreatic β-cells are thought to develop 
from progenitors located in the foetal pancreatic duct epithelium (Bouwens et al ., 1997), 
the presence of HCN channels in the duct epithelium may prove to be important in 
research that aims to harness the regenerative capacity of the pancreas as a therapy for 
diseases where β-cell mass is reduced (Xia et al., 2009). 
 
At 9+6 wpc no HCN1- or insulin-positive cells were observed in the foetal pancreas 
(Figure 3.9).  By 10+2 wpc scattered individual insulin-positive cells were detected.  
HCN1-positiive cells were predominantly observed in structures resembling the pancreatic 
duct epithelia, whilst staining in the exocrine pancreas was largely absent (Figure 3.9). 
Duct cells were identified as closed structures, defined by a continuous sequence of cells 
(as identified by DAPI) surrounding a central space.  These structures were often, but not 
always, circular and can appear as a tightly clustered group of cells.   Co-staining was also 
observed with HCN1 and insulin in the majority of insulin-positive cells detected.  By 
11+3 wpc, HCN1 staining was particularly strong in structures resembling the pancreatic 
duct epithelia (Figure 3.9).  HCN1 appeared to be largely absent from the exocrine 
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pancreas although some weak staining could be discerned.  Small islet-like structures had 
begun to form at 11+3 wpc, which was evident from the clustering of insulin-positive cells.  
At this stage HCN1 was present in β-cells, evidenced by co-staining with insulin.   
 
Interestingly, HCN1 staining was not observed until insulin-positive cells were detected, 
including the presence of HCN1 in the pancreatic duct epithelium.  This may suggest that 
HCN1 is important in the formation and function of the pancreatic β-cell at this stage of 
development.  
 
The pattern of HCN2 staining in the developing pancreas resembled that of HCN1.  HCN2 
was not detected at 9+6 wpc, but at 10+2 wpc weak HCN2 staining was observed in 
structures resembling the pancreatic duct epithelium (Figure 3.10).  HCN2 was entirely 
absent from the exocrine tissue at this stage.  Insulin-positive cells were not detected at 
10+2 wpc.  As all sections were taken from the same sample, it is likely that the failure to 
detect insulin-positive cells was because this particular section did not bisect these cells, 
rather than representing their absence.  HCN2 may be present in insulin-positive cells at 
this stage but further investigation would be required to clarify this.  Due to the limited 
availability of tissue sections for this sample, it was not possible to repeat.  By 11+3 wpc 
HCN2 co-stained strongly with insulin in islet-like structures, and showed weak expression 
in the exocrine pancreas (Figure 3.10).  HCN2 staining in the pancreatic duct epithelium 
was also notable.  In one of the structures resembling the pancreatic duct epithelium, 
HCN2 and insulin co-staining was observed (Figure 3.12).  This was of particular interest 
as cells appeared to be in transition from the pancreatic duct to an islet-like cluster.  This 
may represent the transition from a progenitor cell type to a more differentiated β-cell 
phenotype. 
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In contrast to HCN1 and HCN2, HCN4 staining was completely absent from the 
developing pancreas up to 11+3 wpc (Figure 3.11).  Single insulin-positive cells were 
again detected at 10+2 wpc, and were seen to form small islet-like clusters by 11+3 wpc. 
In contrast to the immunofluorescence data, mRNA for all HCN isoforms was detected by 
RT-PCR at all stages of development (Figure 3.13).  This may reflect post-transcriptional 
regulation during the examined periods of development.    
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Figure 3.9.  HCN1 is expressed in the human foetal pancreas.  HCN1-positive cells (red) were observed at 10+2 wpc and 11+3wpc.  HCN1 was 
predominantly detected in the pancreatic duct epithelia but also co-stained (yellow) with insulin-positive cells (green).  Nuclei were stained with 
DAPI (blue).  Scale bars = 100µm.     
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Figure 3.10.  HCN2 is expressed in the human foetal pancreas.  HCN2-positive cells (red) were observed at 10+2 wpc and 11+3wpc.  HCN2 was 
detected in the pancreatic duct epithelia from 10+2 wpc.  No insulin-positive cells (green) were detected until 11+3 wpc.  HCN2 and insulin 
showed strong co-staining (yellow) at11+3 wpc.  Nuclei were stained with DAPI (blue).  Scale bars = 100µm.     
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Figure 3.11.  HCN4 protein is not expressed in the human foetal pancreas.  HCN4-positive cells (red) were not observed in the foetal pancreas.  
Single insulin-positive cells (green) were detected at 10+2 wpc. At 11 wpc insulin-positive cell had begun to form islet-like clusters.  Nuclei were 
stained with DAPI (blue).  Scale bars = 100µm.     
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Figure 3.13.  HCN mRNA expression in the human foetal pancreas.  Transcripts 
corresponding to all HCN isoforms were detected in the human foetal pancreas.  G = human 
gDNA, 9 = 9+6 wpc, 10 = 10+2 wpc, 11 = 11+3 wpc, RT- = reverse transcriptase negative 
control, H2O. 
Figure 3.12.  Insulin-positive cells originating from the pancreatic duct epithelium.  Insulin-
positive cells appeared to be growing out of a structure resembling the pancreatic duct 
epithelium (indicated by the arrow).  HCN2-positive cells = red, Insulin-positive cell = green, 
co-staining = yellow.  This figure has been adapted from figure 3.10 and shows the 
expression HCN2 and insulin in the human foetal pancreas at 11 wpc.  
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3.5  HCN Channel Expression in the Adult Human Pancreas 
The expression and localisation of HCN1, HCN2 and HCN4 was examined, for the first 
time, in two human adult pancreata (designated NH-1 and NH-2).  RT-PCR revealed the 
presence of all HCN isoforms in human adult islet and whole pancreas samples (NH-1) 
(Figure 3.14).  Amplification of the housekeeping gene 18s confirmed the integrity of 
cDNA samples for all human samples examined (Figure 3.14).  Variation was observed in 
the intensity of the genomic DNA control.  This is may reflect differences in the efficiency 
of the PCR reaction, or, differences in the initial number of copies of each gene in the 
original sample (although the data is not quantitative).  Immunofluorescence studies 
showed that, in both NH-1 and NH-2, HCN1, HCN2 and HCN4 were present in β-cells, as 
shown by co-staining with insulin (Figure 3.15, Figure 3.17).  In the NH-1 pancreas, no 
HCN staining was observed outside of the co-stain with insulin (Figure 3.15).  In the NH-2 
tissue, HCN2 and HCN4 showed some areas where staining had occurred outside of 
insulin-positive cells (Figure 3.17).  To test whether this represented HCN expression in α-
cells, as has been previously reported with rat islets (Zhang et al., 2008), HCN-glucagon 
co-stain experiments were performed.  In both NH-1 and NH-2 tissue, no co-staining with 
glucagon was observed (Figure 3.16, Figure 3.18).  HCN1, HCN2 and HCN4 staining was 
observed in the central region of islets, reflecting what was likely to be expression in β-
cells, and no staining was observed in the exocrine pancreas.  HCN2 and HCN4 appear to 
show positive staining in the exocrine pancreas (Figures 3.15 and 3.17).  This was 
classified as non-specific due to its relatively weak intensity when compared to positive 
staining in the same sample. 
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Figure 3.14.   HCN mRNA expression human pancreatic islets.  The upper panel shows the 
expression of HCN isoforms in human pancreatic islets.  Transcripts corresponding to all 
HCN isoforms were detected in human pancreatic islets.  G = human gDNA, I = Islet, P = 
Pancreas, RT- = reverse transcriptase negative control, H2O.  The lower panel shows the 
mRNA expression of the housekeeping gene 18s in mRNA isolated from the human adult 
pancreas (NH-1) and from the whole pancreas of the CHI patients examined in this study. 
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Figure 3.15.  HCN1, HCN2, and HCN4 are expressed in human NH-1 pancreatic β-cells.  HCN1-, HCN2, and HCN4-immunoreactive 
antibodies (red) co-stained (yellow) with insulin-immunoreactive antibodies (green) in 17/17, 17/17, and 20/20 islets respectively.  Nuclei were 
stained with DAPI (blue).  Scale bars = 100µm.     
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Figure 3.16.  HCN1, HCN2, and HCN4 are not expressed in human NH-1 pancreatic α-cells.  HCN1-, HCN2, and HCN4-immunoreactive 
antibodies (red) did not co-stain (yellow) with glucagon-immunoreactive antibodies (green) in 16/16, 18/18 and 21/21 islets respectively.  Nuclei 
were stained with DAPI (blue).  Scale bars = 100µm.     
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Figure 3.17.  HCN1, HCN2, and HCN4 are expressed in human NH-2 pancreatic β-cells.  HCN1-, HCN2, and HCN4-immunoreactive antibodies 
(red) co-stained (yellow) with insulin-immunoreactive antibodies (green) in 25/25, 25/25 and 23/23 islets respectively.  Nuclei were stained with 
DAPI (blue).  Scale bars = 100µm.     
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Figure 3.18.  HCN1, HCN2, and HCN4 are not expressed in human NH-2 pancreatic α-cells.  HCN1-, HCN2, and HCN4-immunoreactive 
antibodies (red) did not co-stain (yellow) with glucagon-immunoreactive antibodies (green) in 21/21, 21/21 and 22/22 islets respectively.  Nuclei 
were stained with DAPI (blue).  Scale bars = 100µm.     
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3.6  HCN Channel Expression in CHI 
The most severe cases of CHI are the result of defects in the KATP channel (Dunne et al., 
2004).  In as many as 50% of patients, no genetic basis for CHI has been determined 
(Fournet and Junien, 2003).  If medical treatment fails, partial surgery can cure Fo-CHI 
with little pancreatic insufficiency, no diabetes, and no postoperative recurrence (Adzick et 
al., 2004).  For Di-CHI, medical failure will often result in a near-total pancreatectomy, 
and consequently, diabetes and pancreatic insufficiency (Delonlay et al., 2007).  Hence 
there is a need to improve our understanding of CHI with the aim of reducing the need for 
surgical intervention.   
 
HCN channel expression in CHI was investigated at the mRNA and protein level in order 
to evaluate the potential contribution of HCN channels to CHI pathology, and to explore 
the potential that HCN channel modulation may be of benefit in the therapy of CHI.  All 
patient details including present mutations are summarised in table 2.4. 
 
3.6.1  HCN Channel Expression in Fo-CHI 
Three samples were obtained from a Fo-CHI patient (N139) who had a de novo mosaic 
ABCC8 frameshift mutation (a mutation not identified in either parent and present in some 
but not all cell populations).  Samples were labelled as ‘Lesion’, ‘Suspected’, and 
‘Healthy’ following analysis by the surgical team at Royal Manchester Children's Hospital.  
RNA was isolated from each sample and RT-PCR performed to evaluate HCN mRNA 
presence.  Immunofluorescence studies were utilised to evaluate HCN protein expression. 
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In general, islets in the ‘Healthy’ samples appeared to have normal morphology, whereas 
both ‘Suspected’ and ‘Lesion’ samples contained hyperplastic insulin-positive cells, 
separated by relatively few exocrine cells when compared with the ‘Healthy’ sample 
(Figure 3.19).   
 
 
 
 
 
 
HCN1 protein was absent from insulin-positive cells in all samples, whereas HCN1 
expression in the exocrine pancreas was prominent in all samples (Figure 3.20).  This 
differed from the healthy adult tissue where HCN1 expression was restricted to pancreatic 
β-cells (Figure 3.15, Figure 3.17). 
Figure 3.19.  Pathophysiology of Fo-CHI.  Enlarged and irregular nuclei are evident within focal 
lesions (e.g N139L, N145L).  Outside focal lesions, scant cytoplasm is observed (e.g. N145H).  
Nuclei are stained with DAPI (blue).  Pancreatic β-cells are labelled with an insulin-
immunoreactive antibody (green).  Pathophysiological features (irregular nuclei) of Fo-CHI are 
highlighted by white arrows. 
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In the ‘Healthy’ sample, HCN2 co-stained with insulin indicating its presence in β-cells 
(Figure 3.21).  However, HCN2 was also detected in the exocrine pancreas.  This differed 
from that of the healthy adult pancreas, where HCN2 expression was seen only in the 
endocrine pancreas (Figure 3.15, Figure 3.17).  In ‘Suspected’ and ‘Lesion’ samples HCN2 
expression was lost in insulin-positive cells but retained in the exocrine pancreas (Figure 
3.21). 
 
HCN4 protein distribution did not entirely match with those of HCN1 or HCN2.  HCN4 
protein was completely absent from the ‘Lesion’ tissue.  In the ‘Suspected’ and ‘Healthy’ 
tissue, HCN4 co-stained with insulin and appeared to also be present in exocrine cells 
(Figure 3.22).   
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Figure 3.20.  HCN1 is not expressed in the pancreatic β-cells of N139.  HCN1-immunoreactive antibodies (red) detected the presence of HCN1 protein 
in the exocrine pancreas of the lesion, suspected lesion, and healthy tissue of N139.  No co-staining (yellow) was observed in insulin-positive cells 
(green).   Nuclei were stained with DAPI (blue).  Scale bars = 100µm.     
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Figure 3.21.  HCN2 is not expressed in the pancreatic β-cells of the N139 lesion or suspected lesion.  HCN2-immunoreactive antibodies (red) detected the 
presence of HCN2 protein in the exocrine pancreas of the lesion, suspected lesion, and healthy tissue of N139.  In the healthy tissue, co-staining (yellow) 
was observed in insulin-positive cells (green).   No co-staining was detected in the lesion or suspected lesion.  Nuclei were stained with DAPI (blue).  
Scale bars = 100µm.     
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Figure 3.22.  HCN4 is not expressed in the pancreatic β-cells of the N139 lesion.  In the healthy and suspected lesion tissue, co-staining (yellow) was 
observed with insulin-immunoreactive antibodies (green) and HCN4-immunoreactive antibodies (red).   HCN4 was entirely absent from the lesion.  HCN4 
was detected in exocrine cells of the suspected and lesion tissue.  Nuclei were stained with DAPI (blue).  Scale bars = 100µm.     
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Two samples were obtained from a second Fo-CHI patient (N145); one from the lesion and 
one from surrounding ‘healthy’ tissue.  This patient expressed a previously reported 
mutation in ABCC8.  Islets from the lesion showed abnormal and enlarged nuclei, whereas 
islets outside the lesion appeared to be ‘resting’ as indicated by the scant cytoplasm (Figure 
3.19). 
 
HCN1 protein expression in ‘healthy’ tissue was similar to that found in the healthy adult 
pancreas.  HCN1 co-stained with insulin, indicating its presence in β-cells (Figure 3.23). 
However, HCN1 expression was also evident in the exocrine tissue.  In contrast to the 
N145 ‘healthy’ tissue, tissue from the lesion of N145 showed no HCN1 protein expression 
in either islets or exocrine cells (Figure 3.23). 
 
Similar to patient N139, patient N145 showed co-staining of HCN2 and insulin in 
‘Healthy’ samples.  Expression was also evident in the exocrine tissue.  However, HCN2 
expression was entirely absent from the focal lesion (Figure 3.24).   
 
In the ‘Healthy’ N145 tissue, HCN4 protein was entirely absent (Figure 3.25).  In the 
lesion HCN4 did not appear to co-stain with insulin.    Rather, the staining observed 
appeared to be from a monolayer of exocrine cells lying on top of the insulin-positive cells.  
This differed from the staining pattern observed in tissue N139, where HCN4 was 
completely absent from the lesion. 
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The detection of mRNA for HCN isoforms showed variation between samples.  In N139, 
mRNA isolated from the whole pancreas was shown to contain sequences that matched all 
HCN isoforms in the ‘healthy’, ‘suspected’ and ‘lesion’ samples (Figure 3.26).  
Presumably, the mRNA detected represented the expression of the HCN isoforms in the 
exocrine tissue.  However, HCN4 mRNA was also detected in the lesion sample.  This 
suggests that HCN expression may be altered at the post-transcription level. 
 
In patient N145, HCN1 and HCN2 mRNA was detected in the ‘healthy’ whole pancreas 
mRNA.  HCN2 mRNA was not detected in the mRNA isolated from the ‘lesion’ tissue 
(Figure 3.26).  This was consistent with the immunofluorescence results.  HCN3 and 
HCN4 mRNA were not detected in either the ‘healthy’ or ‘lesion’ sample (Figure 3.26). 
 
Isolated mRNA from the lesion of two other FoCHI patients (N136 and N141), who had 
previously reported mutations in KCNJ11 and ABCC8 respectively, were examined.  All 
HCN isoforms were detected at the mRNA level in patient N141 (Figure 3.28).  Whereas 
HCN1 and HCN2 mRNA were found to be absent in N136 (Figure 3.28).  Only a weak 
signal was discernable for HCN3 and HCN4.  No tissue was available for 
immunofluorescence studies for these patients.    
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Figure 3.23.  HCN1 protein is not expressed in the N145 lesion.  HCN1-
immunoreactive antibodies (red) showed strong co-staining (yellow) with insulin-
immunoreactive antibodies (green) in tissue isolated from outside of the N145 lesion.  
HCN1 protein was completely absent from the N145 lesion.  Islets within the lesion 
were hyperplastic.  Islets outside of the lesion presented with scant cytoplasm as 
indicated by the insulin stain.  HCN1 protein was detected in the exocrine pancreas 
outside of the lesion. Nuclei were stained with DAPI (blue).  Scale bars = 100µm.     
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Figure 3.24.  HCN2 protein is not expressed in the N145 lesion.  HCN2-immunoreactive 
antibodies (red) co-stained (yellow) with insulin-immunoreactive antibodies (green) in tissue 
isolated from outside of the N145 lesion.  HCN2 protein was completely absent from the 
N145 lesion.  HCN2 protein was detected in the exocrine pancreas outside of the lesion. 
Nuclei were stained with DAPI (blue).  Scale bars = 100µm.     
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Figure 3.25.  HCN4 protein is not expressed outside of N145 lesion.  HCN4-
immunoreactive antibodies (red) showed no co-staining with insulin-immunoreactive 
antibodies (green) in tissue isolated from outside of the N145 lesion.  HCN4 protein 
was also absent in the exocrine pancreas from outside the lesion.  HCN4 protein was 
detected in the exocrine pancreas of the lesion.  HCN4 - positive cells appear to be 
present in the same areas as insuli-positive cells.  However, a clear co-stain is not 
achieved. The presence of HCN4 in the exocrine pancreas suggests that this pattern of 
staining may have been caused by a monolayer of cells resting on top of the insulin-
positive cells. Nuclei were stained with DAPI (blue).  Scale bars = 100µm.     
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Figure 3.26.  HCN mRNA expression in Fo-CHI and Di-CHI.  The upper panel shows 
that PCR products corresponding to transcripts of all HCN isoforms were detected in 
mRNA isolated from whole pancreas samples of N139.  A = Suspected lesion, B = 
Lesion, C= healthy.  The lower panel shows the presence of HCN isoform mRNA from 
whole pancreas sections of N145 and N146.  E = N145 healthy, F = N145 lesion, RT- = 
reverse transcriptase negative control, H2O = water control. 
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3.6.2  HCN Channel Expression in Di-CHI  
Tissue from five Di-CHI patients was examined, each with a unique mutation in either 
ABCC8 or KCNJ11.  RNA was extracted and RT-PCR performed to evaluate the presence 
of HCN channel mRNA and immunofluorescence performed to evaluate protein 
expression. 
 
Islets from Di-CHI patients were generally irregular in shape and hyperplastic.  Nuclear 
crowding and the presence of irregular shaped and enlarged nuclei were often observed 
(Figure 3.27).  In this way all Di-CHI tissues examined resembled the classic 
physiopathology (Dunne et al., 2004). 
 
 
 
 
Figure 3.27.  Pathophysiology of Di-CHI.  Nuclear crowding and enlarged, irregular shaped nuclei 
were observed in pancreatic sections isolated from Di-CHI patients (indicated by arrows).  Islets 
were generally hyperplastic and of an irregular morphology.  Nuclei were stained with DAPI (blue) 
and islets were labelled with an insulin-immunoreactive antibody (green).  
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HCN1 protein expression in Di-CHI contrasted with the expression patterns observed from 
the adult pancreas (where HCN1 co-stained with insulin).  HCN1 expression did not co-
stain with insulin in 4/5 Di-CHI patients (Figure 3.29-3.34).  HCN1 staining was largely 
uniformly weak in both exocrine and endocrine tissue suggesting that this was background 
staining.  The exceptions were N138 (ABCC8 mutation), N140 (ABCC8 mutation) (Figure 
3.30) and N146 (ABCC8 mutation) (Figure 3.34) where HCN1 staining was much stronger 
in the exocrine pancreas and appeared genuine.  HCN1 appeared to be present in the β-
cells of N138 (Figure 3.29).  However, staining was weak.  There appears to be no link 
between the gene on which the mutation was found and HCN1 expression pattern.  HCN1 
mRNA was found to be present in all Di-CHI patient tissues (Figure 3.26, Figure 3.28) 
with the exception of N138 (Figure 3.28). 
 
In 4/5 patients with Di-CHI (N140, N142, N144 and N146), HCN2 expression was lost 
from islets (Figure 3.30-3.34).  HCN2 appeared to be absent from all Di-CHI patients with 
the exception of N146 where there appeared to be genuine exocrine staining (Figure 3.34).  
HCN2 co-stained strongly with insulin in N138 (Figure 3.29) resembling the expression 
observed in the adult and foetal pancreas.  HCN2 mRNA was detected in all Di-CHI 
patients with the exceptions of N142 (KCNJ11 mutation), N137 and N138 (Figure 3.26, 
Figure 3.28).  This was surprising given the strong protein expression observed.  It is 
possible that β-cell mRNA was not sufficiently abundant in the mRNA isolated from the 
whole pancreas section to produce an amplified signal.   
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HCN3 mRNA was detected in all Di-CHI patients (Figure 3.26, Figure 3.28).  In patient 
N137 (ABCC8 mutation) only HCN3 and HCN4 mRNA were detectable by RT-PCR.  As 
no tissue was available for immunofluorescence studies, it is unclear whether this 
represents a true absence of the isoform protein.  
 
The expression of HCN4 in Di-CHI was very similar to that of HCN2.  HCN4 expression 
in N138 closely resembled the healthy adult pancreas as defined by the insulin-HCN4 co-
staining (Figure 3.29).  In N140, N142 and N144 (ABCC8 mutation), HCN4 expression 
was almost completely absent from the pancreas (Figure 3.30-3.33).  HCN4 was certainly 
absent from insulin-positive cells in N144 however, HCN4 displayed a sporadic pattern of 
expression in the exocrine pancreas of both N144 and N146.   A minority of islets 
observed in N146 did appear to express HCN4, although this was rare (Figure 3.34).  No 
pattern was discernable between the mutation and observed HCN4 expression pattern.  
HCN4 mRNA was detected in all whole pancreas samples examined (Figure 3.26, Figure 
3.28), and suggests that HCN expression may be regulated at a post-transcriptional level. 
 
Two years after the initial partial pancreatectomy, patient N140 was readmitted for further 
pancreatic resection.  HCN expression was investigated by immunofluorescence and RT-
PCR in tissue from the second operation (N140R).  HCN1, HCN2, and HCN4 protein was 
completely absent from pancreatic tissue removed during the second operation (Figure 
3.31). However, mRNA for all HCN isoforms was detected in whole pancreas mRNA 
samples (Figure 3.28, panel C).  The expression of HCN channels in N140R was identical 
to that from the original operation (N140), with the exception of HCN1, which was 
expressed in the exocrine pancreas of N140. 
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Figure 3.28.  HCN mRNA presence in Di-CHI, Fo-CHI and insulinoma.  PCR summary figures are 
presented to highlight the presence of HCN isoform mRNA in the CHI pancreas. The three upper 
panels (A-C) represent mRNA isolated from whole pancreas sections.  Numbers correspond to CHI 
patients as previously defined.    G = human gDNA, R = N140R, I = N143 non lesion islet, P = non 
lesion pancreas, RT- = reverse transcriptase negative control, H20 = water control. 
A 
B 
C 
D 
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Figure 3.29.  HCN1, HCN2 and HCN4 are expressed in the β-cells of N138.  HCN2- and HCN4-immunoreatcive antibodies (red) co-stained (yellow) 
with insulin-immunoreactive antibodies (green).  HCN1 positive cells (red) were predominantly detected in the exocrine tissue.  HCN1 also appeared 
to be present in insulin-positive cells.  Nuclei were stained with DAPI (blue).  Scale bars = 100µm.     
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Figure 3.30.  HCN1, HCN2 and HCN4 are not expressed in the β-cells of N140. HCN1-, HCN2- and HCN4-immunoreatcive antibodies (red) did not 
co-stain (yellow) with insulin-immunoreactive antibodies (green).  HCN1 positive cells (red) were predominantly detected in the exocrine tissue.  HCN2 
and HCN4 were not detected in the exocrine tissue.  Nuclei were stained with DAPI (blue).  Scale bars = 100µm.     
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Figure 3.31.  HCN1, HCN2 and HCN4 are not expressed in the β-cells of N140R. HCN1-, HCN2- and HCN4-immunoreatcive antibodies (red) did not 
co-stain (yellow) with insulin-immunoreactive antibodies (green).  HCN1,HCN2 and HCN4 were entirely absent from the exocrine tissue.  Nuclei were 
stained with DAPI (blue).  Scale bars = 100µm.     
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Figure 3.32.  HCN1, HCN2 and HCN4 are not expressed in the β-cells of N142. HCN1-, HCN2- and HCN4-immunoreatcive antibodies (red) did not 
co-stain (yellow) with insulin-immunoreactive antibodies (green).  Staining in the exocrine tissue was uniformly weak and not distinguishable from 
background staining.  Nuclei were stained with DAPI (blue).  Scale bars = 100µm.     
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Figure 3.33.  HCN1, HCN2 and HCN4 are not expressed in the β-cells of N144. HCN1-, HCN2- and HCN4-immunoreatcive antibodies (red) did not co-
stain (yellow) with insulin-immunoreactive antibodies (green).  A small number of HCN4 positive cells (red) were detected in the exocrine tissue.  HCN1 
and HCN2 were not detected in the exocrine tissue.  Nuclei were stained with DAPI (blue).  Scale bars = 100µm.     
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Figure 3.34.  HCN1, HCN2 and HCN4 are not expressed in the β-cells of N146. HCN1-, HCN2- and HCN4-immunoreatcive antibodies (red) did not 
co-stain (yellow) with insulin-immunoreactive antibodies (green).  HCN1, HCN2 and HCN4 positive cells (red) were detected in the exocrine tissue.  
HCN4 was detected in a minority of insulin-positive cells but expression was not consistent.  Nuclei were stained with DAPI (blue).  Scale bars = 
100µm.     
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3.7  HCN Channel Expression in Human Insulinoma 
Insulinomas, in common with CHI, cause hypoglycaemia as a result of inappropriate 
insulin secretion.  Of all functioning endocrine pancreatic tumours (EPTs), insulinomas are 
the most common (Jonkers et al., 2007).  Current treatment for insulinoma is dependent 
upon whether the tumour is benign or malignant.  Surgical removal, chemotherapy, and 
drug therapy aimed at palliating the symptoms of hypoglycaemia have all been employed 
(Jonkers et al., 2007). 
 
Although some insulinomas have a similar molecular background to Fo-CHI, relating to 
LOH (Loss of heterozygosity) of chromosome 11p15, they are distinct entities (Patel et al., 
1990; Stumpf et al., 2000, Sempoux et al., 2003).  When compared to Fo-CHI tissue, 
insulinomas show distinct morphological differences both inside and outside of the lesion.  
Outside insulinoma lesions, islets appear normal.  Islets surrounding a Fo-CHI lesion are 
small and have scant cytoplasm, indicating that these islets are in a ‘resting state’ 
(Sempoux et al., 2003).  Inside a Fo-CHI lesion, clusters of β-cells with high proliferation 
rates are surrounded by few exocrine acini and ductal tissues (Kassem et al., 2000).  
Insulinomas are less well separated from adjacent material and are composed almost 
exclusively of β-cells, whereas other islet cell types are often observed in Fo-CHI lesions 
(Sempoux et al., 2003). 
 
Functional differences are also present between insulinoma and Fo-CHI.  In Fo-CHI 
lesions, KATP channels are absent in the majority of cases whereas in insulinomas, these 
channels are often present and give appropriate responses to diazoxide (Hussain et al., 
2002).  Fo-CHI lesions contain significantly more proinsulin than tissue surrounding the 
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lesion but show no difference in insulin storage, suggesting abnormal release (Sempoux et 
al., 2003).  The same study showed that insulinomas contained significantly less proinsulin 
than Fo-CHI lesions.  This indicates that Fo-CHI lesions are in a higher functional state 
than insulinomas.  Insulinomas do, however, show consistently lower insulin levels within 
the lesion when compared to surrounding islets (Sempoux et al., 2003).  This is considered 
to be indicative of either low production or abnormal release. 
 
Evaluating the presence of HCN channels in insulinomas opens the possibility that 
modulation of HCN channel activity may be of potential therapeutic benefit.  Comparison 
of CHI HCN channel expression with that in the healthy adult pancreas will help discern 
whether the observed changes in HCN channel expression are unique to CHI pathology, or 
represent a broader spectrum of disorders potentially due to remodelling of the pancreas 
under pathological conditions. 
 
HCN1 expression was investigated in a patient with a focal-insulinoma (N143) caused by a 
mutation in the ABCC8 gene.  HCN1 expression was entirely absent from endocrine and 
exocrine tissue in both the lesion and non-lesion tissue (Figure 3.35).  There appears to be 
some HCN1 positive cells in the non-lesion tissue.  However, this is likely to be non-
specific staining as it is present also, although to a lesser extent, in the negative control.  
Furthermore, the same pattern of staining is observed in both the non-lesion and negative 
control of figure 3.39.  Therefore, this staining is likely to represent non-specific staining 
associated with the patient sample.  The insulinoma lesion appeared to be consistent with 
published data, in as much as it appeared to be exclusively composed of β-cells that were 
not well separated by exocrine cells (Figure 3.35).  Although it has been previously 
reported that islets surrounding an insulinoma appear to be normal (Sempoux et al., 2003), 
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islets outside of the insulinoma lesion showed areas of scant cytoplasm. Also, HCN1 
expression outside of the lesion was different than that seen in the human adult and foetal 
tissue.  In this way, islets outside the lesion resembled islets from the Fo-CHI patients, and 
suggests that islets outside of the lesion may differ from healthy islets.  
 
The expression of HCN2 in both the insulinoma lesion (ABCC8 mutation) and non-lesion 
tissue was observed and co-stained with insulin (Figure 3.36).  Islets outside the lesion 
appeared to be normal and the expression of HCN2 was similar to that of the healthy adult 
pancreas.  HCN2 expression was examined in a second insulinoma patient (mutation 
unknown) where co-staining with insulin was observed (Figure 3.38).  The tissue from the 
second patient also had the appearance of a classic insulinoma, with the majority of cells 
(as discerned by a DAPI stain) staining insulin-positive. 
 
In the focal-insulinoma (ABCC8 mutation) HCN4 expression was seen in the non-lesion 
tissue but was completely absent from the lesion itself (Figure 3.37).  HCN4 expression 
was also entirely absent from the insulinoma of the second patient (mutation unknown) 
although some non-specific staining was evident (see negative control) (Figure 3.39).  The 
expression of HCN4 in the non-lesion tissue differed from that observed in the healthy 
adult pancreas.  Whilst HCN4 did co-stain with insulin, albeit weakly, expression in the 
exocrine pancreas was also evident whereas it was largely absent in the healthy adult 
pancreas.  This suggests that islets that outside the insulinoma lesion undergo molecular 
changes and as a result may have altered functionality.   
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Figure 3.35.  HCN1 is absent inside and outside of the N143 lesion.  No HCN1-positive 
cells (red) were detected by immunofluorescence.  Insulin-positive cells (green) highlighted 
the distinct pathophysiology of the insulinoma lesion, where β-cells are observed as ‘nests’ 
of cells.  Islets outside of the lesion appeared to display normal morphology, although scant 
cytoplasm was often observed.  Nuclei were stained with DAPI (blue). 
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Figure 3.36.  HCN2 protein is expressed inside and outside of the N143 lesion.  HCN2-
positive cells (red) were detected by immunofluorescence and co-stained (yellow) with 
insulin-positive cells (green).  Nuclei were stained with DAPI (blue).  The left column scale 
bar = 10µm, the right column scale bar = 100µm.   
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Figure 3.37.  HCN4 protein is expressed outside of the N143 lesion.  HCN4-
positive cells (red) were detected by immunofluorescence and co-stained (yellow) 
with insulin-positive cells (green) in tissue isolated outside of the insulinoma 
lesion.  HCN4-positive cells were also evident in the exocrine tissue outside of the 
lesion.  HCN4 was entirely absent within the lesion.  Nuclei were stained with 
DAPI (blue).  Scale bar = 100µm.   
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Figure 3.38.  HCN2 protein is expressed in insulinoma.  HCN2-positive cells (red) were detected 
by immunofluorescence and co-stained (yellow) with insulin-positive cells (green).  Insulinoma 
cells appeared, morphologically as ‘ribbons’ of cells.  Nuclei were stained with DAPI (blue).  Scale 
bar = 100µm.   
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RT-PCR experiments on islets isolated from non-lesion insulinoma tissue (N143) showed 
the presence of mRNA corresponding to all HCN isoforms (Figure 3.28).  These data were 
consistent with immunofluorescence studies with the exception of HCN1.  HCN1 protein 
expression was absent in the non-lesion tissue from patient N143.  The problems faced 
with detecting islet cell mRNA in whole pancreas samples was evident.  Clear signals were 
obtained from mRNA isolated from a pure population of islets, whereas this signal was 
Figure 3.39.  HCN4 protein is absent in insulinoma.  HCN4-positive cells (red) were entirely 
absent from insulinoma.  Insulin-positive cells are labelled green.  Nuclei were stained with DAPI 
(blue).  Scale bar = 100µm.   
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greatly reduced and difficult to discern when mRNA from the whole pancreas was 
screened.  
 
3.8  HCN Channel Expression in the SUR1 KO Mouse 
SUR1 and Kir6.2 defects, which result in KATP channel loss-of-function, underlie many 
cases of CHI (Dunne et al., 1997, Flanagan et al., 2009).  KO mice have been generated 
lacking either ABCC8 or KCNJ11 as an animal model of CHI.  However, mice that 
completely lack KATP channels, as a result of either Kir6.2 or SUR1 deletion, do not always 
mimic the CHI phenotype (Nichols et al., 2007).  Both Kir6.2 and SUR1 knockout mice 
display spontaneous Ca2+ activity similar to that of CHI, but mice are normoglycaemic 
under fed conditions and do not display hyperinsulinism (Miki et al., 1998, Seghers et al., 
2000, Shiota et al., 2002).  Even though the phenotype of KO mice does not match that of 
CHI patients, they were used here as they allowed us to specifically address the 
relationship between SUR1 and HCN channel expression.   
 
Immunofluorescence studies were carried out on three different SUR1-/- mice and three 
wild type mice of the same strain.  All mice were of the same sex (male), approximately 6 
months old and were all born within 3 weeks of each other.   
 
Co-staining of HCN1 and insulin was observed in 17 out of 17 wild type islets (Figure 
3.40).  In SUR1-/- mice HCN1 did not co-stain with insulin in 13 out of 13 islets (Figure 
3.40).  Weak HCN1 staining was observed in insulin-negative cells within the islet and in 
the surrounding exocrine tissue of one mouse but was completely absent in the other mice.  
A similar pattern of expression (the loss of HCN1 from insulin-positive cells) was 
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observed in the majority of Di-CHI patients (4/5), insulinoma (N143), and both Fo-CHI 
lesion and non-lesion tissue (N139). 
 
HCN2 expression differed in SUR1-/- mice as compared with the wild type mice.  In 19 out 
of 19 wild type islets HCN2 co-stained with insulin as was expected (Figure 3.41).  In 
SUR1-/- mice HCN2 co-stained with insulin but was also present in the exocrine pancreas 
(12 out of 12 islets) (Figure 3.41).  HCN2 staining in SUR1-/- mice strongly resembled that 
in N138 (Di-CHI) and the insulinoma patients, but is not consistent with other CHI tissues 
where HCN2 is largely absent from islets. 
 
HCN4 also showed altered expression in the SUR1-/- mice.  HCN4 co-stained with insulin 
in 19 out of 19 wild type islets but was entirely absent from the SUR1-/- mice (13 out of 13 
islets) (Figure 3.42).  Although HCN4 appeared to be absent from the majority of CHI 
patient islets, the staining observed in SUR1-/- mice did not resemble CHI HCN4 
expression.  HCN4 staining in the exocrine tissue was entirely absent in SUR1-/- mice 
whereas it was detected in the exocrine pancreas of some CHI patients.  HCN4 staining on 
the SUR1-/- mice most closely resembled that seen in the insulinoma patients. 
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Figure 3.40.  HCN1 expression in the SUR1-/- mouse.  HCN1-immunoreactive 
antibodies (red) co-stained (yellow) with insulin-immunoreactive antibodies (green) in 
the wild type mouse (17/17 islets).  No HCN1-positive cells were expressed in the 
exocrine pancreas of the wild type mouse.  In the SUR1-/- mouse, HCN1 expression in 
insulin-positive cells was lost (13/13 islets).  Results are representative of experiments 
in 3 seperate mice.   Nuclei were stained with DAPI (blue).  Scale bar = 100µm.   
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Figure 3.41.  HCN2 expression in the SUR1-/- mouse.  HCN2-immunoreactive 
antibodies (red) co-stained (yellow) with insulin-immunoreactive antibodies (green) in 
the wild type mouse (19/19 islets).  No HCN2-positive cells were expressed in the 
exocrine pancreas of the wild type mouse.  In the SUR1-/- mouse, HCN2 expression 
was detected in insulin-positive cells (12/12 islets).  Results are representative of 
experiments in 3 seperate mice.   Nuclei were stained with DAPI (blue).  Scale bar = 
100µm.   
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Figure 3.42.  HCN4 expression in the SUR1-/- mouse.  HCN4-immunoreactive 
antibodies (red) co-stained (yellow) with insulin-immunoreactive antibodies (green) in 
the wild type mouse (19/19 islets).  No HCN4-positive cells were expressed in the 
exocrine pancreas of the wild type mouse.  In the SUR1-/- mouse, HCN4 expression in 
insulin-positive cells was lost (13/13 islets).  Results are representative of experiments 
in 3 seperate mice.   Nuclei were stained with DAPI (blue).  Scale bar = 100µm.   
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3.9  HCN Expression in the NES2Y Cell Line 
The NES2Y cell line was originally derived by continual subculture of pancreatic islets 
isolated from a patient with sporadic CHI that resembled the diffuse form of CHI in 
appearance (Kane et al., 1996, MacFarlane et al., 1997).   
 
NES2Y cells display similar properties to those of isolated insulin-secreting cells of CHI 
patients (Dunne et al., 1999).  No KATP channel activity was detected and as a consequence 
they secreted insulin at constitutively high levels, even in the absence of glucose 
(MacFarlane et al., 1999).  Although no significant difference between insulin release at 
stimulatory and sub-stimulatory levels is observed, insulin release is consistently higher at 
stimulatory glucose concentrations (MacFarlane et al., 1997, 1999, 2000).  Impaired 
expression of PDX1 has also been reported in NES2Y cells.  Triple transfection of Kir6.2, 
SUR1, and PDX1 resulted in the restoration of KATP activity, normal intracellular calcium 
activity and an appropriate insulin response to glucose (MacFarlane et al., 1999). 
 
As CHI is a rare disorder, the NES2Y cell line represents a major advance in CHI research.  
The insulin promoter in NES2Y cells is unresponsive to glucose due to the reduced 
expression of the transcription factor PDX1 (MacFarlane et al., 1997).  However, the 
response to glucose of other genes in the NES2Y cell line has yet to be investigated.  
Determining the presence of HCN channels, and their response to different glucose 
concentrations in culture, (in the NES2Y cell line) may provide further insight into the 
properties of CHI islets, as well as the potential for HCN channel modulation in the 
therapy of CHI. 
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NES2Y cells were cultured in RPMI containing the glucose concentrations 1mM, 3mM, 
5mM, 10mM, 15mM and 20mM.  After 1 week of culture, NES2Y cells were split for 
further culture (1:5), RNA was extracted, and NES2Y cells were cultured overnight (in 
their respective glucose conditions) on glass coverslips for immunofluorescence studies. 
 
Following 1 week of culture, mRNA corresponding to all HCN isoforms was detected at 
all glucose culture conditions with the exception of HCN1 (Figure 3.43, panel A).  At 
1mM and 3 mM glucose no signal for HCN1 was detected.  Immunofluorescence 
confirmed the expression of HCN2 and HCN4 at the protein level (Figure 3.44).  HCN1 
protein expression was not examined at the time due to the absence of a selective HCN1-
immunoreactive antibody. 
 
After 2 weeks of culture, HCN isoform expression was identical to that of week 1 (Figure 
3.43, panel B).  NES2Y cells continued to divide at a similar rate regardless of glucose 
concentration.  Following 3 weeks of culture HCN2 and HCN4 expression appeared 
constant at both an mRNA level (although bands are weak at 3mM and 5mM glucose) and 
protein level (Figure 3.43, panel C, Figure 3.44).  HCN1 expression was not seen at 
glucose concentrations lower than 10mM glucose and HCN3 expression was lost at 1mM 
and 3mM glucose (Figure 3.43, panel C).  A reduction in the intensity of the genomic 
control bands is also seen.  This may reflect a reduction in PCR reaction efficiency and 
therefore account for the weaker bands observed across all samples from panel C.   
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A 
B 
C 
Figure 3.43.  HCN mRNA expression in NES2Y cells cultured at various glucose 
concentrations.  Numbers refer to glucose concentrations in culture (mM).  The top panel 
(labelled A) represents HCN isoform expression after 1 week of culture, the middle (B) 
after 2 weeks of culture, and the the bottom (C) after 3 weeks of culture.  G = human 
gDNA, RT- = reverse transcriptase negative control, H2O = water control.     
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Figure 3.44.  HCN protein expression in NES2Y cells cultured at various glucose 
concentrations.  HCN2- and HCN4-immunoreactive antibodies (red) detected HCN 
protein expression in complete correlation with HCN mRNA presence.  NES2Y cells 
expressed insulin protein (green) at all glucose concentrations following each week of 
culture.  Images were taken from10mM glucose culture but are representative of all 
relevant culture conditions.  Nuclei were stained with DAPI (blue).  Scale bar = 100µm.   
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3.10  Antibody specificity 
These results have largely relied upon immunohistochemical data.  Therefore, the results 
were subject to a number of variables, most notably, the specificity of the antibodies used.  
The specificity of the secondary antibodies is addressed by the inclusion of a negative 
control (omission of the primary antibody) in each figure presented.  In order to determine 
the specificity of the primary antibody, the ideal control would be to test the antibody on a 
tissue devoid of the target antigen, ideally this would be tissue isolated from a knockout 
animal.  However, the use of knockout tissue also has its pitfalls.  The genetic knockout of 
the target can result in the upregulation of a potentially homologous protein (Fritschy, 
2008) and, therefore, has the potential to produce false positives (although this is rare).  As 
knockout tissue for our primary antibodies was not available, we tested the specificity of 
our primary antibodies (HCN1, HCN2, HCN4) on tissue that has independently been 
shown to be absent of our target proteins (Ludwig et al., 1998, Santoro et al., 1998).  
Immunofluorescence revealed that our primary antibodies detected no signal for any of our 
target proteins in the mouse liver (Figure 3.45).  This suggests that our primary antibodies 
were specific for our target proteins. 
 
The majority of primary antibodies used in this study were of a polyclonal nature.  Only 
the glucagon-immunoreactive antibody was monoclonal (IgG).  IgGs are known to bind 
with low affinity to numerous (mostly unidentified) tissue constituents (Fritschy, 2008).  
Therefore, in order to determine the amount of non-specific staining produced by the 
glucagon-immunoreactive antibody, isotype controls were included for both the mouse and 
healthy human pancreatic tissue.  No signal was observed from the mouse or human 
pancreas (Figure 3.46), suggesting that the signal produced by detection of the glucagon-
immunoreactive antibody was of a specific nature. 
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Figure 3.45.  HCN primary antibody specificity.  Primary antibodies detected 
against HCN1, HCN2 and HCN4 and detected indirectly by a secondary antibody 
produced no signal in the mouse liver.  Nuclei were stained with DAPI (blue).  Scale 
bar = 100µm 
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No positive controls were performed for HCN antibodies due to the region specific 
expression of HCN channels.  However, HCN antibodies from the same manufacturer have 
been used by numerous other studies in which antibody specificity was confirmed in 
various tissues, including the heart (Buniel et al., 2008, Brioshi et al., 2009, Tu et al., 
2010). 
 
 
 
 
 
 
 
Figure 3.46.  IgG isotype control.  No signal was observed when the monoclonal 
glucagon-immunoreactive antibody was replaced with a pure IgG preparation.  Nuclei are 
stained with DAPI (blue).  Scale bar = 100µm. 
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3.11  Discussion 
This study provides, for the first time, evidence for the expression of functional HCN 
channels in mouse pancreatic β-cells.  RT-PCR revealed the presence of mRNA 
corresponding to all known HCN isoforms in mouse islets.  This is in agreement with 
previously published QPCR data (El-Kholy et al., 2007).  Immunofluorescence studies 
revealed that HCN1-, HCN2- and HCN4- immunoreactive antibodies co-stained with 
insulin-immunoreactive antibodies, indicating the presence of HCN channels in mouse 
pancreatic β-cells.  Immunofluorescence co-stain studies with glucagon could not rule out 
the expression of HCN channels in mouse α-cells.  Although absent from the majority of α-
cells, HCN1 and HCN4 co-staining was consistently observed in a minority of mouse α-
cells.  This may reflect the presence of two distinct populations of mouse α-cells.  In low 
(or sub-stimulatory) glucose levels, α-cells generate action potentials and secrete glucagon 
in a rhythmic manner.  It has been shown that only a minority of mouse α-cells (25%) 
express Ca2+ channels with the necessary activation thresholds to act as ‘pacemakers’ for 
these cells (Leung et al., 2006).  Therefore, it is possible that the expression of HCN 
channels, in a population of mouse α-cells, may contribute to the rhythmic generation of 
action potentials in low glucose.  Indeed, recent evidence from rat islets indicates that HCN 
channels may have a role in modulating the electrical activity of α-cells via the modulation 
of Na+ and Ca2+ channels (Zhang et al., 2008).  The functional significance of HCN 
channels in mouse α-cells was not addressed in this study. 
 
The function of HCN channels in mouse islets was investigated by insulin ELISA assays.  
Previous attempts to discern the function of HCN channels in rat islets found that the HCN 
channel blocker Cilobradine had no effect on GSIS at 0mM or 11.1mM glucose (El-Kholy 
et al., 2007).  A later study by the same group found that
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β-cells increased insulin secretion at 2.8mM glucose but that suppression of HCN channel 
current, by use of a HCN2 dominant negative construct, had no affect on insulin secretion 
at 2.8mM or 11.1mM glucose (Zhang et al., 2009).  Contrary to these results, we 
discovered that insulin secretion in mouse islets was significantly and selectively inhibited 
by the HCN channel blocker zatebradine in the presence of 10mM glucose.  This result 
was surprising given that the reported midpoint of activation potentials for mouse HCN 
channels in the SAN (Sinoatrial Node) is approximately -87mV (reviewed by Baruscotti et 
al., 2005) and that β-cells are thought to rest at -65mV (Ashcroft and Rorsman, 1989).  
Therefore, we would assume HCN channels are predominantly inactive in the β-cell.  This 
may, in part, be explained by the emerging significance of cAMP with regards to GSIS.  
Stimulatory levels of glucose are known to cause an increase in cAMP concentration in β-
cells (Charles et al., 1973).  As cAMP alone does not trigger insulin secretion it has been 
considered to be of relatively little importance to GSIS (Hellman et al., 1974).  However, a 
recent study demonstrated that glucose-induced cAMP oscillations co-ordinated with 
pulsatile insulin secretion and that these oscillations regulate the magnitude of insulin 
release (Dyachok et al., 2008).  Hence, cAMP may be of greater importance with regards 
to GSIS than was originally conceived.  Elevated concentrations of cAMP also result in a 
positive modulation of HCN channel activity by shifting the activation curves for HCN 
channels by +10mV (Robinson and Siegelbaum, 2003).  Furthermore, cAMP has been 
found to slow the rate of voltage-independent closing rate of HCN channels (Chen et al., 
2007).  This is achieved by the binding of cAMP to the CNBD (see Section 1.6.1).  The 
result is a greater proportion of active HCN channels for a longer period of time.  Hence, 
the link between cAMP elevation and glucose metabolism (Dyachok et al., 2008) may 
provide sufficient stimulation for the activation of HCN channels in β-cells. 
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In order to ensure that the selective inhibition which zatebradine had on insulin secretion 
was genuine, the effect of the established KATP channel opener diazoxide was included in 
the assay.  Diazoxide produced a significant inhibition of insulin secretion at all 
stimulatory glucose concentrations.  This implies that the selective inhibition caused by 
zatebradine was indeed genuine.  The inhibition of insulin secretion produced by diazoxide 
was consistently stronger than that of zatebradine, and significant to a greater degree of 
confidence.  However, this does not detract from the potential therapeutic benefits of HCN 
modulation, especially in disease states, such as CHI, that can be unresponsive to diazoxide 
therapy.  This may be of significant benefit to sufferers of CHI, as a failure to respond to 
therapy will often result in a near total pancrectomy and its related complications. 
 
Although zatebradine is an established HCN channel blocker, some concerns have been 
raised as it is known to also inhibit outward potassium currents at the concentration (3µM) 
used in this study (Bois et al., 1996, El-Kholy et al., 2007).  Voltage-gated K+channels (Kv 
channels) are thought to account for approximately 80% of the outward K+ in β-cells 
(Tamarina et al., 2005) and the opening of these channels is thought to be responsible for 
spike repolarisation in β-cells stimulated with glucose (Smith et al., 1990).  It has been 
shown that both a pharmacological block and genetic knockdown of these channels results 
in enhanced insulin secretion (MacDonald et al., 2001, MacDonald et al., 2002).  
Therefore, it is unlikely that the effects of zatebradine on GSIS were a result of Kv channel 
block.  Importantly, 3µM zatebradine has been shown to have no inhibitory effect on 
VDCCs (Satoh and Yamada, 2002). 
     
Lamotrigine was used to activate HCN channels without elevating cAMP (Zhong and 
Zucker, 2005).  Although lamotrigine has been reported to be a Na+ channel inhibitor (Kuo 
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and Lu, 1997), it activates HCN channels without affecting Na+ channels in pyramidal 
neurons (Poolos et al., 2002) or in rat pancreatic α-cells at a concentration of 10µM (Zhang 
et al., 2008).  Lamotrigine had no effect on GSIS at any concentration of glucose.  This 
may be because all functional HCN channels were already in an open state or at sub-
stimulatory concentrations of glucose the inward current through HCN channels was not 
alone significant to trigger insulin secretion.  
 
The possibility that HCN channels may contribute to the amplification of GSIS caused by 
the elevation of cAMP was investigated.  Although the connection between HCN channels 
and cAMP in β-cells has been previously alluded to (Kim et al., 2008) it had not been 
investigated until recently, and never in mouse islets.  Forskolin was used to elevate cAMP 
and, as expected, caused a significant amplification of GSIS at 10mM.  Forskolin had no 
effect at higher glucose concentrations indicating that the higher concentrations of glucose 
alone were sufficient to elicit a maximal response.  When we compared the response of 
mouse islets at 10mM glucose in the presence of zatebradine to that of islets at 10mM 
glucose with zatebradine and forskolin, we found that forskolin was still able to 
significantly amplify GSIS.  This suggests that the amplification of GSIS by forskolin is 
not mediated by HCN channel activity.  This is consistent with recent results from rat islets 
which found that, at a physiological external K+ concentrations, suppressing HCN2 
expression did not alter the insulin secretion pattern even in the presence of 
forskolin/IBMX (Zhang et al., 2009).  This does not, however, exclude the possibility that 
the glucose-induced rise in cAMP may be essential for HCN channel activity in mouse 
islets.  
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Inconsistencies between this study and published data on HCN channel function in rat 
islets may be partly attributable to species differences.  Interestingly, at a low external K+ 
concentration, block of HCN channels in rat islets inhibited insulin secretion at 16.7mM 
glucose (Zhang et al., 2009).  Theoretically, a low external K+ concentration would shift 
the resting membrane potential to more hyperpolarised potentials, therefore activating a 
greater proportion of HCN channels.  As rat β-cells are thought to have a more positive 
resting potential than mouse β-cells (Antunes et al., 2000), this may partially account for 
the differences observed in this study and the published result from rat islets (El-Kholy et 
al., 2007, Zhang et al., 2009). 
 
In order to fully understand the role of HCN channels in β-cells more data is required.  
Electrophysiological data would likely provide the additional data required to interpret 
these results more completely.  Based on the results of the current study and what is known 
of β-cell electrophysiology from published data, we propose the following model for HCN 
function in mouse pancreatic β-cells (summarised in Figure 3.47).  When stimulated with 
10mM glucose β-cell electrical activity is characterised by ‘bursts’ of activity.  In between 
these bursts, as the β-cell begins to reach the repolarisation potential, HCN channels are 
activated (which is perhaps made possible by the increase in intracellular cAMP).  Under 
physiological conditions, HCN channels predominantly carry an inward current of Na+/K+ 
(Wahl-Schott and Biel, 2009).  Evidence also indicates that HCN channels also conduct 
Ca2+ under physiological conditions (Michels et al., 2008) although this makes up a small 
percentage of the overall current (Yu et al., 2004).  This positive inward current helps 
depolarise the β-cell sufficiently to reach the threshold potential and activate VDCCs, 
resulting in another burst of activity.  Therefore, at this concentration of glucose, our data 
indicate that β-cells are sensitive to modulation by zatebradine.  At higher concentrations 
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of glucose, β-cell electrical activity is characterised by a sustained period of activity.  At 
these more positive potentials, HCN channels are unlikely to be active and therefore 
blocking HCN channels has no effect on insulin secretion. Blocking HCN channel activity 
in rat islets may have produced no effect on GSIS because it has been reported that rat β-
cells do not display oscillations in membrane potential associated with bursting electrical 
activity (Antunes et al., 2000).  Given that human β-cells display similar electrical activity 
and Ca2+ oscillations (in response to stimulatory glucose) as mouse β-cells (Falke et al., 
1989, Martin and Soria, 1996, Antunes et al., 2000), we may expect HCN channels to play 
a common role in both mouse and human β-cells.  
 
       
 
 
 
Figure 3.47.  Proposed model of HCN channel function in mouse β-cells.  The upper panel shows the 
response of the β-cell to stimulation by glucose as recorded by intracellular microelectrodes.  The lower 
panel shows, in greater detail, the period between two bursts of activity as observed at 10mM glucose.  At 
10mM glucose, HCN channels are activated as the β-cell reaches the repolarisation potential (indicated by 
+).  An inward positive current pushes the β-cell towards the threshold potential resulting in another burst of 
activity.  At the more positive plateau potential HCN channels are deactivated (-).  At higher concentrations 
of glucose (≥15mM), mouse β-cells are insensitive to HCN channel inhibition as the sustained level of β-
cell activity prevents HCN channel activity.  Figure adapted from Henquin and Meissner, 1984.      
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Numerous attempts to replicate the methodology outlined by Hjortoe et al., 2004 were 
unsuccessful.  This was due, initially, to the unsuccessful attachment of islets to glass 
coverslips.  Islets only attached consistently to matrigel-coated coverslips.  Excitation of 
diBAC4(3) on matrigel-coated coverslips resulted in a background fluorescence that was 
comparable in strength to that emitted from diBAC4(3) bound to mouse islet proteins.  
Significant changes in fluorescence were consequently undetectable.   
 
Matrigel consists primarily of laminin, collagen IV, and enactin.  It is commonly used as a 
basement membrane preparation to support the growth and maintenance of cells in culture, 
particularly cells that are sensitive to culture conditions, such as stem cells.  Despite the 
common use of Matrigel, its exact composition is unknown.  Matrigel has been shown to 
contain numerous growth factors including basic fibroblast growth factor and insulin-like 
growth factor 1 (Vukicevic et al., 1992).  A recent study showed that numerous 
intracellular proteins, including cytoplasmic and nuclear proteins, are present in Matrigel 
(Hughes et al., 2010).  Upon changes in membrane potential diBAC4(3) is thought to be 
redistributed where it binds to hydrophobic sites in the lipid bilayer or intracellular proteins 
(Epps et al., 1994).  However, exactly which proteins diBAC4(3) binds to remains 
unknown (Epps et al., 1994).  It is possible that the high background fluorescence observed 
was a result of diBAC4(3) binding to intracellular proteins present in the Matrigel, hence 
preventing a workable setup. 
 
In this study I have provided, for the first time, evidence of HCN channel expression in the 
human adult pancreas (summarised in Figure 3.48).  RT-PCR revealed the presence of 
mRNA for all HCN channel isoforms in the human adult pancreas and 
immunofluorescence studies confirmed the presence of HCN1, HCN2, and HCN4 proteins 
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in human adult β-cells.  Co-staining studies showed that HCN channel proteins were not 
found in human α-cells.  The selective expression of HCN channels in human adult β-cells 
suggests that HCN channels may be of importance in the regulation of insulin secretion.  
The absence of HCN channels in human α-cells highlights the presence of species 
differences between human and rat α-cells.   
 
In the human foetal pancreas, HCN mRNA was detected for all isoforms from 9-11 wpc.  
However, HCN1 and HCN2 proteins were not detected until 10 wpc.  At 10 wpc, HCN1 
and HCN2 were present in the pancreatic duct epithelium.  HCN1 was also detected in 
insulin-positive cells.  HCN2 may also be present in insulin-positive cells at this stage of 
development, however; no insulin-positive cells were detected in the sample.  By 11 wpc, 
expression of HCN1 and HCN2 were evident in both the pancreatic duct epithelium and 
insulin-positive cells, which had formed small islet-like structures at this point in 
development.  As pancreatic β-cells are thought to originate from progenitors in the 
pancreatic duct epithelium (Bouwens et al., 1997), the presence of HCN1 and HCN2 in the 
pancreatic duct epithelium and insulin-positive cells indicates that these isoforms may be 
of importance in the formation of β-cells.  Interestingly, HCN4 protein was not detected in 
the foetal pancreas.  This does not necessarily mean that HCN4 is not an important part of 
the β-cell machinery in terms of insulin secretion, as many key components of the β-cell 
are not detected until further on in development (Mally et al., 1994, Weinhaus et al., 2003, 
Richardson et al., 2007).  The presence of HCN isoform mRNA as early as 9 wpc, but 
absence of the protein (until later in development) suggests that there is some post-
transcriptional regulation of HCN channel expression.  
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I found that in the majority of Di- and Fo-CHI lesions, HCN1, HCN2 and HCN4 channel 
expression was generally lost from pancreatic β-cells.  HCN1 and HCN4 were also absent 
from insulinoma lesions and outside of lesions.  However, HCN2 expression was retained 
in both.  Genuine HCN1, HCN2, and HCN4 expression in the exocrine tissue was seen in a 
minority of cases (Figure 3.48 for summary). There are multiple possibilities that could 
explain the changes in HCN channel expression in CHI, the most logical of which is 
remodelling of the β-cell as a result of Ca2+ regulated gene expression.  The relationship 
between KATP channel mutations and inappropriate insulin release in CHI has been well 
characterised (Shepherd et al., 2000).  CHI β-cells have a resting potential close to that of 
the activation threshold of VDCCs (due to KATP channel dysfunction), this leads to the 
inappropriate activity of VDCCs and elevated [Ca2+]i under basal conditions (Kane et al., 
1996, Dunne et al., 2004).  As a secondary messenger, Ca2+ fulfils a wide variety of 
essential cellular functions and one of the longer-term effects of intracellular Ca2+ 
elevation is the regulation of gene expression (reviewed by Barbado et al., 2009).  The 
majority of known pathways by which Ca2+ regulates gene expression all result in the 
activation of transcription factors (Barbado et al., 2009).  However, Ca2+ can also act to 
reduce gene expression.  The release of Ca2+ from the sarcoplasmic reticulum has been 
shown to reduce the amount of mRNA encoding for rat nicotinic acetylcholine receptors, 
therefore exerting some control over muscle fibre differentiation (Adams and Goldman, 
1998).  It is possible that a similar mechanism is responsible for the changes observed in 
HCN channel expression in CHI.  The loss of HCN channel expression in CHI β-cells 
could been seen as advantageous as our results suggest that HCN channel block inhibits 
insulin release.  Our results may therefore indicate a remodelling of the β-cell in an effort 
to adapt to the disease environment.   
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Figure 3.48.   Summary of HCN channel expression.  All HCN isoforms are found in human adult β-cells and in the developing pancreas, with the exception of HCN4 which 
was absent from the foetal pancreas.  This expression was lost in the lesions of diffuse CHI (4/5 patients) and focal CHI patients (2/2).  HCN expression in exocrine tissue was 
sporadic and presented in only a minority of cases.  Outside CHI lesions HCN2 and HCN4 expression in β-cells was retained.  HCN1 expression was entirely lost from disease 
tissue.  In Insulinoma patients, HCN2 and HCN4 expression was seen in β-cells outside of the lesion (2/2 patients).  HCN2 expression was retained in the lesion of one patient. 
HCN1 expression was absent from all insulinoma tissue.  All HCN isoforms examined were present in the wild type mouse pancreas, whereas only HCN2 expression was 
retained in SUR1 KO β-cells.  Figure legend is presented, unboxed, in the top left corner.   
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Interestingly, mRNA corresponding to HCN1, HCN2 and HCN4 was found in a minority 
of patients when no protein was detected.  This may be accounted for if mutations existed 
in the HCN channel which prevented HCN proteins from reaching the membrane, such as 
protein folding or trafficking defects.  These types of defects have been previously 
described in KATP channel subunit mutations that result in CHI (Dunne et al., 2004).  
However, reports of mutations in human HCN genes are rare and restricted to HCN4, 
which result in idiopathic sinus bradycardia (Schulze-Bahr et al., 2003).  The presence of 
mRNAs but not proteins may also be accounted for by the unregulated entry of Ca2+ into 
the β-cell.  Ca2+ has been shown to control post-transcriptional events by influencing 
mRNA splicing and stability in over 5000 transcripts (McKee et al., 2007).  Therefore, 
mRNA may still be detectable by RT-PCR but changes in splicing or mRNA stability may 
prevent a protein from being expressed in the plasma membrane.  Differences between the 
protein expression and mRNA expression of HCN isoforms may not necessarily reflect 
gene mutation or remodelling per se.  Primary antibodies may have binding constants that 
are too low to detect target proteins when expression is particularly low (True, 2008).  
Therefore, mRNA would still be detectable but the corresponding proteins may appear to 
be absent. A further possibility could be that mRNA was isolated from islets was 
contaminated with exocrine tissue (although every effort was made to ensure this did not 
occur).  However, this would only apply to a minority of results as mRNA was generally 
isolated from whole pancreas tissue due to limited tissue quantities.    
 
Mechanical and chemical damage and ischaemia, as a result of surgery, can enhance the 
risk of non-specific binding of IgGs resulting in greater background staining (Fritschy, 
2008).  This may account for the higher level of background and non-specific staining 
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observed in the CHI tissue, which often complicated the interpretation of HCN isoform 
expression in the exocrine pancreas.  
  
By investigating the expression of HCN isoform expression in the SUR1 KO mouse we 
found further evidence for β-cell remodelling under disease conditions.  As with previous 
experiments, HCN1, HCN2 and HCN4 were present in wild type mouse β-cells.  In SUR1 
KO islets, HCN1 and HCN4 expression was completely lost and in this respect resembled 
that seen in CHI, but HCN2 expression in β-cells was retained and expression in the 
exocrine pancreas detected.  This pattern of expression most closely resembles what we 
found in insulinoma patients.  As changes in HCN expression were also seen in the SUR1 
KO mouse it suggests that the changes in HCN expression may not be directly related to 
mutations in HCN channels. As the changes in HCN2 expression were different from those 
observed in the majority of CHI patients, the observed changes are not likely to be directly 
related to KATP mutations per se, but rather are suggestive of β-cell remodelling.  SUR1 
KO mice have been documented to have elevated cytoplasmic Ca2+, similar to that seen in 
CHI patients (Shiota et al., 2002, Dufer et al., 2004, Kane et al., 1996).  This supports our 
original hypothesis regarding the observed changes in HCN expression in CHI pateints.  
This does not, however, account for the differences in HCN2 expression (loss from β-cells) 
seen in the majority of CHI patients but not in the SUR1 KO mouse.  This may be due 
partly to differences in the phenotype of the SUR1 KO mouse and the CHI patients.  It is 
known that the SUR1 KO mouse does not accurately mimic the behaviour of CHI patients, 
in that animals are not hyperinsulinaemic and often display euglycaemia (Shiota et al., 
2002).  Furthermore, the morphological differences used to distinguish CHI lesions from 
healthy tissue cannot be used to distinguish SUR1 KO islets from wild type islets 
(Marhfour et al., 2009).  Insulin is also known to regulate gene transcription, both 
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negatively and positively (reviewed by Mounier and Posner, 2006).  Hence, the changes in 
HCN expression that are not mirrored in the SUR1 KO mouse may be a result of β-cell 
adaptation to inappropriate insulin levels in CHI patients.   
 
The expression and significance of HCN channel expression in the exocrine pancreas, in 
both a minority of CHI patients and the SUR1 KO mouse remains unclear.  As the 
endocrine and exocrine pancreas are closely linked, both anatomically and physiologically, 
any pathological condition that affects the function of the endocrine pancreas could also 
affect the function of the exocrine pancreas, for example, exocrine atrophy and 
insufficiency are well documented in Type 1 Diabetes (Czakó et al., 2009).   However, 
complications arising from the dysfunction of the exocrine pancreas have only been 
reported as a consequence of near complete pancreatectomy, where pancreatic 
insufficiency and exocrine failure are serious risks (Cade et al., 1998).  The appearance of 
HCN expression in the exocrine pancreas of the SUR1 KO mouse (HCN2) and a minority 
of Di-CHI patients may, in part, be accounted for as a result of insulin signalling. Insulin is 
known to bind to its receptor on acinar cells and potentiate amylase secretion via gene 
transcription, protein synthesis and glucose uptake (reviewed by Barreto et al., 2010).  
Prolonged exposure to insulin may switch on HCN channel expression.  In acinar cells, 
HCN channels may function to enhance exocytosis by enhancing the Ca2+ signal, 
particularly in hyperinsulinaemic conditions.    
 
The absence of HCN channels from CHI β-cells and insulinomas negates the possibility of 
HCN modulation in the treatment of these hyperinsulinemic conditions.  However, as HCN 
expression was investigated only in patients that required near total pancreatectomy, 
predominantly as a result of the failure of medical treatment (Delonlay et al., 2007), the 
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expression of HCN channels may be retained in those cases of CHI that are responsive to 
medical treatment.  HCN modulators may be of specific use in patients who suffer from the 
adverse side affects of common drugs used to treat CHI, such as diazoxide (Dunne et al., 
2004).  However, the use of HCN channel modulators may be further complicated as the 
HCN channel blocker Ivabradine is commonly used to treat cardiac arrhythmia and angina 
(Thollon and Vilaine, 2010).  This may therefore result in adverse side affects.  In order to 
overcome such problems, the localisation of HCN isoforms and subunit specificity of 
pharmacological agents may be required to allow more targeted therapy.  
 
I found that all HCN channel isoforms were expressed in NES2Y cells.  HCN channel 
expression was found to be responsive to culture in different glucose concentrations.  
HCN1 and HCN3 were the only isoforms that appeared responsive to glucose.  HCN1 was 
the only isoform absent in low glucose (1mM and 3mM) following 1 week of culture.  
Following 3 weeks of culture, HCN3 mRNA was absent at low glucose and HCN1 at all 
concentrations below 15mM glucose.  The loss of HCN1 at low glucose, particularly at the 
protein level, reflects that seen in the majority of CHI patients that we examined.  Loss of 
HCN3 mRNA suggests that there may also be alteration of HCN3 in CHI patients.  Rat 
islets cultured at low glucose (3mM and 5mM) resulted in apoptosis due to a reduction in 
mitochondrial metabolism (Van de Casteele et al., 2003).  Culture of both human islets and 
animal cell lines in high glucose results in impaired β-cell function, characterised by a 
decrease in insulin mRNA, insulin cell content and insulin secretion eventually 
accompanied by apoptosis (Jonas et al., 1999, Marshak et al., 1999, Roche et al., 2000).  
Although no assay was performed to evaluate the number of live/dead cells, NES2Y cells 
appeared to divide at a similar rate regardless of glucose concentration through all the 
weeks tested.  This may, in part, be due to the phenotype of NES2Y cells.  NES2Y cells 
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show little response to elevated glucose, both in terms of insulin secretion (MacFarlane et 
al., 1997), and changes in [Ca2+]i (MacFarlane et al., 1999).  Furthermore, NES2Y cells 
show defective expression of PDX-1 (MacFarlane et al., 1997).  The absence of PDX1 
resulted in the insulin promoter being unresponsive to glucose but may account for the 
ability of NES2Y cells to continue to divide in culture (MacFarlane et al., 1997, 
MacFarlane et al., 1999).  This may mean that NES2Y cells are resistant, to an extent, to 
culture conditions that would otherwise result in glucose toxicity.  Surprisingly, HCN2 and 
HCN4 expression were unaffected by culture in different glucose concentrations.  The 
reason for this is unclear.  It may be that the absence of PDX1 (and potentially other 
transcription factors) means that certain genes are unresponsive to changes in glucose 
concentration, and this may account for the unaltered expression of HCN2 and HCN4.  
Also, as HCN2 and HCN4 were present in β-cells from a small minority of CHI patients, it 
is possible that the original patient from whom the NES2Y cell line was derived from 
displayed HCN2 and HCN4 expression. 
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Chapter Four:  Characterisation of K2P Channels 
 
K2P channels have been studied in a wide variety of tissues and cell types since their initial 
discovery in 1995 (Ketchum et al., 1995).  To date K2P expression and function have not 
been well defined in the endocrine pancreas, with only a few studies alluding to their 
presence and possible function there.    
 
MIN6 cells have previously been used as a pancreatic β-cell model to investigate the 
presence and function of K2P channels in the endocrine pancreas (Kang et al., 2004).  The 
study was able to detect the functional presence of only TREK-2 in MIN6 cells and 
concluded that TREK-2 may contribute to the regulation of insulin release under 
metabolically stressful conditions (Kang et al., 2004).  TALK-1, originally thought to been 
expressed exclusively in the pancreas (Girard et al., 2001), was later shown to be absent 
from mouse islets but present in the exocrine pancreas (Duprat et al., 2005).  In contrast, 
results from our own laboratory have consistently detected the expression of TALK-1 in 
pancreatic β-cells (Weston, Smith, Dunne, 2009, unpublished data).   
 
TASK-1 and TASK-2 channels have been detected in the human pancreas (Girard et al., 
2001).  TASK-1 and TASK-3 channels represent an interesting K2P channel, with regards 
to the endocrine pancreas, as they have been shown to participate in the glucose-sensing of 
orexin neurons (Burdakov et al., 2006).  Despite this, TASK channels have, to date, not 
been characterised in the endocrine pancreas.   
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TWIK-1 currents have been described in rat acinar cells (Schmid et al., 1997) and TWIK-1 
protein has been detected in the human pancreas (Girard et al., 2001).  Recently, TWIK-1 
expression was found to be upregulated in MIN6 cells cultured in high glucose and 
elevated cAMP (Glauser et al., 2007, see additional files).  To date, this represents the only 
study relating to TWIK-1 in the endocrine pancreas. 
 
Aims: 
 
1. To define the expression of K2P channels in the mouse endocrine pancreas. 
2. To define K2P channel expression, with a focus on TWIK-1, in the human 
endocrine pancreas. 
3. To examine the developmental expression of K2P channels in the human foetal 
pancreas. 
4. To explore the expression of TWIK-1 and other K2P channels in CHI. 
 
As TWIK-1 expression in CHI tissue was profoundly different to controls, an 
additional aim of these studies was; 
 
5. To examine whether loss of KATP channels leads to remodelling of TWIK-1 
channel expression in the mouse endocrine pancreas. 
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4.1  TWIK-1 and K2P expression in the mouse pancreas and MIN6 cell line 
RT-PCR experiments were used to determine the distribution of K2P channel mRNA in 
mouse tissues (Figure 4.1).  Amplification of the housekeeping gene β-actin confirmed the 
integrity of cDNA samples (Figure 3.1).  TASK-1 and TASK-2 mRNA was detected in all 
tissues that were tested.  TASK-3 and TRAAK were only detected in mRNA isolated from 
the mouse brain.  TREK-1 mRNA was detected in all tissues with the exception of the 
tongue, brain and stomach.  TREK-2 was present in the pancreas, kidney, tongue and liver 
but was absent from the brain, spleen and stomach.  TWIK-1 expression was restricted to 
the pancreas, kidney, brain and stomach.  Unlike TWIK-1, TWIK-2 was absent from the 
pancreas and kidney but was detected in the brain, spleen and stomach.  TALK-1 mRNA 
was detected in the pancreas, stomach and spleen but was notably absent from the tongue.  
Interestingly, TALK-2 was not detected in the pancreas.  With the exception of the spleen, 
TALK-2 expression was entirely different from that of TALK-1.  This suggests that 
functional TALK channels are likely to form homodimers.  THIK-1 expression was not 
detected in the pancreas, but was detected in the brain, spleen and stomach.  THIK-2 was 
also not detected in the pancreas, but was present in all other tissues that were examined.  
  
Signals corresponding to the gDNA control for TALK-1 and TWIK-1 were not detected at 
the appropriate size marker.  This was due to the fact that primers spanned an intron.  
Therefore, much larger PCR products were produced which were not able to migrate 
through the gel to the same extent.  Positive signals were still obtained in the gDNA 
controls.        
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Figure 4.1.  K2P mRNA expression in mouse tissues.  Transcripts corresponding to K2P 
channels were detected by RT-PCR.  G = mouse gDNA, P = pancreas, K = Kidney, T = 
tongue, L = liver, Br = brain, Sp = spleen, St = stomach, - = reverse transcriptase negative 
control, H2O = water control. 
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RT-PCR experiments were performed on mRNA isolated from a pure population of mouse 
islets.  TALK-1, TASK-1, TASK-2, TREK-1, TREK-2, and TWIK-1 were found to be 
present in both islet and pancreas mRNA samples (Figure 4.2).   
 
In the mouse pancreas, immunofluorescence studies revealed that TWIK-1 protein 
expression appeared to be ubiquitous (Figure 4.3).  Due to the ubiquitous nature and 
uniform intensity of the stain it was not possible to discern TWIK-1 expression from 
background staining.  This type of staining was seen both in the exocrine and endocrine 
pancreas (20/20 islets) (Figure 4.3).  If the staining did reflect TWIK-1 expression it would 
suggest that TWIK-1 was likely to be present not just in insulin-positive cells but also in 
the other types of endocrine cells found within pancreatic islets.   
 
As TWIK-1 staining in the murine pancreas was uniform and of a relatively weak 
intensity, and therefore difficult to discern, the MIN6 cell line was used as a β-cell model 
to further investigate the presence of TWIK-1 in β-cells.  TWIK-1 mRNA and protein 
expression were clearly evident in the MIN6 cell line (Figure 4.3).  This suggests that 
TWIK-1 may be expressed in mouse pancreatic β-cells.  RT-PCR also showed that, similar 
to mouse islets, TALK-1, TASK-1 and TREK-2 mRNA were present in MIN6 cells 
(Figure 4.2). 
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Figure 4.2.  K2P mRNA is expressed in mouse islets and MIN6 cells.  Results were 
obtained from 1.5% Agarose gels.  The upper panel shows that PCR products of the 
correct size were detected for TASK-1,TASK-2, TREK-1,TREK-2, TALK-1 and TWIK-
1 in mRNA isolated from mouse islets (I) and from whole pancreas samples (P).  The 
lower panel shows that TASK-1, TALK-1, TWIK-1and TREK-2 mRNA were detected in 
MIN6 cells.  No PCR products were detected in the mouse gDNA control (G) for TALK-
1 or TWIK-1 as the primers spanned an intron.  Reverse transcriptase negative control = 
RT- and water control = H20.  
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Figure 4.3.  TWIK-1 is expressed in the mouse pancreatic β-cell line MIN6.  The top panels show 
equivocal TWIK-1 staining (red) in the mouse pancreas.  Insulin staining (green) was used to 
identify pancreatic islets.  TWIK-1-immunoreactive antibodies (red) detected the presence of 
TWIK-1 in MIN6 cells (lower panel).  MIN6 cells were used as a model to clarify potential 
TWIK-1 presence in mouse β-cells.  Nuclei were stained with DAPI (blue).  Scale bars = 100µm  
(top panels)and 10µm (lower panel).     
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4.2  TWIK-1 and K2P channel expression in the human foetal pancreas 
The presence of K2P channels has never been studied in the developing human pancreas.  
Defining K2P expression in the developing pancreas will provide evidence relating to their 
importance in the differentiation and development of the pancreas as well as potential 
implications for general β-cell physiology. 
 
RT-PCR revealed the presence of TALK-1, TASK-1, TREK-2 and TWIK-1 mRNA from 
9+6 wpc to 11+3 wpc in the human foetal pancreas (Figure 4.4).   
 
The presence and localisation of TWIK-1 protein was assessed in the human foetal 
pancreas by using immunofluorsecence.  At 9+6 wpc TWIK-1-immunoreactive antibodies 
revealed the weak expression of TWIK-1 in duct-like structures of the pancreas (Figure 
4.5).  No staining was observed in the exocrine pancreas.  Insulin-immunoreactive 
antibodies did not detect the presence of insulin-positive cells at 9+6 wpc. 
 
At 10+2 wpc, single and small groups of insulin-positive cells were observed.    Pancreatic 
duct structures were more clearly discernable and the presence of the TWIK-1 protein was 
evident within these structures (Figure 4.5).  TWIK-1 was absent from the exocrine 
pancreas as was seen at 9+6 wpc.  TWIK-1 protein expression was not observed in these 
insulin-positive cells. 
 
The expression pattern of TWIK-1 in the developing human pancreas changed at 11+3 
wpc.  TWIK-1 was still present in pancreatic ducts but also showed co-expression in some, 
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but not all, insulin-positive cells (Figure 4.5).  Insulin-positive cells had begun to cluster 
together to form primitive islet-like structures.  Also present, were single insulin-positive 
cells.  TWIK-1 appeared to be absent from all single insulin-positive cells but showed 
strong co-staining in insulin-positive cells that had begun to form small islet-like structures 
(Figure 4.6).  This was a strikingly novel finding and suggests that TWIK-1 may have an 
important role in the developing human pancreas, particularly concerning islet formation. 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.   K2P mRNA expression in the human foetal pancreas.  Transcripts 
corresponding to TASK-1, TALK-1, TWIK-1 and TREK-2 were detected in the human foetal 
pancreas.  G = human gDNA, 9 = 9+6 wpc, 10 = 10+2 wpc, 11 = 11+3 wpc, RT- = reverse 
transcriptase negative control, H2O. 
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Figure 4.5.  TWIK-1 is expressed in the human foetal pancreas.  TWIK-1-positive cells (red) were observed at 10+2 wpc and 11+3wpc.  TWIK-1 
was detected in the pancreatic duct epithelia at 10+2 wpc but not in insulin-positive cells (green).  TWIK-1 and insulin showed strong co-staining 
(yellow) at11+3 wpc in but only in clusters of insulin-positive cells.  Nuclei were stained with DAPI (blue).  Scale bars = 100µm.     
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4.3  TWIK-1 and K2P channel expression in the healthy human adult pancreas 
This represents the first study of TWIK-1 in the human endocrine pancreas.  RT-PCR 
revealed the presence of TALK-1, TASK-1, TREK-2 and TWIK-1 mRNA in both islet 
mRNA and mRNA isolated from whole pancreas samples (Figure 4.7).  The presence of 
TWIK-1 mRNA in islets was a surprising find as no protein was detected by 
immunofluorescence. 
 
In the NH-1 pancreas, in 17 out of 22 islets, TWIK-1 staining was observed in close 
proximity to pancreatic islets (as discerned by insulin-positive staining) (Figure 4.8, 
Region 2).  The remaining five islets displayed no TWIK-1 staining around the islet.  In 
most cases a cluster of exocrine cells in close proximity to islets stained positive for 
Figure 4.6.  TWIK-1 is present in islet-like clusters.  TWIK-1 was only present in β-cells that 
had clustered together to form small islet-like structures (indicated by a yellow TWIK-1 and 
insulin co-stain).  Single β-cells and clusters containing very few β-cells (indicated by the 
arrows), were negative for TWIK-1 protein expression.  This has been adapted from figure 
4.5 and shows  TWIK-1 and insulin expression in the human foetal pancreas at 11+3 wpc.     
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TWIK-1.  In three instances TWIK-1 staining was evident as a cap-like pattern that 
partially surrounded the islet (Figure 4.8, Region 1).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.   K2P mRNA expression human pancreatic islets (NH-1).  Transcripts 
corresponding to TASK-1, TALK-2, TWIK-1 and TREK-2 were detected in human 
pancreatic islets.  G = human gDNA, I = Islet, P = Pancreas, RT- = reverse transcriptase 
negative control, H2O. 
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Figure 4.8.  TWIK-1 is expressed in the human pancreas (NH-1).  TWIK-1-immunoreactive 
antibodies (red) did not co-stain (yellow) with insulin-immunoreactive antibodies (green) in 
22/22 islets.    Two patterns of TWIK-1 staining were observed.  Region 1 (left column) 
represents the staining pattern observed in 3/22 islets and Region 2 (right column) represents the 
staining pattern observed in 14/22 islets.  Nuclei were stained with DAPI (blue).  Scale bars = 
100µm.     
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TWIK-1 protein expression, as determined by immunofluorescence, in a second human 
adult pancreas (NH-2) varied from that found in NH-1.  In the majority of cases, TWIK-1 
staining was absent from β-cells but evident in the exocrine pancreas in areas of close 
proximity to islets (11/19 islets) (Figure 4.9, Region 2).  In one area of the pancreas, 
TWIK-1 staining was observed in islets, single β-cells and the exocrine pancreas (Figure 
4.9, Region 1).  The appearance of single β-cells, small β-cell clusters and islets in this area 
of the pancreas was reminiscent of nesidioblastosis (Dunne et al., 2004).  The difference in 
TWIK-1 expression in this area may, therefore, be of significance for the neogenesis of 
pancreatic islets.  In the exocrine pancreas surrounding 5/19 islets no TWIK-1 staining was 
observed.  TWIK-1 did not co-stain with insulin in 11/19 islets, indicating an absence of 
the protein in the majority of β-cells. 
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Figure 4.9.  TWIK-1 is expressed in the human pancreas (NH-2).  Two patterns of TWIK-1 staining 
were observed.  Region 1 (left column) represents the staining pattern observed in 3/19 islets (yellow 
indicates co-stain with insulin) and Region 2 (right column) represents the staining pattern observed in 
11/19 islets.  No TWIK-1 staining was observed in 5/19 islets.  TWIK-1-immunoreactive antibodies 
(red), insulin-immunoreactive antibodies (green).  Nuclei were stained with DAPI (blue).  Scale bars = 
100µm.     
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4.4  TWIK-1 and K2P expression in Fo-CHI 
K2P channel expression was examined at the mRNA level in three Fo-CHI patients.  
TWIK-1 expression was also examined at the protein level using immunofluorescence.  
Details regarding all Fo-CHI and Di-CHI patients are summarised in table 2.4.    
 
Patient N136 and patient N141 had previously identified mutations in KCNJ11 and ABCC8 
respectively.  Tissue from the lesion was obtained and mRNA extracted.  RT-PCR 
revealed the presence of TASK-1, TALK-1 and TWIK-1 and the absence of TREK-2 in 
N136 (see Figure 4.14, Panel A).  All tested K2P channels were detected in N141 (see 
Figure 4.14, Panel B).  These results were consistent with the expression found in the 
human adult pancreas with the exception of TREK-2.  Insufficient tissue was available for 
immunofluorescence studies (N136/N141). 
 
N139 was identified as Fo-CHI with novel maternal and paternal mutations in ABCC8.  
Tissue was obtained from three different areas of the pancreas, ‘Healthy’, ‘Lesion’, and 
‘Suspected’, as identified by the surgeon.  RT-PCR experiments were performed on 
mRNA isolated from whole pancreas sections of each sample.  In all three samples mRNA 
was found corresponding to all examined K2P channels (Figure 4.10).  
Immunofluorescence studies were performed on each sample using a TWIK-1-
immunoreactive antibody.  In the ‘Healthy’ sample, TWIK-1 expression was found 
exclusively and ubiquitously in the exocrine pancreas surrounding islets (identified by 
insulin-positive cells) (Figure 4.11).  This differed from NH-1 where TWIK-1 expression 
was limited to small clusters of cells in the exocrine pancreas.  Islet morphology outside of 
the lesion appeared normal.  However, in sections where TWIK-1 expression was 
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examined there was no evidence that islets were in ‘resting’ state (reduced cytoplasm and 
insulin content), as has been previously described (Sempoux et al., 2003) and as was seen 
in the sections examined in Chapter Three.  This may indicate that not all islets outside of 
focal lesions are in a resting state, but that some may retain normal function.  In both the 
‘Suspected’ and ‘Lesion’ samples TWIK-1 was found to co-stain strongly with insulin, 
indicating its presence in β-cells (Figure 4.11).  TWIK-1 expression was also seen in some, 
but not all, areas of the exocrine pancreas. Islet morphology in both the ‘Suspected’ and 
‘Lesion’ sample was that which has been previously described for focal lesions (Sempoux 
et al., 2003).  Nuclear crowding, enlarged nuclei and the poor separation of islets by 
exocrine acini were evident.  The morphology of the ‘Suspected’ sample and the 
similarities in TWIK-1 expression with the ‘Lesion’ sample suggest that this sample was, 
in fact, part of a focal lesion.   
 
 
 
 
 
 
 
Figure 4.10.  K2P mRNA expression in Fo-CHI patient N139.  PCR products 
corresponding to transcripts of TASK-1, TALK-1, TWIK-1and TREK-2 were detected in 
mRNA isolated from whole pancreas samples of N139.  G = human genomic DNA, A = 
Suspected lesion,B = Lesion, C= healthy, RT- = reverse transcriptase negative control, 
H2O = water control. 
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Figure 4.11.  TWIK-1 is expressed in the pancreatic β-cells of the N139 lesion.  In the healthy tissue, co-staining (yellow) was not observed with 
insulin-immunoreactive antibodies (green) and HCN4-immunoreactive antibodies (red).   TWIK-1 expression was evident in exocrine cells of the 
healthy tissue.  TWIK-1 showed strong co-staining with insulin in the Suspected and Lesion samples.  Nuclei were stained with DAPI (blue).  Scale 
bars = 100µm.     
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Mutations in ABCC8 were found to be the underlying cause of CHI in patient N145.  Two 
samples were obtained, corresponding to the focal lesion and the surrounding non-lesion 
tissue.  In both lesion and non-lesion tissue, from whole pancreas samples, mRNAs 
encoding TASK-1, TALK-1 and TREK-2 were detected by RT-PCR (Figure 4.12).  
TWIK-1 mRNA was detected in neither tissue.  However, immunofluorescence revealed 
that TWIK-1 protein was present in both lesion and non-lesion tissue (Figure 4.13).  In 
tissue isolated from outside the lesion, TWIK-1 staining was observed in both islets and 
the exocrine pancreas.  Within the lesion, TWIK-1 expression was found predominantly in 
areas of the exocrine pancreas that were in close proximity to β-cells.  TWIK-1 expression 
was absent from other areas of the exocrine pancreas that did not contain islets.  Staining in 
the islets was comparatively weak and uniform suggesting that it was background staining 
and that TWIK-1 was absent from insulin-positive cells.  This patient represents an 
exception to the pattern of TWIK-1 staining observed in the healthy adult pancreas and the 
Di-CHI pancreas.  In the N145 lesion, TWIK-1 expression most closely resembled that of 
the healthy adult, whereas TWIK-1 expression outside the lesion most closely resembled 
that seen in Di-CHI patients.  The islet morphology, as highlighted by insulin staining, 
suggests that the both the non-lesion and lesion tissue are typical of that found in Fo-CHI 
patients.  This confirms that the labelling of the samples was correct and the staining of 
TWIK-1 seen in N145 represents a genuine exception to what has been observed within 
this sample of patients.     
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The general mRNA profile in Fo-CHI patients was similar to that of the human adult and 
foetal pancreas, with the exception of TREK-2 which was not detected in the lesion of 1/3 
patients. 
 
Figure 4.12.  K2P mRNA expression in Fo-CHI and Di-CHI.  PCR products 
corresponding to transcripts of TASK-1, TALK-1 and TREK-2 were detected in mRNA 
isolated from whole pancreas samples of Di-CHI patient N146 and in both healthy and 
lesion samples of Fo-CHI patient N145.  TWIK-1 mRNA was not detected in N146 
samples or N145 samples.  E = healthy F = lesion, RT- = reverse transcriptase negative 
control, H2O = water control. 
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Figure 4.13  TWIK-1 protein is not expressed in the β-cells of the N145 lesion.  TWIK-1-
immunoreactive antibodies (red) co-stained (yellow) with insulin-immunoreactive antibodies 
(green) in tissue isolated from outside of the N145 lesion.  TWIK-1 protein was present in 
the exocrine tissue from the N145 lesion but appeared absent from β-cells.  Nuclei were 
stained with DAPI (blue).  Scale bars = 100µm.     
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4.5  TWIK-1 and K2P expression in Di-CHI 
The expression of TWIK-1 in the Di-CHI pancreas was investigated in five patients in 
order to determine if TWIK-1, and potentially other K2P channels, may be of importance 
in the pathology of CHI.  TALK-1, TASK-1 and TREK-2 were examined for the presence 
of mRNA only. 
 
In all Di-CHI patients examined, islet morphology closely resembled that which has been 
previously described for Di-CHI (Dunne et al., 2004).  Nuclear crowding was evident in 
the majority of islets and enlarged nuclei were also observed.  Islets were often of an 
irregular shape and not always well separated by exocrine acinar cells (see Figure 3.27). 
 
Patient N137 had a previously reported mutation in ABCC8.  TALK-1 and TWIK-1 mRNA 
were detected (although bands were weak) in whole pancreas samples and TASK-1 and 
TREK-2 were absent (Figure 4.14).  No tissue was available for immunofluorescence 
studies. 
 
Patient N138 had a novel paternal mutation and a documented maternal mutation in the 
gene ABCC8.  TWIK-1 was expressed in both the exocrine and endocrine pancreas of 
patient N138 (Figure 4.15).  Clear co-staining was observed with insulin, indicating the 
presence of TWIK-1 in β-cells.  This represents a change in TWIK-1 expression in β-cells 
when compared with the healthy adult pancreas.  The expression pattern of TWIK-1 in 
N138 was similar to that seen in the human foetal pancreas at 11+3 wpc.  This may be of 
particular importance as at 11+3 wpc the first signs of islet-like structures are observed 
(Piper et al., 2004, Jeon et al., 2009).  RT-PCR revealed the presence of TALK-1, TASK-1 
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and TWIK-1 mRNA in whole pancreas samples (Figure 4.14). TREK-2 mRNA was found 
to be absent.  This differed from the mRNA profile of the human adult and foetal pancreas, 
where mRNA was present for TREK-2. 
 
 
 
 
 
 
Figure 4.14.  K2P mRNA presence in Di-CHI, Fo-CHI and insulinoma.  PCR summary figures are 
presented to highlight the presence of K2P channel mRNA in the CHI pancreas. Figures represent 
mRNA isolated from whole pancreas sections unless stated.  Numbers correspond to CHI patients 
as previously defined.  G = human gDNA, I = N143 non lesion islet, P = non lesion pancreas, RT- = 
reverse transcriptase negative control, H20 = water control. 
A 
B 
C 
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Patient N140 had novel paternal and maternal mutations in ABCC8.  The expression of 
TWIK-1 in N140 closely resembled that of N138.  Strong co-staining was observed with 
insulin and consistent exocrine staining was observed (Figure 4.16).  The apparent increase 
of TWIK-1 in β-cells may be of significance, but, TWIK-1 expression in the exocrine 
pancreas also appeared to be ubiquitous and therefore increased when compared to the 
healthy adult control pancreas.  TALK-1, TASK-1, TREK-2 and TWIK-1 mRNA was 
present in the whole pancreas samples of N140 (Figure 4.14).  This mRNA expression 
profile matched that of both the human adult and foetal pancreas.  Two years after the 
Figure 4.15.  TWIK-1 is expressed in the β-cells of N138.  TWIK-1-immunoreatcive antibodies 
(red) co-stained (yellow) with insulin-immunoreactive antibodies (green).  TWIK-1 positive cells 
(red) were detected also in the exocrine tissue.  Nuclei were stained with DAPI (blue).  Scale bars = 
100µm.     
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initial partial pancreatectomy, patient N140 was readmitted for further pancreatic resection.  
TWIK-1 expression was investigated by immunofluorescence in tissue from the second 
operation (N140R).  TWIK-1 was found to be ubiquitous in the exocrine pancreas but 
showed no expression in islets (Figure 4.16).  This is evident by a much weaker intensity 
of stain.  This was different from that observed in tissue from the original pancreatectomy 
(N140) where TWIK-1 expression in β-cells was clearly evident.  TALK-1, TASK-1, 
TREK-2 and TWIK-1 mRNA was detected in mRNA isolated from the whole pancreas 
(N140R) (Figure 4.17), and in this way K2P expression was identical to that observed in 
N140.     
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Figure 4.16.  TWIK-1 expression in the N140 and N140R.  TWIK-1-immunoreatcive antibodies 
(red) co-stained (yellow) with insulin-immunoreactive antibodies (green) in N140 (left column).  
TWIK-1 positive cells (red) were detected also in the N140 exocrine tissue.  TWIK-1 was not 
detected in the β-cells of N140R (right panel) but was present in the exocrine pancreas.  Nuclei were 
stained with DAPI (blue).  Scale bars = 100µm.     
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Novel mutations in the paternal and maternal KCNJ11 genes sets patient N142 apart from 
the other four Di-CHI patients, all of whom have mutations in ABCC8.  However the 
expression profile of TWIK-1 remained very similar to that of N138 and N140 with the 
exception that expression in the exocrine pancreas was absent (Figure 4.18).  N142 shows 
the clustering of islets around ductal structures.  No change was observed in the mRNA 
profile of the N142 whole pancreas when compared to the human adult and foetal 
pancreas; TALK-1, TASK-1, TREK-2 and TWIK-1 mRNA were all detected (Figure 
4.14). 
 
 
 
 
 
 
 
 
 
 
Figure 4.17.  K2P mRNA presence in N140R.  PCR summary figures are presented to highlight the 
presence of K2P channel mRNA in the N140R pancreas.  Transcripts corresponding to TASK-1, 
TALK-1, TWIK-1 and TREK-2 were detected.  G = human gDNA, R = N140R, RT- = reverse 
transcriptase negative control, H20 = water control. 
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Figure 4.18.  TWIK-1 is expressed in the β-cells of N142.  TWIK-1-immunoreatcive antibodies 
(red) co-stained (yellow) with insulin-immunoreactive antibodies (green).  TWIK-1 positive cells 
(red) were detected also in the N142 exocrine tissue.  Nuclei were stained with DAPI (blue).  Scale 
bars = 100µm.     
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TWIK-1 expression in patient N144 (novel paternal and maternal mutations in ABCC8) 
also closely resembled that of N138, N140, and N142.  In patient N144 TWIK-1 
expression was evident both in β-cells and the surrounding exocrine pancreas (Figure 
4.19).  TWIK-1 mRNA, along with TALK-1, TASK-1 and TREK-2 mRNA, was detected 
in mRNA isolated from the whole pancreas sample of N144 (Figure 4.14). 
 
Patient N146, with novel paternal and maternal mutations in ABCC8, displayed a weaker 
expression of TWIK-1 compared to the other patients.  The majority of acinar cells in 
proximity to islets displayed a small amount of TWIK-1 staining at the periphery of the 
cells.  The majority of β-cells did not express TWIK-1 at a level that was detectable by 
immunofluorescence, although some islets did display the presence of TWIK-1 (Figure 
4.20).  In this way, N146 showed similarity to the human adult pancreas with regards to 
TWIK-1 expression in β-cells.  TWIK-1 mRNA was not detectable by RTPCR, perhaps 
reflecting the relatively poor detection of TWIK-1 protein (Figure 4.14).  TALK-1, TASK-
1 and TREK-2 mRNA was detected by RT-PCR in mRNA isolated from whole pancreas 
samples (Figure 4.14).   
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Figure 4.19.  TWIK-1 is expressed in the β-cells of N144.  TWIK-1-immunoreatcive antibodies 
(red) co-stained (yellow) with insulin-immunoreactive antibodies (green).  TWIK-1 positive cells 
(red) were detected also in the N144 exocrine tissue.  Nuclei were stained with DAPI (blue).  Scale 
bars = 100µm.     
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The general pattern of TWIK-1 expression (4/5 patients), when compared to the human 
adult pancreas, was of a shift in expression to pancreatic β-cells. Expression in the 
surrounding exocrine tissue also changed, becoming more extensive.  This may be of 
significance for general β-cell physiology and CHI pathology and is worthy of further 
investigation.  The mRNA profiles of Di-CHI patients generally matched that seen in the 
human adult and foetal pancreas.  The two exceptions were the loss of TWIK-1 and 
TREK-2 mRNA from separate Di-CHI patients. 
Figure 4.20  TWIK-1 expression in N146.  TWIK-1-immunoreatcive antibodies (red) did not co-
stain (yellow) with the majority of insulin-immunoreactive antibodies (green).  TWIK-1 positive 
cells (red) were detected in some areas of N146 exocrine tissue.  Nuclei were stained with DAPI 
(blue).  Scale bars = 100µm.     
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4.6  TWIK-1 and K2P expression in Human Insulinoma 
K2P and TWIK-1 expression were investigated in a patient with a focal insulinoma 
(N143).  A paternal mutation was identified in the ABCC8 gene and immunofluorescence 
experiments revealed that the focal lesion tissue morphology was typical of insulinoma 
patients (Sempoux et al., 2003) (Figure 4.21).  RT-PCR revealed the presence of TALK-1, 
TASK-1, TREK-2 and TWIK-1 mRNA in mRNA isolated from islets located outside of 
the lesion (Figure 4.14).  Only TALK-1 mRNA was detected in whole pancreas mRNA.  
This is likely to reflect the relatively small proportion of the pancreas that is made up of 
islet cells.  The mRNA profile of N143 non-lesion tissue matched that of the human adult 
and foetal pancreas.  
 
TWIK-1 protein expression in the non-lesion pancreas was similar to that seen in the 
healthy adult pancreas.  TWIK-1 expression was observed in select areas of the exocrine 
pancreas in close proximity to islets (Figure 4.21).  However, in contrast to healthy adult 
pancreas, TWIK-1 co-stained with insulin, indicating its expression in β-cells (Figure 
4.21).  This suggests that, although normal in their morphology, islets surrounding 
insulinoma lesions may have molecular differences to islets from an entirely healthy 
pancreas.  Within the lesion of N143, TWIK-1 co-stained with insulin (Figure 4.21).   
 
In a separate insulinoma patient, who did not have a mutation in either of the KATP channel 
subunits, TWIK-1 protein expression was entirely absent (Figure 4.22).  This suggests that 
the changes in TWIK-1 expression, as observed in the majority of CHI patients and N143, 
may be a result of the consequential pathology associated with KATP channel mutations.   
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Figure 4.21.  TWIK-1 protein is expressed inside (right column) and outside of the N143 lesion 
(left column).  TWIK-1-positive cells (red) were detected by immunofluorescence and co-stained 
(yellow) with insulin-positive cells (green).  TWIK-1 was detected also in the exocrine pancreas 
outside of the lesion.  Nuclei were stained with DAPI (blue).  Scale bar = 100µm.   
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Figure 4.22.  TWIK-1 protein is absent in insulinoma.  TWIK-1-positive cells (red) were entirely 
absent from an Insulinoma with no mutations in the KATP channel genes.  Insulin-positive cells are 
labelled green.  Nuclei were stained with DAPI (blue).  Scale bar = 100µm.   
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4.7  TWIK-1 expression in the SUR1 KO mouse 
In order to investigate the potential link between KATP channel mutations and alterations in 
TWIK-1 expression, TWIK-1 expression was examined in the SUR1 KO mouse.  
Pancreata from three SUR1-/- mice and three wild type mice of the same strain and sex 
were examined.  All mice were approximately six months old and born within three weeks 
of each other. 
 
In all three wild-type mice the same staining pattern was the same as we previously 
observed.  In 17/17 islets TWIK-1 appeared to be absent as staining was ubiquitous and 
therefore difficult to discern from background staining (Figure 4.23).  However, in the 
SUR1-/- mice TWIK-1 co-staining with insulin was clearer (13/13 islets) (Figure 4.23).  
TWIK-1 expression in the exocrine pancreas was also discernable (uneven nature of 
exocrine staining).  This closely resembled the expression of TWIK-1 in the majority of 
Di-CHI patients, N139, and that of N143. 
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Figure 4.23.  TWIK-1 expression in the SUR1-/- mouse.  TWIK1-immunoreactive 
antibodies (red) co-stained (yellow) with insulin-immunoreactive antibodies (green) in 
the SUR1-/- mouse (13/13 islets).  TWIK1-positive cells were expressed also in the 
exocrine pancreas of the SUR1-/-  mouse.  In the wild-type mouse, TWIK-1 expression 
was difficult to discern form background staining due to the ubiquitous nature of the 
staining pattern.  Results are representative of experiments in 3 seperate mice.   Nuclei 
were stained with DAPI (blue).  Scale bar = 100µm.   
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4.8  TWIK-1 and K2P expression in NES2Y cells 
In order to investigate further the presence of K2P channels in CHI, and to explore the 
nature of K2P channel expression in relation to glucose stimulation, K2P channel 
expression in the NES2Y cell line was examined.  
 
The K2P mRNA profile of NES2Y cells cultured in RPMI at different glucose 
concentrations (1mM, 3mM, 5mM, 10mM, 15mM, 20mM) was examined over a period of 
three weeks in order to examine if the expression of K2P genes was sensitive to glucose.  
TWIK-1 was also investigated at a protein level by immunofluorescence. 
 
Following one week of culture, mRNA for TALK-1, TASK-1 and TWIK-1 was detected in 
NES2Y cells at each glucose concentration (Figure 4.24, panel A).  TREK-2 mRNA was 
detected in NES2Y cells cultured only in the highest (20mM) glucose concentration.  This 
indicates that TREK-2 may be immediately responsive to changes in glucose 
concentration.  Immunofluorescence results confirmed the expression of TWIK-1 protein 
at all glucose concentrations (Figure 4.25). 
 
After two weeks of culture, the mRNA profile of the NES2Y cells matched that of the 
previous week (Figure 4.24, panel B).  However, after three weeks culture there was a 
significant change in the mRNA profiles of the K2P channels (Figure 4.24, panel C).  
TALK-1 mRNA was not detected at 1mM, 3mM, 5mM or 10mM glucose culture 
conditions.  TASK-1 and TWIK-1 mRNA was not detected at 1mM and 3mM glucose 
culture conditions.  TWIK-1 protein was also detected only at glucose concentrations 
above 3mM (Figure 4.25).  TREK-2 mRNA was again absent from 1mM to 10mM glucose 
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culture conditions, but was detected at 15mM and 20mM glucose.  Variations in gDNA 
band strength are observed in some samples (such as TWIK-1 compared to TALK-1 panel 
A) and may reflect variations in PCR reaction efficiency.  However, it should be noted that 
data is not quantitative. 
 
 
 
 
 
 
 
 
Figure 4.24.  K2P mRNA expression in NES2Y cells cultured at various glucose 
concentrations.  Numbers refer to glucose concentrations in culture (mM).  The top 
panel (labelled A) represents K2P isoform expression after 1 week of culture, the 
middle after 2 weeks of culture (B), and the the bottom after 3 weeks of culture (C).  G 
= human gDNA, RT- = reverse transcriptase negative control, H2O = water control.     
A 
B 
C 
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Figure 4.25.  TWIK-1 protein expression in NES2Y cells cultured at various glucose 
concentrations.  TWIK-1-immunoreactive antibodies (red) detected TWIK-1 protein 
expression in complete correlation with TWIK-1 mRNA presence.  NES2Y cells 
expressed insulin protein (green) at all glucose concentrations following each week of 
culture.  Images are representative of all relevant culture conditions.  Nuclei were 
stained with DAPI (blue).  Scale bar = 100µm.   
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4.9  TWIK-1 Antibody specificity 
In order to assess the specificity of the TWIK-1 primary antibody, in the absence of 
available TWIK-1 tissue, we tested the TWIK-1 antibody on mouse tissue we have shown 
to be absent of TWIK-1 mRNA (Figure 4.1).  We found that TWIK-1 mRNA is absent 
from the mouse liver (Figure 4.26).  Immunofluorescence data corresponded with this as 
no signal was detected for the TWIK-1 protein.  This suggests that the TWIK-1 primary 
antibody used is likely to be specific, although this could not be proved definitively.  
TWIK-1 negative human tissue was not available for testing.   
 
 
 
 
 
 
 
 
 
Figure 4.26.  TWIK-1 primary antibody specificity.  Primary antibodies detected 
against TWIK-1 and detected indirectly by a secondary antibody produced no signal 
in the mouse liver.  Nuclei were stained with DAPI (blue).  Scale bar = 100µm 
221 
 
4.10  Discussion 
RT-PCR confirmed the presence of six functional K2P channels in the mouse pancreas 
(TASK-1, TASK-2, TREK-1, TREK-2, TWIK-1 and TALK-1) and has provided an 
expression profile for each of these channels in other tissues (Table 4.1).  The results 
highlight that none of the K2P channels were expressed exclusively in the pancreas.  This 
may reflect their proposed (general) role in the maintenance of the resting membrane 
potential (Lesage and Lazdunski, 2000).  TASK-3 and TRAAK both showed selective 
expression in the mouse brain.  This may suggest a unique functional relevance for TASK-
3 and TRAAK in the brain.  This is consistent with Q-PCR data from human tissue 
(Medhurst et al., 2001).  Of all the channels found to be expressed in the pancreas, TALK-
1 showed the most restricted expression profile.  This is also consistent with data from 
human tissue (Girard et al., 2001).  TALK-1 expression was also found in the mouse 
stomach.  This has not previously been reported.  It is not clear what the function of 
TALK-1 in the stomach is, as the pH in the stomach lumen is approximately pH 4.5.  
Therefore, TALK-1 would be relatively inactive (assuming that is located in the stomach 
lumen).  Many of the differences seen in expression may simply represent a species 
difference.  However, it is possible that the differences in expression, which are 
particularly notable in the liver and kidney, may have a functional relevance.  
 
Expression of TREK-1 and TREK-2 was difficult to discern in the pancreas owing to faint 
bands.  This may have been due to selective expression in islets or a specific islet cell.  
Therefore, a smaller quantity of cDNA containing the TREK-1 or TREK-2 gene would 
have been synthesised.  TREK-1 and TREK-2 have both been identified in the human 
pancreas.  However, Q-PCR revealed that this expression was relatively low (Medhurst et 
al., 2001).  
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 Pancreas Kidney Tongue Liver Brain Spleen Stomach 
Channel H M H M H M H M H M H M H M 
TASK-1 + + + + / + + + + + + + + + 
TASK-2 + + + + / + + + - + + + + + 
TASK-3 - - - - / - - - + + - - + - 
TRAAK - - - - / - - - + + / - - - 
TREK-1 + + + + / - - + + - - + + - 
TREK-2 + + + + / + - + + - + - + - 
TALK-1 + + - - / - - - - - - + / + 
TALK-2 + - - - / - + + - + / + / - 
TWIK-1 + + + + / - + - + + + - + + 
TWIK-2 + - + - / - + - - + + + + + 
THIK-1 / - + - / - / - / + / + / + 
THIK-2 / - - + / + / + / + / + / + 
 
 
 
 
RT-PCR confirmed the presence of HCN1-4, TASK-1, TASK-2, TREK-1, TREK-2, 
TWIK-1 and TALK-1 in mouse pancreatic islets.  TWIK-1 protein expression in the mouse 
pancreas was investigated by immunofluorescence.  Due to the ubiquitous and uniform 
nature of the staining, the presence of TWIK-1 could not be discerned from background 
staining.  If the pattern of staining produced by the TWIK-1-immunoreactive antibody was 
genuine, TWIK-1 is likely to be expressed in both β-cells and the exocrine pancreas.  To 
Table 4.1.  A comparison of mouse RT-PCR data for K2P channels with currently published Human 
data (see text for references).  + indicates the presence of channel mRNA, - indicates no mRNA 
detected and / indicates that no data is available.  H = human, M = mouse. 
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further investigate the presence of TWIK-1 in mouse pancreatic β-cells, the MIN6 cell line 
was used as a β-cell model.  Immunofluorescence confirmed the presence of TWIK-1 
protein expression in MIN6 cells.  The presence of several K2P channels in MIN6 cells has 
been previously reported but experiments were not repeated in islets.  This study found that 
TASK-1, TASK-2, TASK-3, and TREK-2 but not TALK-1 or TREK-1 were expressed in 
MIN6 cells (Kang et al., 2004).  Our results indicate the expression of both TALK-1 and 
TREK-1 in mouse islets and the absence of TASK-3. Furthermore, we conducted RT-PCR 
and confirmed the expression of TALK-1 in MIN6 cells.  This highlights differences 
between MIN6 and islet expression of K2P channels and indicates that caution must be 
taken when drawing comparisons between data gathered from MIN6 cells and islet cells.  
The reason for the differences between the two studies may be a result of the unstable 
phenotype of MIN6 cells in culture.  It has been shown that MIN6 cells can lose their 
ability to secrete insulin in response to glucose as passages progress, and that this may be a 
result of alterations in key glucose-sensing β-cell machinery such as the KATP channel 
(Minami et al., 2000).  Cells in the previous study were documented to be at passage 39 
(Kang et al., 2004), whereas mRNA was isolated from our MIN6 cells at passage 28.  
Therefore, it is possible that the differences between the two sets of results represent 
different phenotypic populations of MIN6 cells. 
 
I describe, for the first time, the expression of TALK-1, TASK-1, TREK-2, and TWIK-1 in 
human pancreatic islets.  RT-PCR revealed the presence of mRNA corresponding to all 
K2P channels examined, in both islet mRNA and whole pancreas mRNA of the human 
adult.  The presence of K2P channels in human pancreatic islets may be indicative of their 
proposed role in maintaining the cellular resting membrane potential in a wide variety of 
tissues and cells (Lesage and Lazdunski, 2000).  The presence of TALK-1, TASK-1, and 
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TREK-2 could not be confirmed specifically for β-cells from the RT-PCR data.  This does 
not rule out the possibility that these channels may contribute to glucose homeostasis, 
either by functional expression in β-cells or other hormone-secreting islet cells.   
 
The expression of TASK-1 and TWIK-1 in the human pancreas is consistent with 
previously published data (Lesage and Lazdunski, 2000).  However, contrary to a previous 
study (Duprat et al., 2005), which found TALK-1 expression exclusively in the exocrine 
pancreas, we found expression of TALK-1 in human pancreatic islets.  The reason for this 
difference is unclear.  It is unlikely to be a result of splice variants of TALK-1 (Han et al., 
2003) as the design of the probes used in the published study would identify all variants 
(Duprat et al., 2005).  It may be possible that the differences in results represent a variation 
in TALK-1 expression throughout the endocrine pancreas.  As in situ hybridisation studies 
were performed on slides, they represent a relatively small sample size in comparison to 
the large number of islets from which mRNA was isolated in our study. Furthermore, no 
clear method was adopted in the previous study to identify pancreatic islets.  Hence, it is 
possible that TALK-1 expression in islets may have been missed.  Functional evidence of 
TALK-1 activity in the human endocrine pancreas would provide definitive proof of its 
expression and potential function. 
 
TWIK-1 localisation was investigated for the first time by immunofluorescence in two 
human adult pancreata (TWIK-1 expression summarised in Figure 4.27).  Two patterns of 
TWIK-1 staining were evident.  In a minority of islets, TWIK-1 was found to co-stain with 
insulin, indicating its presence in β-cells.  The positive signal obtained from mRNA data is 
likely to reflect the expression of TWIK-1 in this population of β-cells.  As staining was 
also observed outside of insulin-positive cells, it is possible that TWIK-1 is also expressed 
225 
 
in other islet cell types.  In regions where TWIK-1 expression was present in β-cells, single 
β-cells and islets of an irregular shape were observed.  This resembled the appearance of 
nesidioblastosis (Dunne et al., 2004), although nuclei appeared to be normal in shape and 
distribution.  This suggests that the expression of TWIK-1 may be associated with the 
generation of new β-cells. Furthermore, in areas where TWIK-1 was expressed in β-cells, 
TWIK-1 expression was also observed in acinar cells.  Acinar cells show remarkable 
plasticity in vitro and there is growing evidence that acinar cells can be‘re-programmed’ to 
form β-cells (reviewed by Baeyens and Bouwens, 2008).  Whether the expression of 
TWIK-1 is significant in the differentiation of the pancreatic cells is unclear.    
 
TWIK-1 was found to be expressed predominantly in the exocrine pancreas and not the 
endocrine pancreas.  This is consistent with data from rat acinar cells where TWIK-1 
currents have been identified (Schmid et al., 1997).  In the majority of cases, TWIK-1 was 
found to stain only a relatively small number of acinar cells and only in proximity to islets.  
TWIK-1-positive acinar cells appeared to display a degree of hypertrophy when compared 
with TWIK-1-negative acinar cells, although no definitive analysis for cell volume was 
performed.  In rats with arginine-induced pancreatitis, which results in selective acinar 
necrosis, peri-insular acinar cells (acinar cells that surround islets) are found to be intact 
(Takács et al., 2001).  These cells are hypertrophied but thought to be protected due to the 
effects of insulin secreted from nearby islets (Takács et al., 2001).  It is possible that the 
expression of TWIK-1 in acinar cells is regulated by insulin, potentially by binding to 
insulin receptors on acinar cells (Barreto et al., 2010) resulting in the pattern of expression 
observed in the human adult pancreas.  The functional significance of this in the human 
pancreas is unclear.  Published studies show contradictory results, with evidence for both 
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the potentiation of (Kim et al., 1999), and inhibition of (Lam et al., 1999), exocrine 
secretion as a result of insulin binding to the insulin receptor.       
   
K2P expression was investigated for the first time in the human foetal pancreas.  TALK-1, 
TASK-1, TREK-2 and TWIK-1 were all detected by RT-PCR at 9+6 wpc, 10+2 wpc and 
11+3 wpc.  TWIK-1 localisation was investigated by immunofluorescence.  At 9+6 wpc 
and 10 wpc TWIK-1 expression was discernable exclusively in the pancreatic duct 
epithelium.  Although single β-cells were present at 10 wpc, TWIK-1 did not co-stain with 
insulin, indicating its absence in β-cells.  By 11+3 wpc TWIK-1 expression was evident in 
the pancreatic duct epithelium and in β-cells that had begun to cluster together to form 
primitive islets.  However, TWIK-1 was absent from single β-cells.  The presence of 
TWIK-1 in the pancreatic duct epithelium suggests that TWIK-1 may be of importance in 
the differentiation of pancreatic β-cells (Bouwens et al., 1997).  The absence of TWIK-1 
from single β-cells would appear to argue against this.  However, a recent study 
demonstrated that the appearance of endocrine cell clusters, at approximately 12 wpc, 
occurs simultaneously with an exponential increase in hormone expression (Jeon et al., 
2009). Furthermore, the same study found that single cells that are both insulin- and 
glucagon-positive are detected at 9 wpc but are detected less frequently as development 
progresses (Jeon et al., 2009).  Therefore, it is possible that TWIK-1 expression is switched 
on only as α- and β-cells begin to differentiate and increase their expression of their 
representative hormones.  The presence of other K2P channels in the pancreas during 
development may also be significant in the development of cells towards an endocrine 
lineage.  Examining conserved binding elements upstream of TWIK-1 and other K2P 
channels expressed in the foetal pancreas may provide further insight into the significance 
of K2P channel expression in the developing pancreas. 
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K2P and TWIK-1 expression was examined in five Di-CHI patients who displayed the 
typical morphological appearance associated with Di-CHI (Dunne et al., 2004).  All Di-
CHI patients had novel mutations in the KATP channel subunit genes.  In 4/5 patients 
TWIK-1 co-stained with insulin in all observable islets indicating its presence in β-cells 
(Figure 4.27).  In these four patients strong TWIK-1 expression was also observed in the 
exocrine pancreas.  In the other patient TWIK-1 expression was observed only in a 
minority of β-cells and expression in the exocrine pancreas was inconsistent.  The mRNA 
expression of K2P channels appeared relatively stable in Di-CHI patients, although 
expression was not quantified.  Only TWIK-1 and TREK-2 mRNA expression was altered 
in a minority of patients, where expression was not detected.  As previously described, 
CHI β-cells have a resting potential close to that of the activation threshold of VDCCs (due 
to KATP channel dysfunction), which results in the inappropriate activity of VDCCs and 
elevated [Ca2+]i under basal conditions (Kane et al., 1996, Dunne et al., 2004).  This influx 
of Ca2+ has the potential to modulate gene expression both positively and negatively 
(Barbado et al., 2009).  Therefore, it is possible that the expression of TWIK-1 in β-cells is 
attributable to this phenomenon.  Indeed, in healthy β-cells, the KATP channel not only 
serves as a link between glucose metabolism and insulin secretion but also is involved in 
setting the membrane potential under resting conditions (Henquin and Meissner, 1984).  
K2P channels are generally active across the physiological range of membrane potentials, 
and therefore considered to be of importance in setting the resting membrane potential of a 
cell (Lesage et al., 2000).  Therefore, the observed change in the expression of K2P 
channels in Di-CHI may reflect the remodelling of the β-cell, via Ca2+ as a secondary 
messenger, to stabilise the membrane potential.   
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The expression of TWIK-1 and K2P channels was also examined in three Fo-CHI patients 
(Figure 4.27).  All patients had mutations in the KATP channel subunit genes.  TASK-1, and 
TALK-1 mRNA were present in all patients, both inside and outside of focal lesions.  
TWIK-l and TREK-2 mRNA was detected in 2/3 Fo-CHI patients.  TWIK-1 protein 
expression varied greatly between patients.  In N139, TWIK-1 was absent from β-cells 
outside the focal lesion but was present in the exocrine pancreas.  In the lesion, TWIK-1 
expression was expressed in both the exocrine pancreas and β-cells.  This is in contrast to 
N145 where outside of the lesion TWIK-1 expression was observed in β-cells and the 
exocrine pancreas, but inside the lesion TWIK-1 was absent from β-cells and only found in 
exocrine cells.  It is unlikely that this is due to a mix-up of samples as islet morphology 
both inside and outside the lesion is consistent with published data (Sempoux et al., 2003).  
Interestingly, TWIK-1 mRNA was not detected in either the lesion or non-lesion whole 
pancreas samples of patient N145.  The reason for this is unclear.  The absence of mRNA 
but presence of TWIK-1 protein may, in part, be due to mRNA stability/half-life and 
protein turnover.  There are few studies that have monitored both mRNA and protein half-
life in the same cells under the same conditions and so it is unclear how quickly a specific 
change in mRNA expression/stability will result in a change in the expression of a specific 
protein (Ross, 1995).  It is known that mRNAs are often associated with ribosomes and 
that the degradation of mRNAs can be linked directly to their translation (Ross, 1995).  
This may result in the presence of a protein at the membrane without detection of the 
accompanying mRNA.    
 
TWIK-1 and K2P expression was also explored in the insulinoma pancreas (Figure 4.27).  
In a patient with a focal-insulinoma, the result of a mutation in ABCC8, mRNA sequences 
corresponding to TALK-1, TASK-1, TREK-2 and TWIK-1 were detected in mRNA 
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isolated from islets outside of the focal lesion.  This corresponds to the mRNA profile for 
K2P channels from healthy human adult islet mRNA and suggests that islets outside of a 
focal-insulinoma are in a healthy state (Sempoux et al., 2003).  However, 
immunofluorescence revealed the presence of TWIK-1 in non-lesion β-cells and non-lesion 
exocrine pancreas.  The pattern of expression in the exocrine pancreas was consistent with 
that seen in the healthy adult pancreas, but the expression of TWIK-1 in the non-lesion β-
cells was more consistent with that seen in Di-CHI and Fo-CHI lesions.  This suggests that 
the expression of TWIK-1 is related to changes brought about as a result of mutations in 
the KATP channel.  Indeed, TWIK-1 expression was also observed in β-cells found within 
the focal-lesion, but was entirely absent from a separate insulinoma patient who did not 
have a mutation in either KATP channel subunit gene.  The absence of TWIK-1 from the 
insulinoma patient with no recorded KATP channel mutations may be significant.  Silencing 
of TWIK-1 expression has been shown to promote the growth of tumour cells and, indeed, 
has been shown to be downregulated in several different tumours (Beitzinger et al., 2008).  
The authors concluded that TWIK-1 may mediate the effects of the tumour suppressor 
TAp73.  The upregulation of TWIK-1 expression may function to reduce tumour 
aggressiveness and metastasis (Beitzinger et al., 2008). 
 
Further evidence that changes in TWIK-1 expression are a result of remodelling due to loss 
of the functional KATP channel was obtained from the SUR1 KO mouse.  The protein 
expression of TWIK-1 in the SUR1 KO mouse mirrored that seen in the Di-CHI and Fo-
CHI pancreas, in that expression was evident both in the exocrine tissue and in pancreatic 
β-cells (Figure 4.27).  As SUR1 KO mice have been shown to display elevated basal 
cytoplasmic Ca2+, similar to that seen in CHI patients (Shiota et al., 2002, Dufer et al., 
2004, Kane et al., 1996), it is possible that the changes in expression are a result of Ca2+-
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regulated gene expression.  This would indicate that the reported upregulation of TWIK-1 
in MIN6 cells cultured in high glucose (Glauser et al., 2007) may also have been a result of 
Ca2+-regulated gene expression.  Although the pattern of TWIK-1 expression observed in 
the healthy adult pancreas could be due to the affects of insulin on peri-insular acinar cells, 
it is unlikely that insulin is the cause of a change in K2P expression in the SUR1 KO 
mouse.  This is because global SUR1 KO mice do not share entirely the pathology of the 
CHI pancreas; mice are not hyperinsulinaemic (Shiota et al., 2002), and do not show the 
same changes in islet morphology (Marhfour et al., 2009).   
 
An exploration of K2P expression in the human β-cell line NES2Y revealed that the 
expression of K2P channels was sensitive to glucose in long-term culture.  TALK-1, 
TASK-1 and TWIK-1 mRNA was detected at all glucose concentrations tested for the first 
two weeks of culture.  TREK-2 was only expressed at 20mM glucose for the first two 
weeks of culture.  After three weeks of culture K2P expression was generally lost from 
culture at low glucose concentrations.  TREK-2 and TALK-1 were detected only at 15mM 
and 20mM, and TASK-1 and TALK-1 were not detected below 5mM glucose.  The 
general loss of K2P expression from NES2Y cells following three weeks of culture 
indicates that this may be a result of energy depletion (Van de Casteele et al., 2003), as 
during starvation the expression of certain genes maybe switched off to conserve 
resources.  In addition, both islets and β-cell lines have been known to change their 
phenotype during long-term culture (Gilon et al., 1994, Minami et al., 2000).  Therefore, 
changes in K2P expression that occur within the first week of culture may be more 
representative of a genuine cellular response to changes in glucose concentration. 
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Figure 4.27.  Summary of TWIK-1 expression.  TWIK-1protein expression was not discernable in the wild type mouse pancreas.  TWIK-1 expression was found in the 
β-cells of the SUR1 KO mouse.  In the adult human pancreas TWIK-1 expression was rarely observed in β-cells and was commonly found in selective areas of the exocrine 
pancreas in close proximity to islets.  In the majority of Di-CHI patients TWIK-1expression was observed in both islets and the exocrine pancreas.  In one case of Fo-CHI 
TWIK-1 expression was seen in the β-cells within the lesion.  Outside the lesion, TWIK-1 expression was only observed in the exocrine pancreas.  In a focal-insulinoma 
TWIK-1 was present in β-cells both inside and outside of the lesion.  TWIK-1 expression was lost completely in an insulinoma with no recorded KATP channel mutation.   
Interestingly, the K2P channels that showed the greatest changes in their expression, in 
regards to healthy human pancreas and CHI, were those that were sensitive to changes in 
the intracellular pH (pHi); TWIK-1 and TREK-2.  Glucose stimulation of the β-cell causes 
changes in the cytosolic pH.  The majority of reports indicate that high glucose results in 
an alkalisation (Juntti-Berggren et al., 1991, Shepherd and Henquin, 1995, Stiernet et al., 
2007).  There is also evidence to show that the changes in pHi are biphasic; the first 
response being a fast alkalisation; and the second a slower acidification (Salgado et al., 
1996).  The consequences of this change in pHi are unclear.  Published data has proposed 
that alkalisation augments (Juntti-Berggren et al., 1991) and inhibits GSIS (Nabe et al., 
2006).  The alterations observed in the pHi sensitive K2P channels may represent an 
attempt by the β-cell to stabilise the membrane potential during periods of continual insulin 
exocytosis.  If the slower acidification observed in mouse β-cells (Salgado et al., 1996) is 
also observed in human β-cells, this may result in the increased activity of TREK-2 and the 
decreased activity of TWIK-1 (O’Connell et al., 2002).  This may result in a decrease in 
the intracellular K+ concentration, and may therefore aid the β-cell to switch off insulin 
secretion by aiding the repolarisation of the membrane. 
 
The absence of TREK-2 in low glucose conditions is consistent with the proposed role of 
TREK-2 in the pancreas.  A study in MIN6 cells showed that the combined function of the 
KATP channel and TREK-2 accounted for approximately 75% of the cell’s K+ current at 
rest (Kang et al., 2004).  The study therefore proposed that the expression of TREK-2 was 
a safety measure of the β-cell to limit the influx of Ca2+, and consequently insulin release 
in response to metabolic stimulation (Kang et al., 2004).  Indeed, the metabolic stimulation 
of β-cells with glucose causes β-cell swelling sufficient enough to depolarise the cell as a 
result of volume-regulated anion channel activation (Miley et al., 1997).  As TREK-2 
channels are activated by membrane stretch (O’Connell et al., 2002) this would increase 
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the activity of TREK-2 and therefore potentially aid the β-cell in repolarisation.  Our 
results would only add support to this hypothesis.  The expression of TREK-2 at higher 
concentrations of glucose may reflect a remodelling of the NES2Y cell line in response to 
constant stimulation.  TREK-2 expression may be increased to prevent overstimulation of 
the β-cell.  The mechanism by which the observed changes in expression occur in the 
NES2Y cell is unclear.  Previous studies suggest that NES2Y cells show only small 
responses to stimulatory glucose, in terms of insulin secretion and [Ca2+]i (MacFarlane et 
al., 1997, MacFarlane et al., 1999).  Furthermore, NES2Y cells lack PDX1 and therefore 
the expression of insulin does not respond to elevated glucose (MacFarlane et al., 1997).  
Investigating the presence of upstream promoter regions of TREK-2 and may provide 
further insight into the mechanisms behind changes in TREK-2 and K2P expression in 
NES2Y cells.  
 
The function of other K2P channels in the pancreas remains unclear.  TASK-1 and TALK-
1 showed no alteration in expression in the disease tissue that was detectable by the 
methods used.  However, the distribution of these channels may have altered within the 
pancreas.  TASK-1 is of particular interest as it has been implicated in glucose-sensing in 
hypothalamic orexin neurons (Duprat et al., 2007).  Glucose was found to increase the 
amplitude of a hyperpolarising K+ current, which shares the properties of a TASK-
1/TASK-3 heteromer, and consequently reduced the electrical activity of the orexin 
neurons (Burdakov et al., 2006).  Furthermore, recent evidence suggests that the 
counterbalancing modulation of TASK and HCN channels restricts the net effect of 
acidification on the resting membrane potential of thalmacortical relay neurons (Budde et 
al., 2008).  In the light of this, the expression profile of HCN channels and K2P channels 
in the endocrine pancreas may be of particular importance.  If HCN channels and K2P 
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channel activity can be manipulated in CHI, in such a way as to push the membrane 
potential away from the activation threshold for VDCCs, it may be possible counteract 
hypoglycaemia by eliminating the inappropriate secretion of insulin. 
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5.  Conclusions and Future Implications 
The regulation of insulin secretion from pancreatic β-cells is of critical importance to 
glucose homeostasis.  Dysregulation of insulin secretion has a profound effect on blood 
glucose levels; excessive and inappropriate secretion of insulin results in hypoglycaemia 
and insufficient secretion results in diabetes (Ashcroft, 2005).  The secretion of insulin in 
response to glucose stimulation is a tightly regulated process dependent largely upon the 
movement of ions across the plasma membrane.  Of particular importance is the movement 
of K+ and Ca2+ ions (Rorsman, 1997).  We therefore investigated the presence of two ion 
channel families belonging to the potassium ion channel family that have previously not 
been characterised in pancreatic β-cells.  HCN and K2P channel expression was 
characterised in the mouse and human pancreas, the human foetal pancreas, the Di-CHI 
and Fo-CHI pancreas, in the pancreas of patients with Insulinoma/adenoma , mouse and 
human pancreatic β-cell lines, and the SUR1 KO mouse.  The function of HCN channels 
was characterised in the mouse pancreatic islets. The following conclusions were reached 
concerning HCN channels; 
 
• HCN channels are expressed in mouse and human pancreatic β-cells 
• HCN channels are expressed in mouse and human β-cell lines 
• HCN channels are expressed in a sub-population of mouse pancreatic α-cells 
• HCN channels are not expressed in human pancreatic α-cells 
• HCN channels are expressed in β-cells and the pancreatic duct epithelium in the 
developing human foetal pancreas 
• HCN channel expression is altered in insulinoma cells 
• HCN channels are absent from CHI β-cells, possibly as a consequence of 
pancreatic remodelling 
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• HCN channel expression is altered in the SUR1-/- mouse and resembles HCN 
expression in insulinoma cells 
• HCN channel activity is required for optimal GSIS at physiological concentrations 
of glucose in mouse islets 
 
The expression of HCN channels in the human foetal, adult, CHI and insulinoma pancreas 
represents the first evidence of its kind.  The characterisation of HCN channel expression 
and function in the mouse pancreas is also novel.  Electrophysiological studies and further 
functional studies are necessary to fully justify the proposed role of HCN channels in 
GSIS.  An immediately applicable experiment would be to confirm that HCN channel 
activity in mouse β-cells requires the elevation of cAMP (as caused by stimulation by 
glucose).       
 
The function of HCN channels in the human pancreas is of utmost importance in relation 
to future studies.  Determining the contribution of HCN channels to insulin secretion may 
provide new therapeutic avenues to be pursued in the treatment of diseases where glucose 
homeostasis is compromised.  The absence of HCN channels from CHI β-cells with KATP 
mutations negates their therapeutic potential in the therapy of CHI.  It is unknown if HCN 
channel expression is maintained in cases of CHI that are not a result of KATP channel 
mutations.  If HCN channels share a similar function in human β-cells as they do in mouse 
β-cells, HCN channel modulation may provide a new therapeutic target in the treatment of 
CHI where HCN channels are present.   
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HCN channel expression in the diabetic β-cell is unknown.  One possible cause for the loss 
of HCN channels in the CHI β-cell may be as a consequence of Ca2+-dependent gene 
regulation, which is a result of inactivating KATP channel mutations.  Therefore, it may be 
that in β-cells where Ca2+ entry is restricted, due to activating mutations in the KATP 
channel subunits, HCN channel expression may be retained.  Approximately 40% of 
Permanent Neonatal Diabetes Mellitus cases are the result of activating mutations in the 
KATP channel subunits, which result in membrane hyperpolarisation and the inhibition of 
insulin secretion (Edghill et al., 2010).  HCN channel expression and current have recently 
been shown to be enhanced in the nodose ganglion cells of diabetic rats, where they may 
contribute to diabetic neuropathy (Tu et al., 2010).  Furthermore, it has been found that 
HCN channels may play a protective role in hypokalaemic conditions (Zhang et al., 2009), 
commonly found in patients with diabetic ketoacidosis (Kitabchi and Nyenwe, 2006).  
Further study of HCN channels in both the diabetic pancreas and nervous system could 
therefore provide new insights into the mechanisms associated with its pathology, and 
thereby may present new therapeutic applications.   
 
In a minority of cases, mRNAs encoding HCN channels were detected but no protein.  
This may have been a consequence of unregulated Ca2+ entry into the CHI β-cell.  
However, another intriguing possibility is the emerging field of microRNAs (miRNAs).  In 
mammals, miRNAs have been found to control the activity of approximately 30% of 
protein encoding genes (Filipowicz et al., 2008).  These small non-coding RNAs bind to 
their target mRNA and guide translational repression or complete mRNA degradation (Li 
et al., 2009).  Pancreatic islet-specific miRNAs have been identified that can regulate 
insulin secretion both positively and negatively (Poy et al., 2004).  It is possible that 
mRNAs for encoding HCN channel isoforms were still detectable by RT-PCR, but that 
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miRNAs targeting these mRNAs caused translational repression.  Interestingly, miRNAs 
have recently been implicated in diabetes mellitus (Tang et al., 2008).  There is currently 
no published work regarding the presence of miRNAs in CHI tissue.  As miRNAs (as 
opposed to mRNAs) remain largely intact in routinely collected formalin-fixed paraffin-
embedded clinical samples (Li et al., 2009), it would be possible to investigate miRNA 
profiles in a large clinical sample.  This would provide new insights into a disease where 
nearly 50% of cases have no underlying genetic cause (Dunne et al., 2004). 
 
The composition of the functional HCN channels in mouse and human β-cells remains 
unknown.  Determining which HCN isoforms make up the functional channels may be of 
particular value if HCN channels are to be used as a therapeutic target.  The modulation of 
HCN channels in cardiac medicine and their potential as a therapeutic target in the 
treatment of epilepsy may present a complication.  Therefore, the modulation of HCN 
channel activity in these, and potentially pancreatic pathologies, may need to be isoform-
specific.  This would also require the development of isoform-specific modulators.    
 
The expression of profile of K2P channels was defined in the mouse.  For the first time 
K2P channel expression was characterised in the human endocrine pancreas, foetal 
pancreas, CHI pancreas, insulinoma cells, and SUR1 KO mouse.  A focus was given to 
TWIK-1 protein expression and localisation.  The following conclusions were reached 
concerning the expression of K2P channels; 
• TALK-1, TASK-1, TASK-2, TREK-1, TREK-2 and TWIK-1 mRNAs are 
expressed in mouse islets 
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• TALK-1, TASK-1, TREK-2 and TWIK-1 mRNAs are expressed in mouse and 
human β-cell lines 
• TALK-1, TASK-1, TREK-2 and TWIK-1 mRNAs are expressed in human islets 
• TALK-1, TASK-1, TREK-2 and TWIK-1 mRNAs are expressed in the human 
foetal pancreas as early as 9+6 wpc 
• TWIK-1 protein is expressed in the human exocrine pancreas 
• TWIK-1 protein is present in the pancreatic duct epithelium and β-cell clusters in 
the developing human foetal pancreas 
• TALK-1, TASK-1, TREK-2 and TWIK-1 mRNAs are expressed in the CHI 
pancreas  
• TWIK-1 protein is expressed in β-cells with mutations in the KATP channel subunits 
and not in non-lesion β-cells 
• TWIK-1 protein is expressed in SUR1-/- β cells 
• TREK-2 mRNA expression is switched on in NES2Y cells cultured in high glucose 
 
The functional significance of K2P channels in the human endocrine pancreas remains to 
be determined.  This has been hampered, in part, by the lack of selective pharmacological 
agents.  Studies from knockout mice have yet to provide any evidence of a role for K2P 
channels in the endocrine pancreas (reviewed by Sabbadini and Yost, 2009).  However, 
recent evidence suggests that the HCN2 channel and the TASK-3 channel produce 
counterbalancing currents to stabilise the resting membrane potential of TC neurons 
(Meuth et al., 2006).  It is unknown whether this represents a general feature of cells or is 
specific to neurons.  The expression of HCN and K2P channels in human islets may be 
indicative of a dual role in islets cells.  There is also evidence to suggest that K2P channels 
also play a role in the regulation of cardiac action potential duration (Gurney and Manoury, 
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2009).  Given the defined role of HCN channel function in the heart, the dual modulation 
of HCN and K2P channels may provide new therapeutic solutions to cardiac dysfunction.  
The future direction of K2P research may therefore benefit from a combined study with 
HCN channels and may provide new insights into cellular function in a variety of cell 
types. 
 
There is some question as to the level of TWIK-1 functionality in the plasma membrane 
(Enyedi and Czirják, 2010).  Functional evidence of TWIK-1 in the human exocrine 
pancreas may be of particular importance if expression is restricted, in large, to periinsular 
acinar cells.  This may have relevance for chronic pancreatitis.  Further investigation into 
TWIK-1 as a potential mediator of tumour suppressor activity (Beitzinger et al., 2008), 
particularly in insulinomas, may provide potential new therapeutic possibilities. 
 
As K2P channels are considered to be active across the range of physiological membrane 
potentials, the possibility of their modulation for the treatment of disease may depend on 
enhancing or restricting their expression in target cells.  Elucidation of upstream binding 
sites for transcription factors may be of particular importance.  Preliminary searches of 
TWIK-1 show the presence of PAX4, GATA, and PBX binding sites (Karen Piper-Hanley, 
2009, unpublished data).  Research into the regulation of K2P gene expression may also 
help to understand the contribution of these channels in the developing pancreas.  
 
The apparent remodelling of the pancreatic β-cell in CHI patients would benefit from 
further research.  It has been speculated that among the unknown genetic causes of CHI are 
likely to be transcription factors (Giurgea et al., 2006b).  Indeed, mutations in the nuclear 
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transcription factor, HCN4α, have been identified as a common cause of diazoxide-
responsive CHI (Flanagan et al., 2010).  Dysfunction or impaired expression of 
transcription factors that are key to β-cell identity, may also contribute to the CHI 
phenotype.  Further investigation of other changes in gene expression in the CHI β-cell and 
the presence of transcription factor binding sites within these genes may present further 
insight into CHI and potential new therapies.  
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